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Abstract: Any drug prescription requires careful weighting of risks vs. benefits. Failure to do so or
to ignore known contraindications, recommended dose-adjustments and other precautions represents a
medication error that may result in adverse drug events, i.e. harm to the patient. Clinical decision
support systems can routinely detect potential medication errors and issue automated alerts for their
prevention. However, current systems typically focus on high sensitivity at the price of low specificity
regarding relevance of their alerts. In clinical practice this results in an excessive number of alerts to
prescribers with subsequent alert fatigue and indiscriminate alert overriding, i.e. even important warn-
ings are ignored. So medication errors continue to be a theoretically avoidable yet persistent burden for
healthcare systems and patients. Therefore this thesis pursued the following objectives: I) Systematic
quantification of potential medication errors in a real-life hospital setting. II) Validation of the clini-
cal relevance of selected potential medication errors and associated adverse events. III) Development,
implementation and outcome assessment not only of highly sensitive but also of highly specific alert
algorithms for the prevention of clinically relevant medication errors. I) Two studies were performed in
order to systematically quantify potential medication errors: A local pharmacoepidemiological database
including 6.6 million drug administrations during approximately 82000 hospitalizations was successfully
developed based on raw data extracted from the electronic medical records system of a tertiary care
hospital. After its validation, highly efficient algorithms were developed that identified potential med-
ication errors. They allowed the retrospective assessment of a considerable number of contraindicated
and/or critical prescriptions. Sensitivity and specificity regarding clinical relevance of these potential
medication errors was enhanced by the use of additional patient-specific laboratory data and repeated
clinical validation procedures. With the help of a newly developed interface with ID PHARMA CHECK®
- a commercially available clinical decision support system - several ten thousand potential drug inter-
actions, contraindications and dosing errors were identified and assigned to formal severity categories.
48 distinct contraindicated drug interactions were considered as clinically relevant and suitable for dis-
play of highly specific alerts within a clinical information systems; 32 alert algorithms required retrieval
and implementation of current patient-specific information such as laboratory results in order to reach
high specificity. The resulting algorithms were subsequently programmed for routine use with the clini-
cal decision support system. II) Three sub-studies were conducted within the pharmacoepidemiological
database and addressed specific safety concerns of pharmacotherapy in clinical practice: The first of these
studies identified 1136 hospitalizations with exposure to second-generation antipsychotics. Blood pres-
sure, blood glucose, lipids and body mass index should be routinely monitored in those patients, however
they were found to be documented in 97.7, 75.7, 24.6 and 77.4 % of hospitalizations, respectively. 63.4,
70.8 and 37.1% of the patients with hyperglycemia, dyslipidemia and hypertension, respectively, had no
pharmacotherapy for these conditions. Among patients exposed to second-generation antipsychotics and
concomitant use of drugs featuring a high risk for potentially severe adverse drug events, one case with
associated neutropenia and four cases with abnormal QTc-interval were detected. Specific monitoring
for such adverse drug events was not performed in 89.8% of patients with related high-risk drug com-
binations. The second sub-study analyzed the use of benzodiazepines (including “Z-drugs”) that were
found to be administered to 48.3% of 53081 patients hospitalized in 2011 and 2012. Validated algo-
rithms identified 3372 patient-days (2.9%) with comedication that significantly inhibits the respective
benzodiazepines’ metabolism. Validation revealed 205 cases with clinically relevant medication errors.
Among those, 23 cases with associated adverse drug events such as severe CNS-depression, falls with
subsequent injuries and severe dyspnea were detected. The third sub-study analyzed 3444 hospitaliza-
tions with administrations of selected macrolide and quinolone antibiotics and identified concomitant
use of additional QT-prolonging drugs in 1332 (38.7%). Among those we identified 7 events of related
QTc-prolongation, but 50.4 % had no ECG-monitoring. Of all patients exposed to the studied antibiotics
547 (15.9%) featured episodes of hypokalemia, an important additional risk factor for potentially lethal
Torsade de Pointes arrhythmia. Clinically relevant QT-prolongation was detected in 7 patients. Another
31 patients were exposed to contraindicated comedication with simvastatin, atorvastatin or tizanidine
where the risk of pharmacokinetic drug-drug interactions clearly outweighed benefits, 3 thereof with as-
sociated adverse events. III) These two studies then aimed to develop new solutions for the prevention of
such avoidable potential medication errors and associated adverse drug events: According to our phar-
macoepidemiological database overdosing of paracetamol occurred in 988 hospitalizations per year, but
in only 11 (0.4 %) this was judged as clinically relevant (￿ 5 g on ￿ 3 consecutive days). A new alert
algorithm was developed as part of this study, and in 2014 it was implemented into the hospital-wide
electronic drug prescribing system. It automatically detects cases of paracetamol overdosing, and after
manual assessment alerts were issued in 23 cases, with subsequent changes to prescriptions in 21 (91.3
%) thereof. While the occurrence of mild and therefore clinically irrelevant acetaminophen overdosing
changed only marginally in 2014 (n = 914), no clinically relevant overdosing occurred anymore. The
second automated alert concerned metformin overdosing in renal impairment. It has been used in routine
clinical practice for three years and generated 2145 automated alerts (about 2 per day). Validated expert
recommendations regarding metformin therapy, i.e. dose reduction or stop, were issued for 381 patients
(about 3 per week). Follow-up was available for 240 cases, and prescribers’ compliance with recommen-
dations was 79 %. Furthermore, during 3 years we identified 8 local cases of lactic acidosis associated
with metformin therapy in renal impairment that could not be prevented, e.g. because metformin over-
dosing had occurred before hospitalization. Besides these principal studies, spontaneous reports from
international pharmacovigilance databases on liver disease associated with the new oral anticoagulant
rivaroxaban and allergy-like reactions to herbal medicines were analyzed in two additional studies. In
conclusion, local pharmacoepidemiological databases can be created using already available electronic
medical information systems. They are an innovative and promising new approach for the identification
and management of medication errors and resulting adverse drug events. Such databases are able to
quantify clinically relevant medication errors and thereby provide data for a rational selection of targets
for new and highly specific preventive safety measures. Any such measures must be integrated into a
comprehensive hospital safety concept where local drug safety experts play an important role for the
evaluation and communication of medication errors. Within such a system, automated alert algorithms
that use also patient-specific information are a cornerstone for the proactive prevention of medication
errors and resulting adverse drug events.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-124894
Originally published at:
Niedrig, David Franklin. Improving hospital drug safety - identification of medication errors and subse-
quent development, implementation and outcome evaluation of alert algorithms for their targeted pre-
vention. 2016, University of Zurich, Faculty of Medicine.
2
  
DISS. ETH NO. 23313 
 
 
 
 
IMPROVING HOSPITAL DRUG SAFETY 
 
IDENTIFICATION OF MEDICATION ERRORS AND SUBSEQUENT 
DEVELOPMENT, IMPLEMENTATION AND OUTCOME EVALUATION 
OF ALERT ALGORITHMS FOR THEIR TARGETED PREVENTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAVID FRANKLIN NIEDRIG  
  
DISS. ETH NO. 23313 
 
 
IMPROVING HOSPITAL DRUG SAFETY 
 
IDENTIFICATION OF MEDICATION ERRORS AND 
SUBSEQUENT DEVELOPMENT, IMPLEMENTATION AND 
OUTCOME EVALUATION OF ALERT ALGORITHMS FOR THEIR 
TARGETED PREVENTION 
 
 
A thesis submitted to attain the degree of 
DOCTOR OF SCIENCES of ETH ZURICH 
(Dr. sc. ETH Zurich) 
 
 
presented by 
DAVID FRANKLIN NIEDRIG 
fed. pharmacist ETH Zurich 
born 25.07.1978 
citizen of  Zurich 
 
 
accepted on the recommendation of 
Prof. Dr. Hanns U. Zeilhofer 
Prof. Prof. Dr. Stefan Russmann 
Prof. Dr. Gerd A. Kullak-Ublick 
Prof. Dr. Cornelia Halin Winter 
 
 
Zurich 2016
3 
Table of Contents 
1. Summary Zusammenfassung 7 
2. Background, Current State of Research and Principal Methods 14 
2.1. Drug Safety and Adverse Drug Events 14 
2.1.1. Detection and Quantification of Adverse Drug Events 16 
2.2. Medication Errors, Adverse Drug Events and Risk Factors 17 
2.2.1. Applying Pharmacovigilance and Pharmacoepidemiology 18 
2.2.2. Medication Errors in Hospitals: Common 19 
2.2.3. Medication Errors in Hospitals: Expensive 20 
2.2.4. Medication Errors in Hospitals: Harmful 21 
2.3. Computerized Physician Order Entry 22 
2.3.1. Clinical Decision Support Systems 22 
2.3.2. Alerts: Acceptance, Fatigue and Override Rates 24 
2.4. Comprehensive Hospital Drug Safety Concept 26 
2.4.1. Hospital Safety Culture 26 
2.4.2. Selection and Planning 27 
2.4.1. Implementation 27 
2.4.2. Creation of a Local Pharmacoepidemiological Database 28 
2.4.3. Evaluation 29 
2.5. Ethical Considerations and Data Protection 31 
3. Results 34 
3.1. Creation of a Pharmacoepidemiological Database: Highly Efficient 
Pharmacoepidemiological Analysis of Hospital Drug Prescriptions with Target 
Identification for the Prevention of Medication Errors 34 
3.1.1. Authors 34 
3.1.2. Remarks 34 
3.1.3. Background 35 
3.1.4. Objectives 35 
3.1.5. Methods 35 
3.1.6. Results 35 
3.1.7. Conclusions 36 
3.2. Retrospective Mass-Analysis of Hospital Prescription Data for Medication 
Errors and Subsequent Development of Highly Specific Alert Algorithms with ID 
PHARMA CHECK® 37 
3.2.1. Authors 37 
4 
3.2.2. Remarks 37 
3.2.3. Background 38 
3.2.4. Objectives 38 
3.2.5. Methods 38 
3.2.6. Results 38 
3.2.7. Conclusions 39 
3.3. Second-generation antipsychotics in a tertiary care hospital: prescribing 
patterns, metabolic profiles, and drug interactions 40 
3.3.1. Authors 40 
3.3.2. Remarks 40 
3.3.3. Background 41 
3.3.4. Objectives 42 
3.3.5. Methods 42 
3.3.6. Results 46 
3.3.7. Conclusion 53 
3.4. Benzodiazepine Use During Hospitalization: Automated Identification of 
Potential Medication Errors and Systematic Assessment of Preventable Adverse 
Events 56 
3.4.1. Authors 56 
3.4.2. Remarks 56 
3.4.3. Background 57 
3.4.4. Objectives 58 
3.4.5. Methods 58 
3.4.6. Results 62 
3.4.7. Conclusion 71 
3.5. Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care 
Hospital: Administration of Contraindicated Comedication and QT-Prolongation 75 
3.5.1. Authors 75 
3.5.2. Remarks 75 
3.5.3. Background 76 
3.5.4. Objectives 77 
3.5.5. Methods 77 
3.5.6. Results 80 
3.5.7. Conclusion 87 
3.6. Acetaminophen Overdosing in a Tertiary Care Hospital: Implementation and 
Outcome Analysis of an Automated Preventive Alert Program 90 
3.6.1. Authors 90 
5 
3.6.2. Remarks 90 
3.6.3. Background 91 
3.6.4. Objectives 91 
3.6.5. Methods 91 
3.6.6. Results 92 
3.6.7. Conclusion 95 
3.7. Development, Implementation and Outcome Analysis of Semi-Automated 
Alerts for Metformin Dose-Adjustment in Hospitalized Patients with Renal 
Impairment 97 
3.7.1. Authors 97 
3.7.2. Remarks 97 
3.7.3. Background 98 
3.7.4. Objectives 98 
3.7.5. Methods 98 
3.7.6. Results 101 
3.7.7. Conclusion 103 
4. Conclusions and Outlook 104 
4.1. Preventing Medication Errors in the Past 104 
4.2. Preventing Medication Errors Today 104 
4.1. Preventing Medication Errors in the (not too Distant) Future 105 
5. Acknowledgements 108 
5.1. Potential Conflicts of Interests 108 
5.2. Thank you! 108 
6. Statement of Originality 110 
7. Scientific Publications and Presentations 111 
8. Appendix 114 
8.1. Rivaroxaban postmarketing risk of liver injury 114 
8.1.1. Authors 114 
8.1.2. Remarks 114 
8.1.3. Background 115 
8.1.4. Objectives 115 
8.1.5. Methods 115 
8.1.6. Results 115 
8.1.7. Conclusion 123 
6 
8.2. Allergy-like immediate reactions during the use of herbal remedies as 
reported in VigiBase® 127 
8.2.1. Authors 127 
8.2.2. Remarks 127 
8.2.3. Background 128 
8.2.4. Objectives 128 
8.2.5. Methods 128 
8.2.6. Results 132 
8.2.7. Conclusion 140 
9. References 143 
 
  
7 
1. Summary 
Any drug prescription requires careful weighting of risks vs. benefits. Failure to do so 
or to ignore known contraindications, recommended dose-adjustments and other 
precautions represents a medication error that may result in adverse drug events, i.e. 
harm to the patient. Clinical decision support systems can routinely detect potential 
medication errors and issue automated alerts for their prevention. However, current 
systems typically focus on high sensitivity at the price of low specificity regarding 
relevance of their alerts. In clinical practice this results in an excessive number of 
alerts to prescribers with subsequent alert fatigue and indiscriminate alert overriding, 
i.e. even important warnings are ignored. So medication errors continue to be a 
theoretically avoidable yet persistent burden for healthcare systems and patients. 
Therefore this thesis pursued the following objectives: 
 
I) Systematic quantification of potential medication errors in a real-life hospital 
setting. 
II) Validation of the clinical relevance of selected potential medication errors and 
associated adverse events.  
III) Development, implementation and outcome assessment not only of highly 
sensitive but also of highly specific alert algorithms for the prevention of 
clinically relevant medication errors. 
 
I) Two studies were performed in order to systematically quantify potential 
medication errors: 
A local pharmacoepidemiological database including 6.6 million drug administrations 
during approximately 82000 hospitalizations was successfully developed based on 
raw data extracted from the electronic medical records system of a tertiary care 
hospital. After its validation, highly efficient algorithms were developed that identified 
potential medication errors. They allowed the retrospective assessment of a 
considerable number of contraindicated and/or critical prescriptions. Sensitivity and 
specificity regarding clinical relevance of these potential medication errors was 
enhanced by the use of additional patient-specific laboratory data and repeated 
clinical validation procedures. 
With the help of a newly developed interface with ID PHARMA CHECK® - a 
commercially available clinical decision support system - several ten thousand 
potential drug interactions, contraindications and dosing errors were identified and 
assigned to formal severity categories. 48 distinct contraindicated drug interactions 
8 
were considered as clinically relevant and suitable for display of highly specific alerts 
within a clinical information systems; 32 alert algorithms required retrieval and 
implementation of current patient-specific information such as laboratory results in 
order to reach high specificity. The resulting algorithms were subsequently 
programmed for routine use with the clinical decision support system. 
 
II) Three sub-studies were conducted within the pharmacoepidemiological database 
and addressed specific safety concerns of pharmacotherapy in clinical practice: 
The first of these studies identified 1136 hospitalizations with exposure to second-
generation antipsychotics. Blood pressure, blood glucose, lipids and body mass 
index should be routinely monitored in those patients, however they were found to be 
documented in 97.7, 75.7, 24.6 and 77.4 % of hospitalizations, respectively. 63.4, 
70.8 and 37.1% of the patients with hyperglycemia, dyslipidemia and hypertension, 
respectively, had no pharmacotherapy for these conditions. Among patients exposed 
to second-generation antipsychotics and concomitant use of drugs featuring a high 
risk for potentially severe adverse drug events, one case with associated neutropenia 
and four cases with abnormal QTc-interval were detected. Specific monitoring for 
such adverse drug events was not performed in 89.8% of patients with related high-
risk drug combinations. 
The second sub-study analyzed the use of benzodiazepines (including “Z-drugs”) 
that were found to be administered to 48.3% of 53081 patients hospitalized in 2011 
and 2012. Validated algorithms identified 3372 patient-days (2.9%) with 
comedication that significantly inhibits the respective benzodiazepines’ metabolism. 
Validation revealed 205 cases with clinically relevant medication errors. Among 
those, 23 cases with associated adverse drug events such as severe CNS-
depression, falls with subsequent injuries and severe dyspnea were detected. 
The third sub-study analyzed 3444 hospitalizations with administrations of selected 
macrolide and quinolone antibiotics and identified concomitant use of additional QT-
prolonging drugs in 1332 (38.7%). Among those we identified 7 events of related 
QTc-prolongation, but 50.4 % had no ECG-monitoring. Of all patients exposed to the 
studied antibiotics 547 (15.9%) featured episodes of hypokalemia, an important 
additional risk factor for potentially lethal Torsade de Pointes arrhythmia. Clinically 
relevant QT-prolongation was detected in 7 patients. Another 31 patients were 
exposed to contraindicated comedication with simvastatin, atorvastatin or tizanidine 
where the risk of pharmacokinetic drug-drug interactions clearly outweighed benefits, 
3 thereof with associated adverse events. 
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III) These two studies then aimed to develop new solutions for the prevention of such 
avoidable potential medication errors and associated adverse drug events: 
According to our pharmacoepidemiological database overdosing of paracetamol 
occurred in 988 hospitalizations per year, but in only 11 (0.4 %) this was judged as 
clinically relevant (≥ 5 g on ≥ 3 consecutive days). A new alert algorithm was developed 
as part of this study, and in 2014 it was implemented into the hospital-wide electronic 
drug prescribing system. It automatically detects cases of paracetamol overdosing, 
and after manual assessment alerts were issued in 23 cases, with subsequent 
changes to prescriptions in 21 (91.3 %) thereof. While the occurrence of mild and 
therefore clinically irrelevant acetaminophen overdosing changed only marginally in 
2014 (n = 914), no clinically relevant overdosing occurred anymore. 
The second automated alert concerned metformin overdosing in renal impairment. It 
has been used in routine clinical practice for three years and generated 2145 
automated alerts (about 2 per day). Validated expert recommendations regarding 
metformin therapy, i.e. dose reduction or stop, were issued for 381 patients (about 3 
per week). Follow-up was available for 240 cases, and prescribers’ compliance with 
recommendations was 79 %. Furthermore, during 3 years we identified 8 local cases 
of lactic acidosis associated with metformin therapy in renal impairment that could 
not be prevented, e.g. because metformin overdosing had occurred before 
hospitalization.  
 
Besides these principal studies, spontaneous reports from international 
pharmacovigilance databases on liver disease associated with the new oral 
anticoagulant rivaroxaban and allergy-like reactions to herbal medicines were 
analyzed in two additional studies. 
 
In conclusion, local pharmacoepidemiological databases can be created using 
already available electronic medical information systems. They are an innovative and 
promising new approach for the identification and management of medication errors 
and resulting adverse drug events. Such databases are able to quantify clinically 
relevant medication errors and thereby provide data for a rational selection of targets 
for new and highly specific preventive safety measures. Any such measures must be 
integrated into a comprehensive hospital safety concept where local drug safety 
experts play an important role for the evaluation and communication of medication 
errors. Within such a system, automated alert algorithms that use also patient-
specific information are a cornerstone for the proactive prevention of medication 
errors and resulting adverse drug events.  
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Zusammenfassung 
Bei der Verordnung eines Arzneimittels sollten stets dessen Risiken und Nutzen 
gegeneinander abgewogen werden. Wird dies nicht gemacht, oder werden bekannte 
Kontraindikationen, empfohlene Dosis-Anpassungen und andere 
Vorsichtsmassnahmen nicht berücksichtigt, stellt dies einen Medikationsfehler dar. 
Dieser kann zu einer unerwünschten Arzneimittelwirkung führen und dem Patienten 
schaden. Software zur Unterstützung klinischer Entscheidungen kann 
standardmässig potentielle Medikationsfehler identifizieren und automatisch 
Warnmeldungen zu deren Verhinderung auslösen. Derzeit fokussieren solche 
Systeme auf hohe Sensitivität, was eine geringe Spezifität bezüglich der klinischen 
Relevanz der Warnmeldungen zur Folge hat. Im klinischen Alltag hat dies eine 
übermässige Anzahl Warnungen zur Folge, welche zu einer Abstumpfung (alert 
fatigue) der Verschreiber führt. Schliesslich werden alle Warnmeldungen komplett 
übergangen und somit auch wichtige Hinweise ignoriert. Daher sind 
Medikationsfehler noch immer eine nur theoretisch vermeidbare und in der Praxis 
weiterhin bestehende Belastung für das Gesundheitswesen und die betroffenen 
Patienten. Daraus leiteten sich folgende Ziele für diese Doktorarbeit ab: 
 
I) Die systematische Quantifizierung von potentiellen Medikationsfehlern 
welche sich im praktischen Alltag eines Spitals ereignen. 
II) Die Validierung der klinischen Relevanz von ausgewählten potentiellen 
Medikationsfehlern und damit assoziierten unerwünschten 
Arzneimittelwirkungen. 
III) Die Entwicklung, Implementierung und Auswertung von sowohl 
hochsensitiven als auch hochspezifischen Warn-Algorithmen zur 
Verhinderung von klinisch relevanten Medikationsfehlern. 
 
I) Die zwei ersten Studien dienten der Analyse potentieller Medikationsfehler:  
Aus Rohdaten, welche aus dem klinischen Informationssystem eines Tertiärspitals 
extrahiert wurden, konnte eine lokale, validierte, pharmakoepidemiologische 
Datenbank erstellt werden. Diese enthält ca. 6.6 Millionen 
Arzneimittelverabreichungen verteilt auf rund 82000 Hospitalisierungen. Es wurden 
hocheffiziente Algorithmen entwickelt, welche eine beachtliche Anzahl potentieller 
Medikationsfehler identifizierten. Darunter fanden sich zahlreiche übergangene 
Kontraindikationen und andere kritische Verordnungen aus dem klinischen Alltag. 
Die Sensitivität und Spezifität bezüglich der Detektion von klinisch relevanten 
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Medikationsfehlern wurde durch wiederholte Validierungsprozesse erhöht und durch 
die zusätzliche Verwendung patientenspezifischer Laborwerte weiter gesteigert. 
Mit Hilfe einer neu entwickelten Schnittstelle zu ID PHARMA CHECK® - einer 
kommerziellen Software zur Unterstützung klinischer Entscheidungen - konnten 
anhand einer Massenanalyse mehrere Zehntausend potentiell gefährliche 
Arzneimittelinteraktionen, Kontraindikationen und Dosierungsfehler identifiziert und in 
formale Gefahren-Kategorien eingeteilt werden. Davon wurden bislang 48 
verschiedene kontraindizierte Arzneimittelinteraktionen als klinisch relevant beurteilt 
und als passend für eine aktive Warnung befunden. Weitere 32 Warn-Algorithmen 
benötigten die Berücksichtigung von aktuellen patientenspezifischen Informationen, 
z.B. Laborwerte, um eine hohe Spezifität zu erreichen. Diese Algorithmen wurden 
daraufhin zum routinemässigen Gebrauch in die Software einprogrammiert und 
werden jetzt im klinischen Alltag eingesetzt.  
 
II) Mit der pharmakoepidemiologischen Datenbank wurden daraufhin drei Sub-
Studien durchgeführt, welche sich spezifischen Fragestellungen zur 
Arzneimittelsicherheit im klinischen Alltag widmeten: 
Die erste solche Untersuchung analysierte 1136 Hospitalisierungen bei denen 
atypische Neuroleptika eingesetzt wurden. Bei diesen Patienten sollten Blutdruck, 
Blutzucker, Lipidstoffwechsel und der Body-Mass-Index routinemässig überwacht 
werden. Dies war jedoch nur in 97.7, 75.7, 24.6 und 77.4 % der Hospitalisierungen 
der Fall. Patienten welche an Bluthochdruck, Hyperglykämie oder Dyslipidämie litten 
erhielten in 63.4, 70,8 und 37.1 % der Fälle keine entsprechende Pharmakotherapie. 
Unter den Patienten, welche zu den atypischen Neuroleptika zeitgleich weitere 
Arzneimittel erhielten, die zusammen zu potentiell schweren Nebenwirkungen führen 
können, wurden ein Fall mit assoziierter Neutropenie und vier Fälle mit abnormalem 
QTc-Intervall entdeckt. Eine spezifische Überwachung bezüglich solcher 
unerwünschten Arzneimittelwirkungen wurde in 89.9 % der Fälle mit hochriskanter 
Co-Medikation nicht durchgeführt. 
Eine zweite Sub-Studie analysierte den Gebrauch von Benzodiazepinen (inklusive 
der sogenannten Z-Wirkstoffe), welche bei 48.3 % der 53081 Patienten angewendet 
wurden, welche 2011 und 2012 hospitalisiert waren. Validierte Algorithmen infizierten 
3372 Patiententage (2.9%) mit einer Co-Medikation, welche den Metabolismus der 
entsprechenden Benzodiazepine erheblich beeinträchtigten. Deren Validierung 
zeigte 205 Fälle mit klinisch relevanten Medikationsfehlern, welche in 23 Fällen mit 
assoziierten unerwünschten Arzneimittelwirkungen, darunter ausgeprägte ZNS-
Dämpfung, Stürze mit Verletzungen und Atemstillstand. 
12 
Die dritte Sub-Studie untersuchte 3444 Hospitalisierungen mit Verabreichungen von 
ausgewählten Makrolid- und Chinolon-Antibiotika und ergab eine zeitgleiche 
Anwendung weiterer QT-verlängernder Wirkstoffe bei 1332 (38.7 %) davon. Dabei 
fand bei 50.4 % keine EKG-Überwachung statt. Bei 15.9 % traten Hypokaliämien auf, 
ein wichtiger und vermeidbarer Risikofaktor für potentiell tödliche Torsade de Pointes 
Arrhythmien. Eine klinisch relevante QT-Verlängerung wurde bei 7 Patienten 
festgestellt. Bei weiteren 31 Patienten wurden die untersuchten Antibiotika zeitgleich 
mit Simvastatin, Atorvastatin oder Tizanidin verabreicht. Aufgrund von ausgeprägten 
pharmakokinetischen Wechselwirkungen übersteigen dabei die Risiken klar jeden 
Nutzen. Bei 3 dieser Patienten wurden assoziierte unerwünschte 
Arzneimittelwirkungen festgestellt. 
 
III) Zwei weitere Studien widmeten sich danach der Entwicklung neuer 
Lösungsansätze zur Verhinderung solcher potentieller Medikationsfehler und den 
damit assoziierten unerwünschten Arzneimittelwirkungen: 
Gemäss der verwendeten pharmakoepidemiologischen Datenbank wird jährlich bei 
988 Hospitalisierungen Paracetamol überdosiert. Dies wurde jedoch nur in 11 
(0.4 %) Fällen als klinisch relevant (≥ 5 g / d für ≥ 3 aufeinander folgende Tage) 
eingestuft. Ein neuer Warn-Algorithmus wurde für diese Studie entwickelt und 2014 
in das spitalweite elektronische Verordnungssystem implementiert. Dieser detektiert 
Paracetamol-Überdosierungen, welche nach einer manuellen Evaluation durch 
lokale Experten für Arzneimittelsicherheit in 23 Fällen an die verschreibenden Ärzte 
weitergeleitet wurden. Diese änderten die Paracetamol-Verordnungen in 21 Fällen 
(91.3 %). Währen sich die Anzahl klinisch irrelevanter, moderater Paracetamol-
Überdosierungen 2014 nicht veränderte, fanden keine klinisch relevanten 
Überdosierungen mehr statt. 
Der zweite automatisierte Warn-Algorithmus zielte auf Metformin-Überdosierungen 
bei Patienten mit eingeschränkter Nierenfunktion ab. In den 3 Jahren seit der 
Implementierung 2012 generierte ein Screening-Algorithmus 2145 Warnmeldungen 
an lokale Experten für Arzneimittelsicherheit (ca. 2 pro Tag). Nach deren Evaluation 
wurden in 381 Fällen spezifische Empfehlungen zur Dosisanpassung (Reduktion 
oder Stopp) an die verschreibenden Ärzte weitergeleitet (ca. 3 pro Woche). Für 240 
Fälle standen Informationen für weitere Auswertungen zur Verfügung wobei bei 79.3 
% davon die Empfehlungen umgesetzt wurden. Innerhalb dieser 3 Jahre wurden 8 
Patienten mit Metformin-assoziierter Laktatazidose identifiziert. Diese ereigneten sich 
jedoch in Situationen, in denen eine zeitnahe Warnung nicht möglich war, z.B. weil 
Metformin schon vor Spitaleintritt überdosiert worden war. 
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Zwei zusätzliche Studien widmeten sich nebenher der Analyse von 
Spontanmeldungen aus internationalen Pharmakovigilanzsystemen. Dabei wurden 
Leberschäden, welche mit dem Gebrauch des neuen oralen Antikoagulans 
Rivaroxaban assoziiert waren, sowie allergie-ähnliche Reaktionen auf 
Phytotherapeutika untersucht. 
 
Folgende Schlussfolgerungen können gezogen werden: Bereits bestehende 
elektronische Verordnungssysteme ermöglichen die Erstellung lokaler 
pharmakoepidemiologischer Datenbanken. Diese ermöglichen einen neuartigen und 
innovativen Ansatz zur Identifikation und Verhinderung von Medikationsfehlern und 
damit assoziierten unerwünschten Arzneimittelwirkungen. Solche Datenbanken 
erlauben die Quantifizierung von klinisch relevanten Medikationsfehlern. Dies kann 
die Basis für eine rationale Auswahl von Zielen darstellen, anhand derer 
hochspezifische Präventivmassnahmen entwickelt werden können. Jede solche 
Massnahme muss in ein umfassendes Spital-Sicherheitskonzept eingebettet werden, 
in dem lokale Experten für Arzneimittelsicherheit eine tragende Rolle bei der 
Kommunikation und Verhinderung von Medikationsfehlern spielen. Innerhalb eines 
solchen proaktiven Systems können automatisierte Warn-Algorithmen, welche 
patientenspezifische Informationen berücksichtigen, einen fundamentalen Beitrag zur 
Verhinderung von Medikationsfehlern und daraus resultierten unerwünschten 
Arzneimittelwirkungen leisten.  
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2. Background, Current State of Research and Principal Methods 
 
2.1. Drug Safety and Adverse Drug Events 
For any drug with granted marketing authorization its label, i.e. its approved 
indication and usage, is initially based on the properties that have been previously 
assessed in clinical trials, i.e. ‘premarketing’ data. By administering a drug according 
to its label, clinicians and patients can expect benefits to usually outweigh currently 
known potential risks. Nevertheless, using a drug not in accordance with its label is 
common in clinical practice and may indeed be unavoidable. Sometimes even the 
use in spite of explicit contraindications may be justifiable. In these situations 
prescribers must carefully assess the risks for adverse drug events (ADE), monitor 
the patient’s reactions to the drug and consider therapeutic alternatives. 
 
 
 
 
Figure 1: Integrative Assessment of Clinical Drug Safety Based on Available Data from Different 
Sources, adapted from: Arzneimitteltherapie, Wirksamkeit - Sicherheit - Praktische Anwendung, page 
28.  
15 
Due to their high costs studies that provide the evidence for granting marketing 
authorization are limited in size and scope and often only include a few hundred or 
thousand usually highly selected patients, which are not necessarily representative of 
the population that will receive the drug after market approval. Therefore some risks 
such as delayed or rare ADE or potentially dangerous drug-drug interactions (DDI) 
are often not detected before the drug is widely used in clinical practice. 
Approximately 80% of all ADE can be classified as “Type-A” ADE or ‘augmented 
effects’. These ADE are typically dose-dependent and can be explained by the 
pharmacological properties of the drug and typically affect particular organs. Such 
ADE usually cease after dose reduction or drug withdrawal and are reproducible in 
individual patients. Type A ADE are preventable and represent a well-known risk that 
can be managed accordingly, e.g. by choosing another drug with a different mode of 
action or by careful dose-titration. Type-B ADE or ‘bizarre effects’ on the other hand 
are unexpected and rare reactions. They are often caused by immunological 
reactions to a drug and may be associated with previous exposure to similar drugs. 
In Type-B ADE even low doses of a drug can affect multiple organs and lead to 
severe complications. Type-B ADE are sometimes also referred to as ‘idiosyncratic 
ADE’ and are usually not predictable and therefore difficult to prevent. Additional 
classifications for ADE have been proposed such as Type C for ‘chronic effects’, 
Type D for ‘delayed’ effects, Type E for ‘end of treatment effects’ and Type F for 
‘failure of therapy’. Other classifications, e.g. according to affected organs or severity 
of the adverse event are also applied. Idiosyncratic adverse drug events are usually 
not preventable, and such non-preventable adverse drug events are designated 
adverse drug reactions (ADR).1 The WHO definition of ADR from 1972 differs from 
this definition as it does not relate to the preventability of an adverse event, but to the 
presence of a suspected causal relationship between a drug and an adverse event. 
The WHO definition will not be used in this thesis - with exception of the study on 
herbal drugs which exclusively used data from the WHO pharmacovigilance 
database.2,3  
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2.1.1. Detection and Quantification of Adverse Drug Events 
There are three different principal sources of information to detect ADE: clinical trials, 
individual cases as reported to and collected in pharmacovigilance systems and 
pharmacoepidemiological studies (see also Figure 1).3 Each source has its inherent 
strengths and limitations. 
Clinical trials have major limitations mentioned above, but their typical strengths 
include the quantification of absolute and relative risks of frequent ADE. 
In the postmarketing phase spontaneous reports to pharmacovigilance systems allow 
the identification of rare ADE and are important for the generation of safety signals 
that may warrant increased surveillance or further studies. If an ADE is observed and 
a causal relationship to a recently administered drug is suspected, it must be 
reported to pharmacovigilance systems. Certain ADE are of special interest, e.g. 
those that are life-threatening, causing permanent harm or leading to otherwise 
clinically relevant consequences. In order to evaluate whether a drug is responsible 
for an observed adverse event, ADE reported to pharmacovigilance-systems are 
subject to a standardized causality assessment as defined by the WHO applying a 
semi-quantitative categorization, i.e. the criteria of the Council for International 
Organizations of Medical Sciences CIOMS.2 Because of the unknown number of 
exposed patients and the unknown true number of ADE (due to underreporting),an 
exact quantification of the risk for an ADE is not possible based on 
pharmacovigilance data. 
Pharmacoepidemiological studies can provide a reliable quantitative assessment of a 
drugs’ risks and benefits representative of real-life settings. Due to the lack of 
randomized treatment assignment their biggest challenge is the control of 
confounding, but sophisticated study designs and data analysis techniques can 
minimize the influence of potential confounders. Pharmacoepidemiological studies 
complement the other sources of information in drug safety by allowing quantitative 
analyses of potential safety-issues that could not be studied in clinical trials due to 
ethical or financial restrictions. 
Once an ADE is established as a previously unknown or underestimated risk 
associated with the use of a drug, changes to its label may be required or the drug 
may even be withdrawn from the market.3  
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2.2. Medication Errors, Adverse Drug Events and Risk Factors 
Any failures in the drug treatment process that may lead to harm to the patient are 
designated as medication errors (ME).4 They represent the most common 
preventable cause for ADE and are a major public health burden. While mistakes 
regarding storing and preparation of drugs are also considered ME, errors during the 
prescription or administration process account for about 90% of preventable ADE.5,6 
Inadequate prescriptions, i.e. with risks clearly exceeding benefits, are of special 
interest: these decision-based ME are theoretically preventable by automated alerts 
that trigger upon ordering of the medication. For the studies subsequently presented 
in this thesis, a ME is primarily considered any drug prescription or administration 
featuring an unfavorable benefit-risk situation. While it is usually difficult to predict the 
risk for Type B ADE, there are well-established risk factors for more frequent Type A 
ADE and it is easier to quantify the risks of most potential ME. Being dose 
dependent, Type A ADE are more common in patients continuously exposed to the 
responsible drug or in situations where unintentionally high drug concentrations are 
achieved. Such overdosing may result from: 
- Reduced drug clearance without accordingly reduced dosing, e.g. in patients with 
renal- or hepatic failure. 
- Exposure to pharmacokinetic DDI that significantly reduce the enzymatic 
metabolism of certain drugs. 
- Known genetic polymorphisms that affect patients’ metabolic capacity, i.e. slow 
metabolizers for which certain drugs’ dosing need to be carefully titrated. 
Additionally, pharmacodynamic DDI can increase the risk for Type A ADE, e.g. by 
synergistic modes of action that result in an increased overall toxicity for certain 
organs. Further risk factors for ADE may not be directly responsible for the 
development of an ADE but are strongly associated with the previously mentioned 
factors, e.g. high age, polymorbidity and pronounced polypharmacy. They can also 
predispose to more severe outcomes of an ADE and are characteristic for frail 
patients in whom an especially careful benefit-risk assessment is warranted. 
Any ADE that results from DDI or lack of dose adjustments denotes a ME that is 
clinically relevant and therefore represents a suitable target for preventive 
countermeasures such as automated alerts.3  
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2.2.1. Applying Pharmacovigilance and Pharmacoepidemiology 
The distinction of clinically relevant ‘true’ from irrelevant ‘formal’ ME remains a major 
challenge. ‘True ME’ have a high risk to harm patients, whereas in case of only 
‘formal ME’ a drug may not be used according to its label, but the risk for an ADE is 
acceptable as compared to the drug’s benefits. However this discrimination is crucial 
if efficient preventive measures are to be developed and implemented. And while the 
presence some patient-related risk factors for an ADE can be easily identified and 
may therefore be used systematically to assess the clinical relevance of a ME, there 
are other important circumstances that need to be considered as well in order to 
validate a potential ME: 
- Prescribers may carefully monitor drug levels or the patients’ reactions. 
- Exceedingly high doses are administered in patients with established poor drug 
absorption or genetically determined ultra-fast metabolism. 
- Ongoing use of drugs only intended for short-term administration may be preferable 
to applying drugs from other classes that are not well tolerated in certain patients 
- Drugs and doses may be used in palliative situations when their benefits 
categorically outweigh any risks. 
 
 
 
 
Figure 2: Potential and Relevant Medication Errors, Preventable and Generally Non-preventable 
Adverse Reactions and Intercepted Errors. Modified according to: Preventing Medication Errors: Quality 
Chasm Series, The National Academic Press 2007, page 36.
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In order to quantify potential and true ME, their relevance can be validated in the 
individual clinical context by applying concepts and methods from 
pharmacoepidemiology and pharmacovigilance. These methods allow the 
identification of validated ME, e.g. by using administrations of highly specific 
antidotes as a marker for cases with manifest drug-related ADE. Cohort studies can 
provide the absolute number of patients exposed to ME, with and without 
consideration of relevant risk factors. Formal causality assessment on a case-by-
case basis according to the WHO / CIOMS criteria is an important tool to prevent 
overestimation of the relevance of ME and concurrently manifest adverse events by 
excluding ADE that are not primarily related to a ME but were unavoidable, i.e. an 
ADR. In the context of this thesis and the therein-presented studies, ‘clinically 
relevant ME’ refers to ME that have management implications, i.e. that the 
responsible prescriber would need to take an action because the ME has a relevant 
potential for harming the patient as compared to the benefits of the assessed 
medication. 
 
 
2.2.2. Medication Errors in Hospitals: Common 
The internationally renowned, government-independent non-profit Institute of 
Medicine (IOM) in the USA published a comprehensive report on medication errors in 
2006. It defines medication error as “any error occurring in the medication-use 
process. Examples include wrong dosage prescribed, wrong dosage administered for 
a correctly prescribed medication, or failure to give (by the provider) or take (by the 
patient) a medication”.1 The IOM estimates that on average, hospitalized patients are 
exposed to at least one ME per day, which they deem a conservative assessment 
subject to considerable variation depending on the studied institution and applied 
criteria. According to the IOM, ME occur most frequently upon prescription and 
administration but can also concern drug dispensing or inadequate monitoring of the 
patient’s response to the drug. Also the lack of prescribing drugs known to be 
effective in patients with established conditions (e.g. heart failure) are known 
medication errors. Insufficient prophylaxis against infections or thrombosis can also 
be considered a ME in hospitalized patients. Data published from a survey 
representative for the Swiss general population from 2011 revealed  that 
approximately 5 % were exposed to a ME in the last year. Regarding medical errors, 
33 % of the patients indicated that the incidence occurred during a hospitalization. 
Length of hospital stay, has been found to be associated with the exposure to these 
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self-reported medical errors.7 Evidence from studies performed in Swedish and 
Spanish hospitals indicates that 
30 % and 37 % of the adverse events in hospitals are caused by the patients’ 
medication, and that of those 27 % and 35 %, respectively, could have been 
prevented.8,9 In the setting of a tertiary care hospital exposure to potential ME is likely 
higher compared to primary care: risk factors such as polymorbidity and subsequent 
polypharmacy are very common. In addition, prescribers are working in highly 
specialized units that are often unfamiliar with drugs prescribed by other specialists. 
The Swiss Federal Office of Public Health published a fact sheet in 2015 that 
confirmed that ME are a major concern for patient safety and that they occur 
especially frequent upon hospital admission and discharge.10 Finally, the “incidence 
of ME varies substantially depending on the clinics: they are much more frequent in 
intensive care units, for example, where patients receive an average of 25 
medications per day, and much less of a problem in areas such as obstetrics, where 
medications are generally avoided.”(Bates and Slight 2014).11 
 
 
2.2.3. Medication Errors in Hospitals: Expensive 
As with any health-related costs, it is challenging to assess the financial impact of 
ME in hospitals. Additional in-hospital costs have been estimated to amount to 
approximately $ 3000 - $ 6000 for a preventable ADE, a figure which is based on US 
healthcare data from 1993 and only includes costs occurring in the hospital12,13 A 
more recent study using an advanced methodology and data from 2005 and 2006 
basically confirmed these findings with estimated incremental treatment costs of 
approximately $ 8500 per ME. Data from Swiss studies suggests yearly costs of 70 - 
100 millions due to ME.14 Similar to the incidence of ME, the related costs of ME may 
vary greatly, depending on the studied setting: a recent study performed in patients 
with kidney transplants reveal median incremental costs consequent to ME of 
approximately $ 18000 with an interquartile range of approximately 
$ 3000 - $ 56000.15  
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2.2.4. Medication Errors in Hospitals: Harmful 
Although potential ME are common, most of them do not result in harm. However 
those ME that cause ADE in hospitalized patients frequently occur at the prescribing 
or administering stages,11 such as potentially avoidable DDI that are responsible for 
5 - 26 % of the observed ADE in hospitals.16-18 The IOM has estimated that ME 
cause one of 131 outpatient and one of 854 inpatient deaths.19 Approximately 1 - 7 % 
of the patients exposed to ME have been identified to experience an associated 
ADE.12,20,21 Further studies from the Netherlands have assessed medication as cause 
of permanent injury or death in 2.6 - 10.5 %.22 
In clinical practice ME related to DDI may often not be recognized as a cause for an 
ADE, subsequently leading to an underestimation of ME-associated harm. 
Additionally, overseeing a ME as a cause of or significant contributor to an ADE may 
trigger a prescription cascade: signs and symptoms of an ADE that is not recognized 
as such are treated with another drug that also has the potential to cause DDI and 
further or even more severe ADE.23 
 
 
 
Figure 3: Example for a Preventable ME that Caused an ADE as Detected in the Study Presented in 
section 3.5., i.e. Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care Hospital: 
Administration of Contraindicated Comedication and QT-Prolongation. 
The patient received the antibiotic drug ciprofloxacin on day 2 in addition to his current medication. 
Through a pharmacokinetic drug-drug interaction the muscle-relaxing drug tizanidine accumulated, 
causing pronounced hypotension (nadir systolic / diastolic blood pressure: 71 / 47 mmHg), with nausea, 
severe dizziness and fatigue. Instead of replacing, reducing or stopping tizanidine, the prescribers first 
stopped the antihypertensive therapy with lisinopril and then prescribed etilefrine, a sympathomimetic 
drug to treat the ADE. Fortunately the patient recovered without experiencing permanent harm. Figure 
adapted from the poster presented at the GSASA congress 2015 in Zurich.  
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2.3. Computerized Physician Order Entry 
Clinical information systems (CIS) may electronically document any information 
related to hospitalized patients including administrative information, lab data, 
prescribed and administered drugs, results from imaging procedures and admission- 
and discharge reports. All this information can be displayed in an electronic medical 
record. As an integral part of any CIS, computerized physician order entry (CPOE) 
systems principally refer to electronic prescription software. The abbreviation CPOE 
is sometimes also used as abbreviation for computerized provider order entry, since 
these systems may allow non-physicians to enter orders and usually are also used to 
record drug administrations and other procedures by additional caregivers. 
Compared to paper-based prescription, introduction of a CPOE has been shown to 
dramatically reduce certain ME, e.g. transcription errors, with an overall reduction of 
all ME by approximately 50 %.24 Results from any such assessment greatly depend 
on the parameters that defined the baseline for ME and need to be viewed in their 
methodological and institutional context. Some studies also found CPOE to allow or 
even promote new and potentially dangerous ME.6,25 
Besides the obvious advantages of CPOE in clinical practice, they can provide a 
database for highly efficient evaluations of prescription patterns, quality controls and 
many other automated administrative, logistic or financial analyses. 
Based on survey-data from 2011 that was published in 2013, approximately 40% of 
the Swiss hospitals used CPOE.5 
 
 
2.3.1. Clinical Decision Support Systems 
Clinical decision support systems (CDSS) may be defined as: “knowledge software 
designed to support clinical processes by linking patient data with medical and / or 
drug-specific knowledge and to provide advice for healthcare professionals while 
diagnosing, treating or monitoring patients” ( Carli-Ghabarou et. al. 2013).5 The 
information processed by CDSS may come from many different subsystems of a 
CIS: lab data, drug prescriptions and actual administrations, diagnoses, vital 
parameters such as blood pressure or heart rate and any other information that can 
be documented in a standardized structured way, i.e. not as free text or images, but 
in pre-defined terms. Considering that much of this information may constantly 
change during a hospitalization, quality and timeliness of the data is essential for 
providing reliable, useful and comprehensive decision support.26 
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Approximately half of the hospitals that feature CPOE also use integrated CDSS, i.e. 
20% of all hospitals, as assessed in 2011.5 Among these CDSS, most provided 
passive, i.e. on-demand or non-interruptive, decision support for pairwise drug-drug 
interactions (DDI), pre-set protocols to facilitate prescriptions of common drug 
combinations and provided information on the hospital formulary. Despite the 
potential for a multitude of comprehensive preventive alerts, only a very limited 
fraction of the available patient-related data was used by the CDSS to prevent ME.5 
 
 
 
 
Figure 4: Potential Contribution of Computerized Physician Order Entry (CPOE) and Clinical Decision 
Support Systems (CDSS) to Increase Drug Safety. The overall comprehensive integrated information 
system managing all related data is designated Clinical Information System (CIS). Adapted from: 
Arzneimitteltherapie, Wirksamkeit, Sicherheit - Praktische Anwendung, page 31. 
 
Some CDSS are available for free, can be used on mobile devices and use public 
knowledge databases. Depending on the hospital, CDSS may also be highly 
customized to local clinical practice and adapted to the used CPOE and CIS using 
specially developed interfaces. The knowledge displayed in CDSS and used for 
decision support algorithms may be based on textbooks, official national and 
international summary of product characteristics (SPC), peer-reviewed scientific 
publications or pharmacovigilance data. Comparisons of individual CDSS have 
shown considerable differences regarding the identification, categorization and 
concordance with clinical assessment of DDI.27-29 
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2.3.2. Alerts: Acceptance, Fatigue and Override Rates 
Advice regarding the prevention of ME that were identified by a clinical 
pharmacologists or clinical pharmacists or can improve patient-related outcomes and 
reduce costs.30-32 If such advice is provided face-to-face, e.g. during clinical ward 
rounds, it can reach rates of acceptance by clinicians of approximately 80 - 90 %, 
depending on the setting, threshold for- and nature of such advice.33,34 Automated 
alerts for the prevention of ME also need to accurately identify clinically relevant ME 
and provide meaningful management-suggestions such as therapeutic alternatives, 
adequate dose reductions or practical recommendations regarding therapeutic drug 
monitoring.26 However, despite intense and ongoing efforts to improve CDSS, alerts 
from fully automated systems are usually only accepted by clinicians in 
approximately 5-10 %.35 Physicians who are repeatedly exposed to high numbers of 
alerts - which are consistently not leading to clinical problems - may develop a 
“pragmatic skepticism regarding the daily false alarms” issued by CDSS, especially 
for DDI (Briant et al. 2014).36 They acknowledge that high alert override rates may 
lead to potentially valuable warnings being ignored,37,38 but state that due to the 
excessively high number of alerts they receive, the warnings are perceived to be of 
low-value in general.39,40 Although the sheer number of alerts is usually found to be 
associated with their poor acceptance by clinicians,41 the concept of alert fatigue has 
recently been challenged - suggesting that there are other, more important factors 
that lead to alert fatigue, foremost the perceived lack of clinical relevance. Besides 
the involved drugs and type of DDI, factors associated with alert override include age 
of physicians and patients, unit of hospitalization, number of daily alerts and lengths 
of patients’ stay. 36,42 Unfortunately, “current CDSS have been found to be least 
effective when they should protect the most vulnerable patients from the most 
dangerous medications, particularly when they are prescribed by the most 
inexperienced physicians” (Knight et al. 2015).35 
Pharmacotherapy with DDI that trigger automated alerts has been studied 
extensively, and usually similar drugs appear in the ‘top 20’ that generate the most 
alerts.43 However there is little evidence that alerts regarding these drugs are 
associated with a higher acceptance or clinical relevance.35 Most commonly used 
CDSS for the prevention of DDI do not consider the drugs dose and are not (yet) 
using additional patient-specific information, which is likely a key factor in order to 
improve the current lack of their clinical relevance.26,29 Alerts by CDSS are usually 
divided into categories of severity and include information on the background, 
mechanism, recommendation and consequence of potential ME.44   
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Recently published recommendations suggest that alerts for DDI should contain the 
following 7 information components: “drugs involved, seriousness, clinical 
consequences, mechanism of the interaction, contextual information / modifying 
factors, recommended actions and evidence” (Payne et al. 2015)26  
Irrespective of the role of alert fatigue, inappropriate alert overriding for DDI and drug 
related allergies has been reported to be involved in ADE.45,46 Numerous 
recommendations for improving alerts exist, and these suggest a categorization of 
alerts according to the severity of the expected outcome into non-interruptive alerts 
vs. high priority DDI that should not be allowed at all.47-49 Furthermore it has been 
suggested that the alerts should be presented using “a consistent use of terminology, 
visual cues, minimal text, formatting, content, and reporting standards to facilitate 
usability” (Briant et al. 2014).36  
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2.4. Comprehensive Hospital Drug Safety Concept 
2.4.1. Hospital Safety Culture 
Improving hospital drug safety requires more than just a fully automated CDSS, it 
requires the implementation of a comprehensive concept. The following section 
provides a conceptual framework developed by Stefan Russmann that links previous 
research in this field with clinical practice, existing safety systems and 
complementary methods from pharmacovigilance and pharmacoepidemiology to be 
applied by local drug safety experts.50  
 
 
 
Figure 5: Broad Integrative Concept for Improved Hospital Drug Safety, closed quality loop concept 
adapted from: Russmann S, Praxis und Perspektiven der Arzneimittelsicherheit: Pharmakovigilanz, 
Pharmakoepidemiologie und elektronische Expertensysteme, Ärztewoche 2012 and described in SNF 
Project Nr. 143867.  
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2.4.2. Selection and Planning 
Performing regular safety ward rounds contributes to the promotion of a local hospital 
safety culture. Individually reviewing the pharmacotherapy of currently hospitalized 
patients for ME and using their electronic medical records to detect ADE may not be 
efficient for reducing the absolute number of ME. But the highly specific 
recommendations contribute to individual patient’s safety and a generally increased 
awareness of the prescribers for drug safety issues. Although not formally evaluated, 
it was observed that regular participation during ward rounds at the Department of 
Neurology resulted in an increased reporting rate of ADE and persistent 
implementation of orally communicated recommendations, such as the age-
dependent use of zolpidem or the use of pantoprazole instead of omeprazole in 
patients using clopidogrel. 
Face-to-face recommendations to the prescribers, local clinical expertise and regular 
safety ward rounds make major contributions to the detection of ME. Seeing patients 
exposed to potential ME in their comprehensive clinical context and subsequent 
feedback from the prescribers is invaluable for the development of highly specific 
alert algorithms. Detecting and reporting ADE during ward rounds contributes to 
proactive pharmacovigilance and may aid to the further detection of clinically relevant 
ME. Finally, participation of local drug safety experts in ward rounds also allows to 
complement the detection of “near misses” that are not reported to critical incident 
reporting systems (CIRS), i.e. an anonymized system where hospital personnel can 
voluntarily report potential or actual safety issues. 
 
 
2.4.1. Implementation 
CIS that feature integrated, currently available CDSS may allow a highly sensitive 
on-demand screening for potential ME related to DDI in individual patients. Typically, 
these systems rarely use additional patient-specific information and are not setup to 
issue automated alerts for all potential ME due to the above-described issue of 
overalerting. A recent system analysis at the University Hospital of Zurich revealed 
that the integrated on-demand CDSS for DDI is rather used almost exclusively as a 
screening tool by local drug safety experts such as clinical pharmacologists and 
pharmacists whereas physicians treating patients and prescribing their 
pharmacotherapy in first-line rarely use it.34 
Complementary to such highly sensitive but insufficiently specific and efficacious 
screening tools, additional highly specific alerts have recently been developed and 
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implemented. Besides the automated alerts regarding acetaminophen and metformin 
subsequently presented in this thesis, warnings regarding the prevention of venous 
thromboembolism51,52, drug-induced hyperkalemia53 and methotrexate overdosing54 
have recently been successfully implemented. Besides specifically developed 
automated alerts personal teaching of prescribing physicinas regarding current safety 
issues, e.g. drug-induced QT-prolongation, remains an important local contribution 
for the improvement of drug safety. 
 
 
2.4.2. Creation of a Local Pharmacoepidemiological Database 
A major part of the presented thesis is the creation of a local 
pharmacoepidemiological database based on an existing electronic CIS (see also 
chapter 2.1). It used the following data extracted on patient-level: 
- ATC-code of relevant drugs to identify the used drugs 
- Name of applied drug as entered into the electronic medical records 
- Date and time of drug administrations 
- Applied drug dose 
- Route of administration such as oral, intravenous, etc. 
- Potassium and creatinine levels (lab data) 
- Age of patient in years at time of administration of drug (in 2011 or 2012) 
Incomplete raw data after an automated extraction, such as missing ATC-codes, may 
be complemented manually for some of the parameters, especially if free-text entries 
were allowed upon prescribing drugs in the CPOE. Implausible data, such as non-
physiological potassium values due to haemolysis, also need to be corrected or 
marked as missing if applicable. The database then must be thoroughly checked for 
quality, plausibility and validity. Two principal methods can be applied in order to 
characterize prescription patterns and to detect potential ME: Either fully automated 
mass-analyses can be performed by using commercially available CDSS. This 
requires a high quality of the extracted data and a corresponding interface for the 
CDSS to process the data. Alternatively, individual algorithms for the detection of 
potential medication errors can be developed, programmed and then applied to the 
data. Such an approach allows a more specific assessment of certain ME. 
Data extracted from the CIS can also be used to monitor effectiveness of preventive 
strategies, e.g. by assessing the prevalence of potential ME before and after 
implementation of a newly implemented alert.  
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Figure 6: Interventional Pharmacoepidemiology, concept adapted from: Cartwright on Russmann in 
International Innovation 2014.55 Processes involved for developing and implementing new preventive 
algorithms based on the raw data extraction of documented drug administrations in the hospitals CIS. 
 
 
2.4.3. Evaluation 
In order to validate potential ME regarding their clinical relevance, retrospective 
review of selected original electronic medical records in the CIS is necessary. This 
allows the detection of expected ADE known to be associated with the respective 
ME. By specifically searching for an ADE during an appropriate time window 
following the potential medication error, clinical relevance can be established. If for 
example, an overdose of paracetamol, a drug known for its dose-dependent liver-
toxicity, is detected, a specific search for signs (i.e. increase in liver enzymes) and 
symptoms (e.g. nausea, vomiting, jaundice) of liver disease in the days following the 
overdose can be performed. Additionally, by reviewing the electronic medical record 
of the exposed patient, certain risk factors for paracetamol toxicity that are not 
available in the pharmacoepidemiological database, such as alcoholism or anorexia, 
can be detected. Furthermore, alternative causes for liver disease such as viral 
hepatitis or exposure to other liver-toxins must be assessed and excluded. 
Subsequently a formal causality assessment according to WHO / CIOMS can be 
performed for a semi-quantitative assessment of the relation of ME and ADE.   
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Figure 7: Detail of the Setup for Validating Potential ME as Detected in a Hospital 
Pharmacoepidemiological Database: Assessment of clinical relevance, associated ADE and 
preventability by compilation of additional parameters as documented in the patients’ electronic medical 
records. 
 
Because the structured data that was extracted for the compilation of the 
pharmacoepidemiological database does not encompass all information that is 
available and necessary for the validation of potential ME, the following additional 
parameters can be of special interest and may need to be compiled manually or have 
to be extracted additionally in order to efficiently validate the clinical relevance of 
potential ME: 
 
- Indication of studied drugs 
- Liver function parameters 
- Plasma protein levels 
- Heart- and muscle parameters 
- Glucose and lipid-metabolism parameters 
- Endocrine functions 
- Drug levels from therapeutic drug monitoring, substance- and alcohol levels 
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- Blood gas analyses 
- Infectious parameters 
- Immune system parameters 
- Blood pressure and heart rate 
- ECG readouts 
- BMI / nutritional status 
 
The validation of potential ME therefore requires access to the patients’ complete 
electronic medical records including entry- and discharge reports, anesthesia- and 
surgical reports, counsels, nurses’ and physicians’ ward round reports and any other 
notes documenting suspected or confirmed ADE. Only such an encompassing 
analysis allows consideration of the clinical context of potential ME and provides the 
information to understand the physicians benefit-risk assessment upon prescription. 
 
 
2.5. Ethical Considerations and Data Protection 
The studies presented in this thesis were primarily of non-interventional, 
observational character using only already existing data. Nevertheless, any such 
study is subject to the new Federal Act on Research involving Human Beings, also 
known as Human Research Act, HRA) as effective since January 2014.56 Therefore 
the research presented in this study needed to be re-assessed by the ethics 
committee in 2014 to which the following statements were presented: 
 
The primary goal of the presented studies was the identification and subsequent 
reduction of risks associated with pharmacotherapy, and they are expected to 
improve patient safety. Since all analyses were performed with already collected data 
that was further used for research, the retrospective analyses for potential 
medication errors posed no immediate risk for patients. A potential risk would have 
been an unwanted identification of project participants from published results. 
However, only anonymous results were published. Unwanted identification of 
patients was also prevented by the coding of the dataset, e.g. study-files did not 
contain any non-encoded information such as patient's names or initials. No patient-
related data was distributed by Email. Any data displayed in any presentations, 
scientific conventions or in scientific journals was anonymous. For the identification 
of patients in the CIS the case number issued by the University Hospital Zurich 
served as a unique patient identifier.  
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Data generation, transmission, storage and all analysis of health related personal 
data for the presented study strictly followed current Swiss legal requirements for 
data protection and were performed according to the Ordinance HRO Art. 5. All 
investigators were fully aware that the presented studies involved potentially 
sensitive and strictly confidential personal data. All investigators were healthcare 
professionals (pharmacists and clinical pharmacologists) who are generally bound to 
medical confidentiality and additionally signed an obligation featuring the following 
measures to guarantee data protection: 
 
- Access to computers must be password protected, see criteria for these passwords 
below 
- Access to all study files must be password protected, see criteria for these 
passwords below 
- All passwords will be changed every 6 months and must contain at least 12 digits 
and must contain at least one special character and must at least contain one 
capitalized letter and must contain at least one non-capitalized letter and must 
contain at least one number. 
- Passwords must never be passed-on, or stored, or saved in any way. 
- Whenever the workplace is left, the computer(s) must be locked. 
- If accessing patient's original electronic medical records, only potentially error-
specific parameters and reports will be reviewed. 
- All study related data must exclusively be handled and stored on encrypted data 
mediums. The BitLocker technology of Microsoft and the FileVault technology of 
MacOS were used to guarantee a high level of data-protection. 
 
Every access to every document within the patients’ electronic medical records was 
automatically logged by the CIS of the University Hospital of Zurich to prevent abuse. 
No coding in the formal sense of HRO Art. 26 and 27 was applicable. However, 
patients’ numbers are used to combine parameters from drug prescriptions, 
documented drug administrations, lab data and other data (such as ECG, blood 
pressure, co-morbidities etc.) for all analyses and therefore represent a code to 
identify a patient. In order to identify a patient through the patient’s number one 
needs access to the clinical information system of the University Hospital of Zurich. 
However, access to the clinical information system is only granted under the 
condition of medical confidentiality. The patients' numbers therefore serve as 
encoding to prevent unauthorized patient identification: Without access to the clinical 
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information system under the condition of medical confidentiality it is not possible to 
determine the patients' identities with the patient number. 
 
The validation of potential medication errors in selected electronic medical records 
required review of non-anonymized existing data. Such additional non-routine access 
to the already existing data imposes no direct burden or risk to the patient. The 
investigators act under their routine mandate of pro-active quality-management of 
hospital pharmacotherapy and patient safety. There was no special risk or burden for 
vulnerable patients. Indeed, in some situations such patients may have been 
especially vulnerable for certain medication errors and were therefore expected to 
benefit at least as much or even more than other patients. 
 
In summary the performed studies presented no risk for the patients. To the contrary, 
the primary aim of the studies was the systematic identification of risks and 
subsequent improvement of patient safety. Furthermore the performed studies are 
beneficial for the hospital and its prescribers due to a pro-active quality management 
that aimed for a reduction of ME and associated ADE, reduces avoidable costs, and 
prevents potentially considerable reputational damage. 
 
The cantonal ethics committee, the hospital’s medical director and the hospital’s 
center for clinical research had approved the data extraction, the setup and analysis 
of the anonymized pharmacoepidemiological database, and the access to original 
medical records for research purposes.  
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3. Results 
3.1. Creation of a Pharmacoepidemiological Database: Highly Efficient 
Pharmacoepidemiological Analysis of Hospital Drug Prescriptions with 
Target Identification for the Prevention of Medication Errors 
 
3.1.1. Authors 
David Niedrig, Caroline Schmidt, Stefan Russmann 
 
3.1.2. Remarks 
Significance for thesis & notable features 
The creation of a local pharmacoepidemiological database was the first milestone of 
this thesis and literally represents the (data)base for all subsequent studies regarding 
ME in hospitalized patients hereafter presented. It is designed for analyses by highly 
efficient algorithms that can detect a multitude of potential ME. Developing, 
programming and validating these algorithms provided crucial information to prioritize 
targets for further in-depth analyses of potential ME. 
The raw data is derived from multiple components of the CIS of the University 
Hospital Zurich, i.e. KISIM by Cystec AG. Whereas the raw data extracted from the 
CIS comes from an underlying relational database where the data is arranged and 
stored in a large number of different files that can be linked with a unique patient 
identifier, the master file of the pharmacoepidemiological database was created as a 
single file using STATA (STATA Corporation, College Station, TX, USA). Of special 
interest not only drug prescriptions by the physician, but also their actual 
administration (or non-administrations) confirmed by the drug-administering staff are 
documented in the underlying raw data. Only confirmed drug administrations were 
used for all further analyses. At the time of extraction no comparable database was 
available for such a highly efficient, systematic exploration of potential ME.  
 
Contributions of the author of this thesis 
David Niedrig compiled, structured and formatted the database, developed the 
algorithms and performed database- and algorithm validation. 
 
Publication 
This study was presented as an abstract and poster at the Pharmacology & 
Toxicology Poster Day 2013 in Zurich.  
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3.1.3. Background 
Electronic medical records with electronic drug prescription provide new 
opportunities for pharmacoepidemiological analyses in health care systems. 
Very large automated pharmacoepidemiological databases have recently been 
established in several countries and become a leading source of information for 
research and public health decision-making. In contrast, the potential 
of “small-scale hospital pharmacoepidemiology” for local improvements of 
pharmacotherapy, pharmacoeconomics and particularly drug safety is not sufficiently 
used.  
 
3.1.4. Objectives 
Therefore, we developed new concepts and solutions for data management, 
analyses and proactive quality and safety management of hospital pharmacotherapy. 
 
3.1.5. Methods 
We obtained comprehensive anonymous patient level drug prescription data plus 
selected laboratory results of a tertiary care hospital for the calendar years 2011 and 
2012. Raw data comprising >7 million lines of text were reformatted, additional codes 
included and variables generated, and the data was optimized for fast and efficient 
analyses. Data management and analyses were executed on a high performance 
computer system and software that can simultaneously run on four processor 
cores. For our final analyses we included only those prescriptions that were flagged 
as actually administered to patients. 
 
3.1.6. Results 
We successfully completed the development, quality control and validation of a 
pharmacoepidemiological hospital prescription database. Subsequently, we 
developed analytical protocols for the ultra-fast identification of potential medication 
errors that allowed us to retrospectively find and validate a considerable number of 
specific real-life contraindicated and/or critical prescriptions in individual patients. 
Sensitivity and specificity regarding clinical relevance was enhanced by the use of 
additional patient-level laboratory data and repeated validation procedures. 
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3.1.7. Conclusions 
The presented methods and results provide the basis for the development and 
implementation of automated alerts that are sufficiently sensitive and specific for use 
in clinical practice. These are expected to achieve effective and efficient 
improvements of pharmacotherapy leading to a relevant reduction of medication 
errors and associated adverse reactions and costs.  
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3.2. Retrospective Mass-Analysis of Hospital Prescription Data for 
Medication Errors and Subsequent Development of Highly Specific 
Alert Algorithms with ID PHARMA CHECK® 
 
3.2.1. Authors 
David F. Niedrig, Andre Sander, Daniel Diekmann, Stefan Russmann 
 
3.2.2. Remarks 
Significance for thesis & notable features 
This study complements the initial individual analyses of individually selected 
potential ME by using a commercially available CDSS. Unlike many other currently 
available CDSS, ID PHARMA CHECK® considered the dose of the drugs, available 
lab data and codes for diagnoses, allowing an assessment of potential drug-disease 
related ME and many other fully automated analyses. As expected, such a highly 
sensitive screening generated an excessively high number of alerts that were 
summarized in 166 individual lists. Focusing on the list with ME with a clear potential 
for severe ADE, i.e. the list of absolutely contraindicated DDI, the manufacturer of the 
CDSS was provided with suggestion regarding the improvement of the specificity of 
these alerts. 
 
Contributions of the author of this thesis  
David Niedrig contributed to the assessment of the clinical relevance of detected 
potential ME and the subsequent development of suggestions to improve the alerts 
for contraindicated DDI. 
 
Publication 
This Study was presented as a poster and abstract in 2015 at the International 
Conference of Pharmacoepidemiology (ICPE) in Boston, MA, USA. It was also 
presented as a poster, abstract and oral presentation at the Congress of the Swiss 
Association of Public Health Administration and Hospital Pharmacists (GSASA) 2015 
in Zurich where it won the award for the congress’ best oral presentation. 
It is published as a congress abstract in: Pharmacoepidemiology and Drug Safety 
2015; 24: 65-66. 
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3.2.3. Background 
Clinical decision support software (CDSS) identifies potential medication errors in 
individual patients, typically with a focus on high sensitivity but low specificity 
regarding clinical relevance. Our concept of Interventional Pharmacoepidemiology 
applies real-life data to retrospective analyses of medication errors in order to identify 
targets for highly specific alerts that can effectively prevent the most relevant 
medication errors. 
 
3.2.4. Objectives 
We aimed to identify and quantify medication errors that actually occur in clinical 
practice and use the results for programming CDSS alert algorithms with high 
specificity regarding clinical relevance. 
 
3.2.5. Methods 
We applied real-life data from a clinical information system of a tertiary care hospital 
covering one calendar year and approximately 250’000 patient-days and 3.5 million 
individually documented drug administrations along with laboratory results and 
medical diagnoses to retrospective mass-analyses using the ID PHARMA CHECK® 
database. Identified potential medication errors were quantified and used for the 
development of refined alert algorithms. 
 
3.2.6. Results 
ID PHARMA CHECK® identified several ten thousand potential drug interactions, 
contraindications and dosing errors, and assigned them to formal severity categories. 
There were 3’460 cases of 64 distinct formally contraindicated drug interactions. 
Among those we evaluated 48 interactions as clinically relevant and suitable for 
display of highly specific alerts within clinical information systems; 32 alert algorithms 
require retrieval and implementation of current patientspecific information such as 
laboratory results in order to reach high specificity. The resulting algorithms were 
subsequently programmed for routine use with ID PHARMA CHECK®.  
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3.2.7. Conclusions 
Application of CDSS to large prescription datasets can retrospectively identify 
medication errors and therefore play an important role for proactive quality 
management of pharmacotherapy in hospitals. Vice versa systematic mass analyses 
of real-life data can support CDSS development with a focus on clinical relevance 
and efficacy.  
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3.3. Second-generation antipsychotics in a tertiary care hospital: 
prescribing patterns, metabolic profiles, and drug interactions 
 
3.3.1. Authors 
David F. Niedrig, Carmen Gött, Anja Fischer, Sabrina T. Müller, Waldemar Greil, 
Guido Bucklar, Stefan Russmann 
 
3.3.2. Remarks 
Significance for thesis & notable features 
This study was the first in-depth analysis of potential ME related to a specific group 
of drugs within the local hospital pharmacoepidemiological database and the CIS of 
the University Hospital Zurich. Besides analyzing well known and potentially severe 
ME related to DDI it also takes advantage of ethically approved access to original 
electronic medical records. Equally important drug safety aspects of 
pharmacotherapy with second-generation antipsychotic drugs, i.e. their potential to 
induce metabolic complications, was explored and a significant potential for 
improvements regarding their monitoring and management was detected. 
Obtaining reliable information on the indication of drugs is challenging in 
pharmacoepidemiology. This study features the categorized indications of second-
generation antipsychotics as documented in the patients’ original medical records 
and revealed a high proportion of off-label use for these drugs. Additionally, 
laboratory data on multiple metabolic parameters and leukocytes was systematically 
evaluated in order to assess monitoring for ADE. 
 
Contributions of the author of this thesis 
David Niedrig contributed to the study design, algorithm development and 
programming, data compilation and interpretation, and wrote the first version of the 
manuscript. 
 
Publication 
This Study has been published as original research in: International Clinical 
Psychopharmacology: January 2016; 31(1): 42-50.  
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3.3.3. Background 
Second-generation antipsychotics (SGA) are primarily indicated for the treatment of 
schizophrenic disorders, and some SGA such as quetiapine, risperidone, aripiprazole 
and lurasidone also have labeled indications for other psychiatric disorders including 
bipolar diseases. A pronounced rise in the use of antipsychotics has been observed 
over the past 20 years, which is mostly attributable to the increased prescription of 
SGA since their introduction in the mid 90's.57,58 Off-label use has also been reported 
to be very common for SGA in clinical practice, e.g. for the treatment of dementia 
and symptoms of anxiety, sleep and neurotic disorders.59,60 
SGA are not generally more effective than first-generation antipsychotics (FGA),61 
but they have a distinct profile of adverse effects. Fewer extrapyramidal adverse 
effects are traded for more metabolic adverse effects including weight gain, 
hyperglycemia and dyslipidemia.62,63 The risk of such metabolic abnormalities 
appears to vary for different SGA, and to lower this risk has been an important goal 
in the development of more recently approved substances such as aripiprazole, 
ziprasidone and lurasidone.64,65 Nevertheless, current drug labels as well as 
international guidelines recommend that the metabolic profile should be monitored 
before and during treatment with SGA, particularly in patients with preexisting 
metabolic disorders and other cardiovascular risk factors.66 Therefore, studies on the 
frequency of metabolic disorders, their management, and the actual implementation 
of labeled recommendations in SGA users in routine clinical practice are an 
important contribution for the post-marketing evaluation of real-life risks and benefits 
of SGA.57,66 
Furthermore, SGA can prolong the QTc interval with an associated increased risk of 
ventricular arrhythmia and sudden cardiac death.63,67 The risk for cardiac and other 
adverse drug reactions may be enhanced by clinically relevant drug interactions. 
Pharmacokinetic interactions may occur with inducers or inhibitors of the CYP450 
enzyme system and may alter the plasma concentrations of SGA such as the 
CYP3A4 substrates clozapine and quetiapine. Pharmacodynamic interactions may 
also be problematic, e.g. when several QT-prolonging drugs are combined. 
Consequently a considerable number of drug combinations with SGA are labeled as 
formally contraindicated, and other potentially interacting combinations have labeled 
warnings requiring that the risk-benefit ratio must be carefully assessed, and that 
close monitoring for adverse events must be performed. However, there is limited 
real-life data on the actual prevalence and clinical relevance of potentially interacting 
co-medication with SGA. 
 
42 
3.3.4. Objectives 
The trend towards increased use of SGA may also be observed in tertiary care 
hospitals where patient characteristics, indications and usage patterns are different 
compared to psychiatric hospitals or outpatient settings. The current study therefore 
had three main aims that we wanted to evaluate in the real-life setting of a tertiary 
care hospital. First to explore prescribing patterns of SGA, second to analyze how 
metabolic complications of patients receiving SGA are monitored and managed, and 
third to analyze the prevalence, monitoring and clinical relevance of potential drug 
interactions with SGA. 
 
3.3.5. Methods 
We conducted a retrospective observational study that analyzed SGA use and 
related population characteristics, metabolic profiles, concomitant pharmacotherapy 
and adverse events in a tertiary care hospital. The cantonal ethics committee, the 
hospital’s medical director and the hospital’s center for clinical research had 
approved the data extraction, the setup and analysis of the anonymized 
pharmacoepidemiological database and the access to original medical records for 
our research studies. 
 
Data Source 
For the current study we used comprehensive data for the time period from 1 
January 2011 to 31 December 2012 from our anonymized pharmacoepidemiological 
database containing information on demographics, laboratory results and electronic 
drug prescriptions for hospitalized patients of a tertiary care hospital. The hospital 
provides medical care to a population of about 1.5 million people and has 
approximately 1000 beds and 40 clinical specialty divisions.  The database builds on 
information extracted from the hospital’s electronic clinical information system 
featuring electronic drug prescription (computerized physician order entry, CPOE). 
The system records not only prescriptions but also a confirmation for each drug’s 
actual administration (and its time) to the patient. Our analyses included all 
prescriptions with documented administration from all hospitalized patients during the 
study period, except patients staying at intensive care units, where CPOE has not yet 
been introduced. We performed extensive reformatting, quality controls and matching 
of ATC codes to ensure identification of all administered drugs and their doses. In 
addition, we also compiled information on indication for SGA use, metabolic 
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parameters, blood counts and ECG QTc-interval measurements for the population of 
the current study. 
 
Study population and design 
Selection of the study population and the overall study design are presented in 
Figure 8. All patients with at least one full calendar day of hospitalization and a 
documented administration of SGA were included into the study. The admission and 
the discharge day of each hospitalization were excluded from our analyses because 
drug administrations and events are not comprehensively recorded in the available 
data for those days. We included all SGA from our dataset that were defined as such 
by the US Federal Drug Administration and the German Psychiatrist's 
Association,68,69 i.e. amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, 
quetiapine, risperidone and ziprasidone. Within the resulting study population we 
analyzed the following outcomes: 1. SGA usage patterns; 2. metabolic parameters 
and their monitoring; 3. potential drug-drug interactions including associated adverse 
events and their monitoring. 
 
SGA usage patterns 
SGA use was descriptively analyzed regarding patient characteristics, primary 
diagnoses, indications and prescription frequencies. Indications for SGA use were 
determined according to all related information found in the electronic medical 
records and classified to one of the following 7 categories: 1. endogenous psychotic 
disorders (schizophrenia, schizoaffective disorders, other psychotic non-organic 
disorders); 2. exogenous psychotic disorders (substance induced behavior disorder 
or delirium, delirium in acute organic psychosis, dementia in chronic organic 
psychosis); 3. affective disorders (bipolar disorder with depressive or manic episode, 
depression); 4. personality disorder (borderline, emotional instability, other); 5. 
anxiety disorder and state of anxiety or excitation; 6. sleeping and eating disorders; 
7. other indications (hallucination, agitation, somatogenic psychic disorder).  
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Figure 8: Study design and selection of the study population 
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Metabolic parameters and their monitoring 
Metabolic abnormalities were defined according to a published joint scientific 
statement of six international organizations and assessed for each hospitalization. 
Mean blood pressure was calculated from the first documented measurement on 
each patient day with SGA exposure for each hospitalization.70 Body mass index 
(BMI) was calculated from the first recorded measurement of height and weight 
during hospitalization or, if not available, derived from other information on nutritional 
status in the medical records. For metabolic laboratory values (blood glucose, 
HbA1c, and blood lipids) all measured values during hospitalization were recorded. 
We identified treatment with antidiabetic, antihypertensive and lipid-modifying drugs, 
and we also recorded treatment with glucocorticoids because these may increase 
blood glucose and therefore act as confounders. 
 
Potential drug interactions and associated adverse events 
We identified potential drug-drug interactions of SGA with all contraindicated drugs 
that were administered on the same calendar day. For that purpose we first 
established a list of formally contraindicated drugs according to the manufacturers’ 
national drug labels for each SGA (www.swissmedicinfo.ch). For labeled 
contraindications that referred to specific drug characteristics (e.g. drugs known to 
cause QTc prolongation, agranulocytosis or drug metabolizing CYP450 enzyme 
inhibition) we established lists of drugs fulfilling those criteria. These were based on 
comprehensive available scientific information sources including specialized drug 
interaction software and websites.71-75 For drug combinations with SGA that were not 
formally contraindicated but require careful monitoring of the QTc-interval according 
to the manufacturers’ national drug labels, we established additional lists with the 
drugs’ Anatomical Therapeutic Chemical Classification System (ATC) codes. For all 
potentially interacting drugs that prolong QTc interval or inhibit CYP450 enzymes, we 
only included drugs that exhibit a strong or moderate effect according to at least one 
reference. We only analyzed hospitalizations where at least one strong CYP450 
inhibitor or at least two moderate CYP450 inhibitors were co-administered at the 
same patient day. For every hospitalization for which we identified potential 
interactions with SGA, we validated whether any adverse events known to be 
associated with those interactions had actually occurred, and whether active 
monitoring for such events had been performed. We reviewed the original medical 
records for any events and clinical diagnoses that might represent an adverse drug 
reaction caused by the respective drug interactions. We checked whether ECG was 
monitored on days on which SGA were co-administered with contraindicated or 
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potentially critically interacting drugs. Monitoring for QTc-prolongations was 
evaluated by reviewing all ECGs of all hospitalizations with QTc-prolonging drug 
combinations in the medical records. A QTc-interval >450 ms in men and >460 ms in 
women is associated with increased cardiovascular mortality and defined the upper 
limit of normal by the American Heart Association, and this was accordingly 
categorized as "abnormal QTc" for the present study. A QTc-interval >500 ms 
significantly increases the risk of Torsades de Pointes tachycardia and sudden 
cardiac death  and was defined as "long QTc" in our study.73,76 
For contraindicated drug combinations with an increased risk of agranulocytosis that 
had been co-administered for at least three consecutive days, we reviewed results of 
all available blood counts. Neutropenia was defined as a neutrophil blood count <1.4 
G/l, and agranulocytosis as a count <0.5 G/l. 
If an associated adverse event was documented, three investigators with special 
expertise in pharmacovigilance and formal causality assessment (SR, DN and CG) 
assessed the causal relationship of the adverse event with the interacting drug 
combination using internationally standardized WHO/CIOMS causality assessment 
criteria.2 
 
Data analysis 
Data analysis is descriptive with presentation of results in tables as appropriate. 
Frequencies were calculated regarding individual patients, hospitalizations and 
patient days. Data management and analyses were done using STATA Version 13.1 
(STATA Corporation, College Station, TX, USA). 
 
3.3.6. Results 
The source population consisted of 53081 individual hospitalized patients 
contributing 82358 hospitalizations and 495813 patient-days. After exclusion of 
patients without SGA use and less than at least one full calendar-day of 
hospitalization the resulting study population included 872 patients with 1136 
hospitalizations and 9165 patient-days. In total, we analyzed the circumstances of 
14214 single SGA administrations (Figure 8). 
 
SGA usage patterns 
Characteristics of the study population are presented in Table 1. Females accounted 
for SGA use in 50.9% of the hospitalizations and 60.1% of the patient-days. Mean 
and median duration of hospitalization for all patients on SGA was 14 and 7 days, 
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respectively. Quetiapine was the most frequently used SGA in the studied population 
(46.7% of all patient-days with SGA exposure), followed by olanzapine (27.9%) and 
risperidone (13.7%). The three most frequently co-administered drug groups with 
SGA were analgesics (ATC class N02, 8210 patient days, 10.0% of all co-
administered drugs), antithrombotic agents (ATC class B01, 7485 patient days, 
9.2%) and psychoanaleptics (ATC class N06, 6027 patient days, 7.1%). The small 
unit of psychiatry and psychotherapy (accounting for only 2.2% of all patient-days in 
the source population) expectedly had the highest prevalence of SGA use (on 23.8% 
of the patient-days in the unit) and accounted for 19.3% of all patient-days with SGA 
exposure in the hospital. The remaining 80.6% of SGA-use occurred in non-
psychiatric units. In the neurology unit SGA were used on 6.5% of the patient-days, 
representing 14.5% of all SGA use at the hospital. Besides the psychiatry and 
neurology units, we found the highest prevalence of SGA exposure in the units of 
plastic surgery and infectious diseases (on 4.2% and 4.0%, respectively, of all patient 
days in these units). Due to their large absolute number of hospitalizations, trauma 
surgery and internal medicine were also major contributors to SGA use in the studied 
population (9.8% and 9.5%, respectively, of all patient-days with SGA exposure in 
the hospital). Indications for SGA prescriptions were identifiable in 899 
hospitalizations and are also presented in Table 1. Affective disorders (31.9%), 
endogenous psychotic disorders (24.9%) and exogenous psychotic disorders 
(19.6%) were the three most frequent documented indications for SGA. Most 
common primary diagnoses of patients receiving SGA during hospitalization 
according to their documented ICD-10 codes were cerebrovascular disorders (ICD 
codes I60-I69, 4.2%), behavioral disorders with somatic disorders and factors (ICD 
codes F50-F59, 3.9%) and other forms of heart disease (ICD codes I30-I52, 3.9%). 
During most hospitalizations only one SGA was administered per day, but in 5.7% of 
the analyzed hospitalizations two SGA were administered simultaneously on at least 
one patient-day, and in 0.2% three SGA.
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TABLE 1: Characteristics of the study population of second-generation 
antipsychotics (SGA) users in a tertiary care hospital 
 
Characteristics Hospitalizations n (%) 
Patient-days 
n (%) 
   
All analyzed SGA users 1136 (100) 9165 (100) 
   
 
Sex   
    Female 578 (50.9) 5506 (60.1) 
    Male 558 (49.1) 3659 (39.9) 
   
Age (years)   
    <18 8 (0.7) 131 (1.4) 
    18-44 280 (24.6) 3119 (34.0) 
    45-64 430 (37.9) 2787 (30.4) 
    65-84 357 (31.4) 2766 (30.2) 
    ≥85 61 (5.4) 362 (3.9) 
   
Use of different SGA1   
    Quetiapine 599 (52.7) 4276 (46.7) 
    Olanzapine  234 (20.6) 2543 (27.9) 
    Risperidone 170 (15.0) 1214 (13.7) 
    Clozapine 115 (10.1) 866 (9.4) 
    Aripiprazol 51 (4.5) 379 (4.1) 
    Amisulpride 22 (1.9) 102 (1.1) 
    Paliperidone 13 (1.1) 49 (0.6) 
    Ziprasidone 1 (0.1) 11 (0.1) 
   
Units with highest use of SGA2,3   
    Neurology 167 (14.7) 1325 (14.5) 
    Trauma surgery 134 (11.8) 900 (9.8) 
    Internal medicine 92 (8.1) 873 (9.5) 
    Neurochirurgy 66 (5.8) 455 (5.0) 
    Plastic surgery 66 (5.8) 457 (5.0) 
   
    Psychiatry-psychotherapy 37 (3.3) 1772 (19.3) 
   
Documented indications for SGA use4   
    Affective disorders 287 (31.9) 1897 (24.3) 
    Endogenous psychotic disorders 224 (24.9) 1439 (18.5) 
    Exogenous psychotic disorders 176 (19.6) 1278 (16.4) 
    Sleeping disorders and eating disorders 84 (9.3) 2110 (27.1) 
    Anxiety disorders 57 (6.3) 593 (7.6) 
    Other 48 (5.3) 361 (4.6) 
    Personality disorders 23 (2.6) 115 (1.5) 
   
    No indication documented5 237 (20.9) 1372 (15) 
       
 
Legend for Table 1 
1 Total of hospitalizations / patient-days exceeds number of analyzed hospitalizations / patient-days due 
to use of multiple SGA on some patient-days. Total of % therefore exceeds 100. 
2,3 % of hospitalizations: hospitalizations of all analyzed cases with use of SGA (1136 hospitalizations) 
    % of patient-days: prevalence of patient-days on these wards with use of any SGA in 2011 and 2012 
4 % of hospitalizations where indication was available (899 hospitalizations) 
5 % of hospitalizations with no indication of all hospitalizations (1136) / % of patient-days with no 
indication of all patient-days (9165)  
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Metabolic parameters, their monitoring and treatment 
The monitoring of metabolic parameters in SGA users as well as the prevalence of 
metabolic disorders among those where monitoring was performed are presented in 
Table 2. Blood glucose and lipid profiles had not been determined in 24.3% (n=276) 
and 75.4% (n=856) of SGA users, respectively. In 58.3% of the cases in which any 
lab data on any metabolic status was available we found at least one metabolic 
abnormality. Furthermore, SGA users with prevalent metabolic disorders had no 
pharmacotherapy for those conditions in 63.4% of the hospitalizations with 
hyperglycemia, as well as in 70.8% and 37.1% with dyslipidemia and hypertension, 
respectively. Among all patients on SGA, 244 (28.0%) met the diagnostic criteria for 
metabolic syndrome as defined by a consensus group.70 There were no apparent 
major differences in the prevalences of metabolic abnormalities between users of 
different SGA.
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TABLE 2: Prevalence of metabolic disorders and of their monitoring and 
pharmacotherapy 
 
 Absolute and relative frequencies  
Total number of hospitalizations with SGA use  1136 (100%) 
  
Obesity  
 No weight, height or nutritional status documented 256 (22.6% of total) 
 BMI based on weight, height or additional data 880 (77.4% of total) 
        BMI ≥25 kg/m²     459 (52.1% of those with available BMI) 
        BMI ≥30 kg/m² (=“obesity”)     203 (23.1% of those with available BMI) 
  
Glycemic disorder  
 Blood glucose not measured 276 (24.3% of total) 
 Blood glucose values available 860 (75.7% of total) 
        Glycemic disorder1     194 (22.6% of those with glucose values) 
              Pharmacotherapy for diabetes         71 (36.6% of those with glycemic disorder) 
              Glucocorticoids co-administered         36 (18.6% of those with glycemic disorder) 
  
Lipid disorder  
 Blood lipids not measured 856 (75.4% of total) 
 Blood lipid values available 280 (24.6% of total) 
        Lipid disorder2     171 (61.1% of those with lipid values) 
             Pharmacotherapy for lipid disorder         50 (29.2% of those with lipid disorder) 
  
Hypertension  
 Blood pressure not measured 26 (2.3% of total) 
 Blood pressure values available 1110 (97.7% of total) 
     Hypertension3     410 (36.9% of those with blood pressure values) 
         Pharmacotherapy for hypertension         258 (62.9% of those with hypertension) 
 
Legend for Table 2 
Criteria for metabolic disorders were defined according to published consensus guidelines77 
1 Fasting glucose ≥5.6 mmol or spontaneous glucose ≥11.1 mmol/l or HbA1c > 5.9% (women) or >5.7% 
(men) 
2 Total cholesterol ≥5 mmol/l and/or HDL cholesterol ≤1mmol/l and/or triglycerides ≥1.7mmol/l 
3 Systolic blood pressure ≥130 or diastolic blood pressure ≥85 mmH
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Potential drug interactions and associated adverse events 
Prevalence of combined use of SGA with drugs that are formally contraindicated, as 
well as with drugs that are not formally contraindicated but have a labeled high risk of 
QTc-prolongation in combination with SGA, are presented in Table 3. 
Co-administration of formally contraindicated drugs with SGA was present on 614 
patient-days emerging from 112 hospitalizations. Among those we identified 3 cases 
with clinically relevant adverse events that were related to the respective co-
administrations with a “probable” causal relationship according to WHO/CIOMS 
causality criteria: one case with neutropenia and two with abnormal QTc. However, in 
51 of the 112 hospitalizations, there was no monitoring of blood count or QTc 
interval, so the presence of related adverse events cannot be excluded for those 
patients. Co-administrations of QT-prolonging combinations that were not formally 
contraindicated but potentially dangerous were identified in 176 hospitalizations. 
Among those, ECG-monitoring for adverse events was performed in only 18 patients 
(10.2%), and among those we identified 2 cases with abnormal QTc and a “probable” 
causal relationship with the critical combination. 
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TABLE 3: Drug interactions with SGA including their monitoring and associated adverse events 
 
 Overall use of 
involved SGA 
Use of SGA with 
contraindicated drug 
Use of contraindicated 
combination without 
monitoring 
Adverse events 
 Hospita-
lizations 
(n) 
Patient-
days (n) 
Hospita-
lizations 
(n) 
Patient-
days (n) 
Hospitalizations (n) Case description 
Potentially interacting drug 
combinations 
      
a) Combinations with a labeled contraindication 
Clozapine and drugs that increase 
the risk of agranulocytosis 
 
114 866 68 349 15 Neutropenia under combined therapy of clozapine with metamizole 
(neutrophils 1.01 G/l, normal >1.4 G/l). Full recovery to normal values 
after stop of metamizole. 
Quetiapine and CYP3A4 inhibitors 
 
599 4276 30 182 25 Abnormal QTc (463 ms) under combined therapy of quetiapine with 
voriconazole. Therapy continued, no follow-up ECG. 
 
Amisulpride and drugs with high or 
moderate potential of QTc-
prolongation 
 
22 102 13 72 10 One case identified as part of internal quality management, but no 
documented consent from patient to publish details from original medical 
records for research purposes. 
Ziprasidone and drugs with high or 
moderate potential of QTc-
prolongation 
 
1 11 1 11 1 0 
b) Combinations with a labeled high risk of QT-prolongation without formal contraindication 
Clozapine and drugs with high and 
moderate potential of QTc-
prolongation 
 
115 866 58 388 51 Abnormal QTc (477 ms) under combined therapy of clozapine with 
quetiapine, sertindole, lithium, amitriptyline and ciprofloxacin. Therapy 
continued, no follow-up ECG. 
 
Risperidone and drugs with high 
and moderate potential of QTc-
prolongation 
 
170 1214 111 647 100 Abnormal QTc (487 ms) and symptomatic supraventricular extrasystoles 
under therapy with risperidone 5 hours after intravenous administration 
of ondansetrone. Normal QTc (435 ms) after stop of ondansetrone. 
 
Paliperidone and drugs with high 
and moderate potential of QTc-
prolongation 
13 49 7 31 7 0 
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3.3.7. Conclusion 
The current study analyzed SGA use and associated metabolic profiles and potential drug 
interactions including their outcomes in a real-life inpatient setting of a tertiary care hospital. 
We found that 1.6% of all hospitalized patients received SGA, about one third of SGA users 
were 65 years and older, more than 80% of SGA were prescribed to patients admitted for 
non-psychiatric primary diagnoses, and that cerebrovascular disorders and heart disease 
ranked among the top three primary admission diagnoses. These features characterize SGA 
users in a tertiary care hospital as a high risk population for cardio- and cerebrovascular 
events and frequent polypharmacy, the latter predisposing to a high risk for drug 
interactions.27 Quetiapine and olanzapine accounted for the majority of SGA use, and both 
are well known to cause metabolic disorders and QT-prolongation. The predominant use of 
quetiapine is also in line with previous reports.58,78 and quetiapine is subject to drug 
interactions with inducers and inhibitors of CYP3A4 drug metabolizing enzymes. Inducers 
and inhibitors of CYP450 enzymes are frequently used in tertiary care hospitals including 
e.g. several antiepileptic, antifungal and antibiotic drugs. Aripiprazole with its presumably 
lower risk for causing adverse metabolic effects was not as frequently used, but it is also 
subject to interactions via CYP2D6 and CYP3A4, and QT-prolongation is a well-known 
associated risk. Clozapine accounted for 10% of SGA use, and bone marrow suppression is 
a major concern in addition to its associated risk of interactions and QT-prolongation. This 
risk is further elevated in combination with other drugs that may cause neutropenia and 
agranulocytosis such as metamizole, methotrexate or azathioprine and requires regular 
blood count monitoring. Ziprasidone and lurasidone, which are comparable to aripiprazole in 
that they are also considered to have a low risk of metabolic disorders, were not (yet) 
marketed in Switzerland during the study period. 
Furthermore, documented indications suggest that off-label prescriptions account for a major 
part of SGA use in the studied setting, particularly for sleeping and eating disorders. This is 
in accordance with other studies in different populations and confirms the common practice 
of prescribing SGA beyond their labeled indication.59,60 In some cases off-label use may 
constitute an avoidable risk and a formal and clinically relevant medication error. However, 
off-label use as well as the co-prescription of potentially interacting drugs does not 
necessarily have to be problematic, sometimes even for formally contraindicated drug 
combinations. In many instances it can be justified if possible risks are thoroughly weighed 
against benefits, and if there are no alternatives and no clear evidence regarding clinical 
relevance of risks. Nevertheless, such practice always implies at least an increased burden 
of responsibility for the prescribing physician and the hospital where it occurs. Therefore, in 
all those instances at least monitoring for adverse events should be taken seriously. From a 
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broader perspective the growing number of persons exposed to SGA call for population 
studies assessing risks vs. benefits of SGA use, also for disorders other than psychosis and 
for unlabeled use.57 
Our study provides a two-sided answer to these issues. On the one hand it is reassuring that 
we identified only five adverse events related to drug interactions with SGA use in our study 
population over a time of two calendar years, and none of them was irreversible. Given our 
thorough case-by-case evaluation we also consider it as unlikely that we missed serious 
adverse drug reactions caused by interactions with SGA during hospitalization. On the other 
hand, we found that among SGA users with according monitoring the prevalence of 
hypertension, hyperglycemia, dyslipidemia and BMI ≥30 kg/m² was 36.9, 22.6, 61.1 and 
23.1%, respectively, and that of those 37.1, 63.4 and 70.8%, respectively, had no 
pharmacotherapy for these conditions. Equally important we also found that a large 
proportion of SGA users had insufficient monitoring regarding adverse metabolic effects and 
QT-prolongation. Furthermore, if problematic medication is continued, adverse events 
occurring after discharge may have remained undetected, particularly arrhythmia associated 
with QT-prolongation and long-term adverse effects of metabolic disorders.67 Indeed, in our 
function as a regional pharmacovigilance center we regularly receive reports of avoidable 
serious and sometimes fatal adverse drug reactions (particularly torsade de pointes 
tachycardia) associated with drug interactions with SGA, underlining their clinical relevance. 
Severe adverse effects of SGA and a need for improved monitoring in clinical practice are 
also documented in the literature. Girardin and colleagues reported fatal cases of arrhythmia 
associated with SGA in their well-designed prospective study.79 And a study in a Swiss 
psychiatric outpatient setting systematically screened SGA users for dyslipidemia and 
reported a prevalence of 21 to 27%.80 The low proportion of SGA users that are screened for 
metabolic abnormalities in the present study is also in line with results from a recent meta-
analysis, which found that monitoring of metabolic risks in patients treated with antipsychotic 
medication is routinely performed in only 69.8 % (blood pressure), 44.3% (glucose), 59.9% 
(triglycerides) and 41.5% (cholesterol).66 And in the CATIE landmark trial, 89% of patients 
with dyslipidemia and 45% of patients with diabetes were untreated.81 
For the interpretation of our findings, one has to consider some limitations imposed by the 
data source and study design. We followed patients during hospitalization, but for the time 
before admission and after discharge we were not able to collect comprehensive information 
on the duration of SGA use, metabolic profiles and adverse events. Therefore, frequencies 
of metabolic abnormalities must be seen as cross-sectional prevalence data, whereas no 
conclusions can be drawn on their incidence and causal relationship in relation to SGA use. 
Furthermore, some patients may have received SGA only for a short time, which may still be 
relevant for the risk of QT-prolongation, but less so regarding adverse metabolic outcomes. 
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In addition prevalent metabolic abnormalities do not always equal an indication for 
pharmacological treatment. Nevertheless and regardless of these limitations, we must 
assume that monitoring of the QT interval and/or metabolic parameters, management 
implications such as glucose and lipid lowering pharmacotherapy or switching to other SGA 
and avoiding interacting drug combinations would have been indicated in a considerable 
proportion of SGA users. 
 
From a pragmatic perspective one must realize that it is a challenging task to achieve 
changes in the prescribing and monitoring of SGA therapy with the aim to avoid critical 
interactions and adverse effects in clinical practice. However, the introduction of electronic 
medical records with electronic drug prescription provides new opportunities for efficient and 
effective clinical decision support. Today we already screen pharmacotherapy for potential 
medication errors in the electronic medical records at our institution as part of our proactive 
quality management efforts. We have also started the implementation of semi-automated 
screening algorithms for specific medication errors into our electronic prescribing system, 
followed by recommendations on patient management in case of clinical relevance. 
Implementation of such clinical decision support measures for SGA could help preventing 
associated adverse effects. Switching to SGA that are less likely to cause metabolic 
complications in patients with metabolic abnormalities has shown promising results and - if 
sufficient efficacy can be achieved - should be preferred over adding pharmacological 
treatment against the metabolic complications, which adds to the patients’ drug burden and 
may compromise their compliance.62,82,83 
 
In conclusion, our findings suggest that serious adverse effects of drug interactions with 
SGA are very rare, but also that a considerable proportion of patients with SGA exposure is 
neither adequately monitored nor managed, particularly concerning metabolic risks and QT-
prolongation. New opportunities through electronic medical records with highly specific 
electronic clinical decision support may play a key role for proactive safety management of 
antipsychotic and other pharmacotherapy in the future. 
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3.4. Benzodiazepine Use During Hospitalization: Automated Identification of 
Potential Medication Errors and Systematic Assessment of Preventable 
Adverse Events 
 
3.4.1. Authors 
David F. Niedrig, Liesa Hoppe, Sarah Mächler, Heike Russmann, Stefan Russmann 
 
3.4.2. Remarks 
Significance for thesis & notable features 
This study represents another in-depth analysis of a drug class with a well-known potential 
for ADE and delivers highly efficient and effective algorithms to detect clinically relevant ME. 
With a systematic assessment of the preventability of validated ME it provides additional 
insights for the development of subsequent automated alert algorithms. This study used the 
administration of a specific antidote (flumazenil) as a surrogate to detect cases with ADE of 
high clinical relevance. In addition, sophisticated algorithms considered multiple relevant DDI 
with respect to secondary metabolic pathways of the studied drugs, even if they were 
administered one or two days before the administration of the studied benzodiazepines. 
 
Contributions of the author of this thesis 
David Niedrig contributed to the study design, algorithm development and programming, 
data compilation and interpretation, and wrote the first version of the manuscript. 
 
Publication 
This Study has been submitted as original research for publication to PLOS ONE and is 
currently in the review process under consideration for publication.  
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3.4.3. Background 
Benzodiazepines and “Z-drug” GABA-receptor modulators (BDZ) are among the most 
frequently used drugs worldwide.84-86 Most BDZ have labeled indications for anxiety and 
sleeping disorders.86,87 BDZ are also used as add-on therapy for psychiatric disorders, for 
pre-operative sedation, and for the prevention and treatment of seizures. They are frequently 
prescribed in hospitals, institutions and community dwelling settings and generally 
considered safe because of their tolerability and wide therapeutic range.88,89 According to 
their summary of product characteristics (SPC), BDZ are not destined for long-term use. 
However, long-term treatment with BDZ is frequent and may lead to tolerance and 
addiction.85,86,90 Tolerance and abuse are well known challenges, for which health authorities 
and insurances often impose special regulations with regard to BDZ prescribing, dispensing 
and compensation.91 
Severe ADE of BDZ, particularly at higher doses, include musculoskeletal weakness with 
falls and subsequent injuries92-94, respiratory depression95-98, paradoxical reactions99-102, or 
increased and prolonged CNS depression.87 If BDZ toxicity is suspected, the antidote 
flumazenil can quickly antagonize the effects of BDZ, and it can also be used in emergency 
care to diagnose BDZ overdose.87 Due to altered pharmacokinetics and increased intrinsic 
sensitivity, BDZ use can be particularly problematic in elderly and frail patients.103,104 
Restrictive use of BDZ and low dosing at treatment initiation is therefore recommended 
according to their labels and expert consensus guidelines such as the “Beers” and “Priscus” 
lists, or the “STOPP” criteria.105-107 Some drugs may also inhibit the metabolism of BDZ via 
cytochrome P450 (CYP) enzymes and therefore cause relevant pharmacokinetic drug-drug-
interactions (DDI).108 Concomitant use of strong CYP inhibitors may lead to five- to tenfold 
increase in BDZ exposure and consequently to dose-dependent adverse drug effects (ADE). 
Furthermore comorbidities such as acute renal impairment or respiratory disease can render 
patients more vulnerable to adverse effects of BDZ. 
Prevalence of formally inadequate use of BDZ has been studied before.90,92,109,110 For 
example Zint et al. found the concomitant use of BDZ with relevant CYP inhibitors to be 
associated with an increased risk of hip fractures in a community dwelling setting.92 
However, there is a paucity of data on the clinical relevance and preventability of BDZ-
related potential medication errors (ME) in tertiary care settings. In such a setting patients 
may frequently be polymorbid and frail, have additional risk factors for BDZ-induced ADE, 
and may also be more often exposed to potent CYP inhibitors as compared to patients in 
other settings. 
In order to analyze and improve drug safety in a tertiary care hospital, we created a local 
pharmacoepidemiological database with data extracted from the hospital’s clinical 
information system. This setup enables us to perform highly efficient retrospective local 
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evaluations of potential ME and associated ADE in clinical practice, and subsequently 
develop recommendations for the effective prevention of ADE.  
 
3.4.4. Objectives 
The current study aimed to perform such analyses and quantify the following outcomes: 1. 
BDZ usage patterns and algorithm-detected potential ME, 2. Validated ME with 
inappropriate BDZ use in a patient’s individual clinical context, 3. Associated ADE. 
3.4.5. Methods 
Study population, data collection and study design 
Selection of the study population and overall study design are presented in Figure 9. We 
conducted a retrospective observational study that analyzed BDZ usage patterns, potential 
ME, and associated ADE in a tertiary care hospital with about 1000 beds and 40 clinical 
specialty divisions. The cantonal ethics committee, the hospital’s medical director and the 
hospital’s center for clinical research had approved the data extraction, the setup and 
analysis of the anonymized pharmacoepidemiological database, and the access to original 
medical records for our research.  
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Figure 9: Study design and selection of the study population 
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Data Source 
We used our previously described comprehensive pharmacoepidemiological database 
containing information on demographics, laboratory results and electronic drug prescriptions 
for hospitalized patients of a Swiss tertiary care hospital covering admissions from the 
calendar years 2011 and 2012.111 ICD-10 codes of primary diagnoses were available for the 
calendar year 2012. For the validation of potential ME and ADE we had access to and 
reviewed comprehensive electronic medical records. 
 
Prevalence of BDZ use and algorithm-based identification of potential medication errors 
We developed and programmed algorithms for the automated detection of patient-days with 
potential medication errors. Algorithms were customized and validated separately for each 
studied BDZ. Our analyses focused on frequently used BDZ with potentially relevant 
interactions via CYP metabolism or with altered pharmacokinetics in renal impairment. 
Clobazam was not analyzed using automated algorithms because in the studied setting it is 
predominantly used for treating post-stroke epilepsy and delirium, two conditions where 
doses are individually titrated.87 In order to identify BDZ administrations and potentially 
interacting co-medication we used ATC-codes provided by the WHO.112 For each BDZ 
undergoing CYP-metabolism we established a list of relevant CYP inhibitors. These were 
based on the drugs’ summary of product characteristics (SPC) and comprehensive scientific 
information sources including specialized drug interaction software and websites.113-116 The 
final lists only included CYP-inhibiting drugs with a strong effect according to at least one 
reference. Certain strong CYP 3A4 inhibitors (e.g. clarithromycin) are known to irreversibly 
bind and inactivate CYP 3A4 enzymes, which results in reduced metabolic capacity until 
they are synthesized de novo.116,117 Other strong CYP 3A4 inhibitors do not exhibit such a 
mechanism-based effect (e.g. itraconazole), but their metabolites may continue to inhibit 
CYP metabolism for some time after cessation.118,119 Hence administration of strong CYP 
3A4 inhibitors was considered potentially relevant if it occurred on the same day or up to two 
days prior to BDZ administration and thus defined our search algorithms for patient-days on 
which BDZ administration represented a potential ME. Furthermore, we also identified 
concomitant use of multiple BDZ, additional relevant CYP inhibitors of CYP 2C19 or 1A2, 
and co-medication of opioids and muscle relaxants on the same day because those may 
contribute to BDZ associated ADE.120-122 
Because severe renal impairment is a formal contraindication to the use of lorazepam 
according to the Swiss SPC, we developed an algorithm that identified all patients with 
lorazepam administrations and a current eGFR < 30 ml/min. Furthermore, we also identified 
and validated any use of the specific BDZ antidote flumazenil as a possible indicator of BDZ-
related ME. 
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Validation of medication errors 
For every hospitalization, during which at least one day with a potential ME was identified 
using the algorithms described above, we validated the clinical context of the BDZ 
administrations. For that purpose we reviewed the original medical records and compiled the 
following additional information: indication, dose and route of administration of any BDZ, 
concomitant use of opioids and muscle relaxants, long-term oxygen therapy before and after 
BDZ administration, alcohol and substance abuse, relevant severe pulmonary and liver 
diseases, organ transplantation, renal replacement therapy, and whether the BDZ was 
administered in a palliative situation. Finally, we assessed the clinical relevance of these 
parameters for each patient’s individual clinical situation and determined whether BDZ 
administration was a validated ME, i.e. a more cautious or no use of BDZ with alternative 
therapy would have been indicated under the given circumstances (Table 4). 
 
 
Table 4: Qualitative impact of patient parameters on validation of ME 
 
  
Parameter Impact on assessment of ME 
Palliative situation Benefit outweighs risk, no ME ✖ 
Known BDZ abuse Tolerance of high BDZ dose, no ME ✖ 
Low dose of BDZ ≤ 1/2 of standard dose  ↓ 
≥ 1 other BDZ depending on number & dose  ↗ 
Respiratory insufficiency If severe  ↗ 
Hepatic impairment If severe  ↗ 
Age ≥ 65 & dose If initial dose not reduced  ↗ 
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Identification and assessment of adverse drug events 
For all validated ME we reviewed comprehensive original medical records for documented 
associated ADE including falls, severe and prolonged CNS depression, respiratory 
depression, apnea, paradoxical reactions, hypoxemia and coma. If an associated ADE was 
documented we assessed the causal relationship using standardized international 
WHO/CIOMS causality assessment criteria.2 We also assessed whether the associated ADE 
may have been prevented if a more cautious BDZ use had been recommended in time to 
the prescribers - such as an initially lower BDZ dose, omission of additional BDZ, reducing 
the amount of possible “on demand” BDZ prescriptions, or using a different BDZ without 
relevant CYP metabolism or one that can be used in renal impairment. 
 
Data analysis 
Data analysis was descriptive with presentation of results in tables as appropriate. 
Frequencieswere calculated with regard to individual patients, hospitalizations and patient-
days. Datamanagement and analyses were done using STATA Version 13.1 (STATA 
Corporation,College Station, TX, USA). 
 
3.4.6. Results 
Prevalence of BDZ use 
Among a source population of 53081 individual patients contributing 82074 hospitalizations 
and 495813 patient-days, we identified the study population of all BDZ users. Frequency of 
BDZ use, demographics and other characteristics of the study population are presented in 
Table 5. BDZ were administered on 23.2% of all patient-days, and at least once in 48.3% of 
all hospitalized patients and in 41.0% of all hospitalizations. Mean duration of hospitalization 
was 10 days (median: 5 days). Polypharmacy was frequent: on 42.0% of patient-days with 
any BDZ use 11 or more additional drugs were administered during hospitalization. 
Most frequently coded primary diagnoses for hospitalizations in 2012 with exposure to BDZ 
were “other forms of heart disease” (I30-I52, 4.1%), “benign neoplasms, except benign 
neuroendocrine tumors” (D10-D36, 4.1%) and “non-inflammatory disorders of female genital 
tract” (N80-N98, 3.1%). While lorazepam was the most frequently administered drug 
regarding patient-days (36.1%), midazolam was the most frequently used BDZ regarding 
individual patients (58.5%) and hospitalizations (52.1%). Zolpidem and oxazepam were also 
among the most frequently used BDZ. The use of some BDZ was marginally low, i.e. the 
combined use of flurazepam, zopiclone, flunitrazepam, clorazepate, lormetazepam, 
nitrazepam, temazepam, prazepam and ketazolam accounted for only 1.4% of all BDZ 
administrations. For zolpidem, pharmacokinetics and pharmacodynamics change with age, 
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and the recommended standard-dose is therefore reduced to 5 mg instead of 10 mg in 
patients ≥65 years of age. It should only be exceeded if efficacy is insufficient with 5 mg 
according to the SPC. Therefore, the age- and dose-distributions for zolpidem users are of 
particular interest. A mildly higher proportion of patient-days with zolpidem use occurred in 
patients ≥65 years of age compared to all BDZ users (45.8% vs. 41.1%, respectively). 
Among all patient-days with zolpidem use the daily dose was at least 10 mg per day in 
74.2%, but for the subpopulation of patients ≥65 years this was almost as high, i.e. 67.4%. 
This is equivalent to the impressive absolute number of 10749 days of zolpidem use with a 
dose ≥10 mg per day in patients ≥65 years in the studied population over two years. 
Administration of two different BDZ at the same day occurred in 7.1% of patient-days, and 
211 patients received three or more different BDZ on the same day, with a maximum of 5 
different BDZ. Co-medication with opioids was common (27.2% of patient-days on any 
BDZ), and on 4.3% of the studied patient-days two or more opioids were administered 
concomitantly. The departments with the highest proportion of BDZ use were the 
departments of reproductive endocrinology, diagnostic and interventional radiology, and 
radio-oncology with BDZ exposure on 45.4%, 34.7% and 33.7% of patient-days, 
respectively.
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Table 5: Characteristics of the study population 
 patient-days patients hospitalizations 
 n % n % n % 
All patients hospitalized in 2011 & 2012 495813  53081  82074  
       
Study population       
Administration of ≥ 1 BDZ 115150 100 25626 100 33661 100 
       
Age       
< 18 1037 0.9 677 2.6 803 2.4 
18 - 44 23831 20.7 7903 30.8 9701 28.8 
45 - 64 42938 37.3 8565 33.4 11632 34.6 
65 - 85 42736 37.1 7608 29.7 10450 31.0 
> 85 4608 4.0 873 3.4 1075 3.2 
       
Sex       
Male 58566 50.9 12860 50.2 17225 51.2 
Female 56584 49.1 12766 49.8 16436 48.8 
       
# of concomitant drugs I       
1 - 5 24113 20.9 8419 32.9 11430 34.0 
6 - 10 42723 37.1 7530 29.4 10138 30.1 
11 - 20 44861 39.0 6360 24.8 9007 26.8 
≥ 21 3453 3.0 3317 12.9 3086 9.2 
       
Most frequently administered BDZ II       
Lorazepam 41540 36.1 8704 34.0 10753 31.9 
Zolpidem 34841 30.3 7150 27.9 8873 26.4 
Midazolam 20362 17.7 14993 58.5 17549 52.1 
Oxazepam 11370 9.9 2487 9.7 2929 8.7 
Clobazam 5285 4.6 617 2.4 760 2.3 
Bromazepam 3232 2.8 453 1.8 541 1.6 
Diazepam 1736 1.5 324 1.3 402 1.2 
Alprazolam 1586 1.4 184 0.7 238 0.7 
Clonazepam 1549 1.3 196 0.8 248 0.7 
Triazolam 569 0.5 48 0.2 75 0.2 
       
Administration of ≥ 2 different BDZ       
Use of 2 BDZ 8119 7.1 2887 11.3 3339 9.9 
Use of 3 BDZ 386 0.3 205 0.8 221 5.9 
Use of ≥ 4 BDZ 23 < 0.1 17 0.1 17 < 0.1 
       
Concomitant use of opioids       
Use of 1 opioid 26351 22.9 6505 25.4 7976 23.7 
Use of 2 opioids 4953 4.3 1725 6.7 1978 5.9 
Use of 3 opioids 16 < 0.1 11 < 0.1 12 < 0.1 
       
Concomitant use of muscle relaxants 1860 1.6 322 1.3 1.3 1.1 
       
 
I Number of concomitant drugs was defined by individual ATC codes. 
II Considers use of multiple BDZ (benzodiazepines) on same patient-day.  
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Drug interactions, renal impairment and potential medication errors 
We identified 19 different BDZ that were administered in the studied setting of a tertiary care 
hospital. For 9 of those we identified possible clinically relevant CYP-related DDI, and for 
lorazepam we identified critical use in severe renal impairment. These patients were further 
analyzed for according potential ME and are presented in Table 6. Overall, our algorithms 
detected potential ME on 4237 patient-days, occurring during 1066 hospitalizations. This 
number is equivalent to an average of 5.8 potential ME regarding BDZ administrations on 
each calendar day in 2011 and 2012. Thereof 3372 patient-days with potential ME were due 
to concomitant administration of BDZ with strong CYP inhibitors. With the exception of 
midazolam, BDZ that were used more frequently also contributed more hospitalizations with 
potential ME. Most were contributed by zolpidem (2555 patient-days, 7.3% of all zolpidem 
patient-days) and midazolam (440 patient days, 2.2% of all midazolam patient-days). 
Alprazolam contributed only 191 patient-days but was the BDZ with the highest proportion of 
potential ME (12.0%). In addition we identified 1197 patient-days with potentially inadequate 
administrations of lorazepam in patients with severe renal impairment. Analysis of flumazenil 
use identified 15 patient-days (occurring during 13 hospitalizations) with potential ME related 
to BDZ use. 
Our algorithms detected sporadic patient-days with exposure to numerous studied drugs, 
e.g. patients concomitantly receiving 2 BDZ and 2 strong CYP 3A4 inhibitors and 2 opioids 
and a muscle relaxant. Other patients received up to 510 mg zolpidem per day, but 
according to the medical records very high doses were prescribed intentionally in patients 
with severe BDZ addiction, and we therefore did not classify those as ME. 
66 
Table 6: Algorithm-based identification of potential ME 
 
 
Mechanism for potential 
ME 
BDZ total use Potential ME 
patient-days hospitalizations patient-days % hospitalizations % 
        
Zolpidem 
Co-medication with 
≥ 1 strong 
CYP 3A4 
inhibitor 
 
34841 8873 2555 7.3 493 5.6 
MidazolamI 1401 /18989  17549 108 / 332 7.7 / 1.7 192 2.5 
Diazepam 1736 402 106 6.1 15 3.7 
Alprazolam 1586 238 191 12.0 16 6.7 
Triazolam 569 75 9 1.6 3 4.0 
Zopiclone 498 93 9 1.8 2 2.2 
Flunitrazepam 349 75 38 10.9 7 9.3 
Clorazepate 202 31 9 4.5 1 3.2 
Nitrazepam 145 20 0 - 0 - 
Prazepam 48 9 0 - 0 - 
        
Lorazepam Severe renal impairmentII 41540 10753 1197 2.9 324 3.0 
        
Flumazenil 
BDZ antidote 
(surrogate for BDZ overdose) 
15 13 15 100.0 13 100.0 
        
 
I Patient-days with p.o. / i.v. administration; hospitalizations with any i.v. or p.o. midazolam administration 
II In order to qualify as potential ME, in addition to eGFR < 30 ml/min, patients hat to EITHER receive lorazepam on ≥ 2 consecutive days OR to also have had co-administered 
≥ 1 additional BDZ 
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Validation of medication errors 
For 1064 available hospitalizations we assessed the clinical relevance of algorithm-identified 
potential ME. After consideration of the patients’ individual clinical situation we classified 205 
of those (19.3%) as validated ME (Table 7). Hospitalizations with potential ME concerning 
lorazepam use in severe renal impairment were classified as validated ME in 41.4%. Among 
potential ME in hospitalizations with exposure to zolpidem and strong CYP inhibitors, 56 
(11.4%) were classified as validated ME. Most cases were assessed as clinically relevant 
due to pre-existing respiratory insufficiency and old age. Among hospitalizations with 
potential ME concerning midazolam, which is frequently administered only once before 
interventions, only 6.3% were confirmed as validated ME. For three hospitalizations with a 
potential ME concerning triazolam, all were confirmed as ME while none out of 15 potential 
ME with diazepam appeared clinically relevant, mostly because the patients were known 
drug addicts. Similarly, the assessment of the clinical context of potential ME with zopiclone, 
flunitrazepam and clorazepate did not contribute any validated ME. 
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Table 7: Potential- and validated ME and associated ADE 
 
hospitalisations 
≥ 1 other BDZ 
(n) 
≥ 1 opioid 
(n) 
Indication I (n) Presence of risk factors (n) 
ADE II 
(n) n % sleep / anx / inv / unkn 
respiratory 
insufficiency 
severe liver 
disease 
Age ≥65 
  
         
Zolpidem potential ME 493 100 
       
 no ME 437 88.6 54 93 432 / 2 / 2 / 1 169 87 109 n.a. 
 validated ME 56 11.4 6 10 55 / 0 / 0 / 1 27 6 38 11 
   validated ME & associated ADE 11 2.2 1 2 11 / 0 / 0 / 0 5 0 5 - 
  
         
Midazolam potential ME 192 100 
       
 no ME 180 93.8 47 51 6 / 24 / 145 / 5 52 18 34 n.a. 
 validated ME 12 6.3 6 6 11 / 0 / 0 / 0 3 1 7 1 
   validated ME & associated ADE 1 0.5 0 1 1 / 0 / 0 / 0 0 0 1 - 
  
         
Triazolam potential ME 3 100 
       
 no ME 0 - - - - - - - n.a. 
 validated ME 3 100.0 1 1 3 / 0 / 0 / 0 1 0 2 1 
   validated ME & associated ADE 1 33.3 0 0 1 / 0 / 0 / 0 1 0 0 - 
          
Lorazepam potential ME 324 100        
 no ME 190 58.6 65 77 99 / 77 / 1 / 13 48 44 106 n.a. 
 validated ME 134 41.4 25 39 100 / 31 / 1 / 2 49 27 82 10 
   validated ME & associated ADE 10 3.1 4 6 7 / 3 / 0 / 0 3 1 8 - 
          
I Indication: anx = anxiety / inv = pre-invasive / unkn = unkown 
II ADE = adverse drug event  
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Identification and assessment of adverse drug events 
In the 205 hospitalizations where a validated ME had occurred we systematically searched 
the original medical records for related ADE. This revealed 23 patients with ADE compatible 
with intrinsic effects of BDZ, i.e. falls, prolonged CNS depression and dyspnea (Table 8). 
According to WHO/CIOMS causality assessment 15 of the ADE had a “probable”, 5 a 
“possible” and 3 an “unlikely” causal relation to the respective BDZ ME. Of the 10 ADE 
associated with lorazepam, 8 occurred in elderly patients and 7 were found to be 
preventable if a more cautious use such as no co-administration of additional BDZ had been 
respected. Of the 11 ADE associated with zolpidem, 6 occurred in patients ≥65 years and 9 
were found to be preventable. According to CIOMS criteria, the ADE associated with 
midazolam was assessed as ‘probable’ and preventable. On the other hand, causality of the 
ADE with tetrazepam was assessed as ‘possible’ and found not to be preventable during 
hospitalization, as BDZ administration and the ADE had actually occurred before admission. 
Finally, the identification of all flumazenil administrations in our dataset revealed four cases 
of severe ADE resulting from inadequate BDZ administrations (Table 8). In two of those 
preventable ME strong CYP inhibitors had been co-administered with BDZ while in one case 
lorazepam had been administered in a patient with severe renal impairment (eGFR of 18 
ml/min). Additional relevant CYP inhibitors and administration of multiple BDZ were also 
present in all four cases. 
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Table 8: Cases with severe ADE 
 
  
total 
number
ADE 
Fall CNS depression  
eGFRI 
<30 ml/min 
CIOMS Presence of risk factors Preventable 
minor 
injury 
major 
injuryII 
 
 with respir. 
depression 
 
 
 unlikely possible probable 
respiratory 
insufficiency 
severe liver 
disease 
age ≥65 yes no 
                
Zolpidem 11 5 2 4 2  1 2 1 8 5 - 5 9 2 
Midazolam 1 1 - - -  - - - 1 - - 1 1 - 
Triazolam 1 - 1 - -  - - 1 - 1 - - - 1 
   
 
  
 
  
  
 
  
 
 
Lorazepam 10 4 4 2 2  10 1 3 6 3 1 8 7 3 
   
 
  
 
  
  
 
  
 
 
Flumazenil 4 - 1 3 1  1 - - 4 2 - 2 4 - 
                
 
I eGFR = estimated glomerular filtration rate according to CKD-EPI 
II Thereof four with subsequent emergency CT scans and one other case with fracture of femur
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3.4.7. Conclusion 
Our study analyzed BDZ usage patterns, potential medication errors and associated 
ADE in the real-life setting of a tertiary care university hospital. In order to perform 
such analyses we had previously extracted electronic drug prescriptions, renal 
function measures and other clinical data from the database of an existing electronic 
clinical information system and set up a local pharmacoepidemiological database. 
This step is essential for two reasons. First, a rational allocation of limited available 
resources to improve hospital drug safety requires systematic retrospective real-life 
data on the frequency of preventable ME, and the usually much lower frequency of 
resulting severe ADE. Besides, nothing is as convincing to local prescribers and 
decision makers as being challenged by opportunities for improvement based on real 
local ME. Second, the setup of such a database requires an interface with the local 
clinical information system. This is a necessary prerequisite for the development of 
real-time analyses and alerts that can be returned through the same interface to local 
safety experts and prescribers. Only such systems may eventually offer the 
necessary efficiency and efficacy in order to have a measurable impact on patient 
safety in clinical practice. 
 
For the currently studied drug class of BDZ we found that their use as well as the risk 
for drug interactions was even higher than we had expected. Approximately one out 
of two patients received at least once a BDZ during hospitalization. Concomitant 
exposure to multiple BDZ is rarely justified but was detected in 7% of patients. And 
polypharmacy with more than 10 additional concomitant drugs was present in 42% of 
patient-days. 
At the same time one has to realize that midazolam contributed 17.7% of patient-
days with BDZ use, but midazolam was frequently only administered as a single 
intravenous dose before smaller diagnostic or therapeutic procedures. Of note, 
midazolam drug interactions with CYP inhibitors are much less important for 
intravenous as compared to oral administration with pronounced first-pass 
metabolism.87,108 
 
For each studied BDZ, we applied an individually programmed algorithm that 
detected patient-days with potential ME. In addition to the co-administration of strong 
CYP 3A4 inhibitors, some patients were exposed concomitantly to inhibitors of CYP 
2C19 or CYP 1A2. This may further reduce the capability to metabolize certain BDZ, 
(i.e. diazepam, clorazepate and prazepam for 2C19; zolpidem for 1A2) through the 
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inhibition of a relevant metabolic bypass.72,86 Furthermore, the concomitant use of 
multiple opioids may further enhance CNS-related ADE of BDZ.120 Algorithm-based 
detection of potential ME was highly efficient, but only clinically relevant prescribing 
errors should be considered as true ME and this distinction requires additional 
manual expert evaluation of individual patients using weighted information from non-
structured data. Adapted dosing (i.e. less than half of the recommended dose), 
palliative situations, or known tolerance of high BDZ doses were the most frequent 
reasons why potential ME were considered as clinically irrelevant. At the other end of 
the spectrum current contraindicated conditions (e.g. severe respiratory failure), co-
administration of multiple additional BDZ and lack of adaptation of the initial dose in 
elderly patients were the most frequent reasons why we assessed a potential ME as 
clinically relevant. Although there is no gold standard for such an expert validation, 
we consider it as the best available method, and we have successfully applied and 
evaluated it in prospective studies and ward rounds with instant feedback from the 
prescribers and subsequent medication changes.27,33 
Even a true ME does not always result in a severe ADE, and although the proportion 
of ME that actually result in severe ADE is most important from a clinical point of 
view, this quantitative aspect is vastly understudied in drug safety research. 
Therefore, our study systematically searched for and quantified ADE following all 
validated ME. As expected, only a small proportion of ME led to severe ADE, but 
over a 2-year period we were able to identify the total number of 20 severe ADE 
following erroneous administrations of zolpidem, midazolam, triazolam or lorazepam 
with a formal causality assessment suggesting a causal role for these BDZ. 
Prospective screening for the underlying ME with our automated algorithms would 
have detected those, and timely alerts could therefore have effectively prevented 
them with high efficiency. 
Furthermore, we also identified and assessed 15 patient-days with flumazenil 
administration, which revealed 4 cases of BDZ related ME that caused severe ADE 
requiring such antidote treatment. Three of those would indeed have been detected 
in time by our algorithms, which identified co-administration of strong CYP inhibitors 
in two cases, and relevant renal impairment with an eGFR < 30 ml/min and 
concomitant exposure to an additional BDZ in another case. Only the remaining 
fourth case with flumazenil administration would not have been detected by our 
algorithms due to the lack of exposure to any strong CYP inhibitors. It involved the 
BDZ oxazepam and alprazolam concomitantly administered with the CYP 3A4 
inhibitor fluconazole, which is considered to be only a moderate CYP 3A4 
inhibitor.72,113 All four flumazenil cases could likely have been prevented by either 
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choosing a lower dose of the involved BDZ or by using BDZ which are not affected 
by CYP inhibition. Of note, a study in a Brazilian Teaching hospital analyzed the use 
of flumazenil in patients exposed to intravenous midazolam and interacting drugs.123 
They identified 23 patients exposed to clinically significant drug-drug interactions 
requiring administration of flumazenil during one year. Most of the cases were related 
to CNS depressing drugs such as opiates, whereas none were related to CYP 3A4 
inhibitors, for which an interaction is much more pronounced if midazolam is 
administered orally. 
Although our study focused on identifiable ME with BDZ one should also realize the 
very high absolute use of BDZ in the studied setting, and that ADE to BDZ may also 
occur without preceding ME. Further interventions should therefore also promote a 
generally more restrictive use of BZD use particularly in elderly patients and are 
supported by expert consensus guidelines such as the “Beers” and “Priscus” lists, or 
the “STOPP” criteria.87,105-107 
Furthermore, our results showed that compliance with dose-adaptation 
recommendations for zolpidem in elderly patients is very low, i.e. two thirds of 
zolpidem users receive ≥10 mg/day. In combination of the high prevalence of 
zolpidem use this resulted in the remarkably high absolute number of 10749 patient 
days with ≥10 mg of zolpidem use per day in patients ≥65 years over two years in a 
tertiary care hospital. An analysis of ADE resulting from all high zolpidem doses in 
elderly patients was beyond the scope of the current study, but our personal 
experience from safety ward rounds shows that most prescribers are not aware of 
recommended dose adaptations for zolpidem in elderly patients and readily change 
the dose when this is brought to their attention. 
 
In conclusion BDZ use was remarkably high in the studied setting of a tertiary care 
hospital. Our algorithms are able to identify potential ME for BDZ prescriptions 
through an automated analysis of interacting co-medication and impaired renal 
function with high efficiency. Although this was done retrospectively in the current 
study, our next aim is the implementation of prospective real-time screening 
algorithms for ME that issue immediate alerts. We found that about 20% of potential 
ME for BDZ prescriptions identified through our automated search algorithms were 
assessed as clinically relevant, i.e. BDZ prescriptions should have been changed. 
This further selection of clinically relevant ME still requires manual expert evaluation 
with a review of patients’ clinical situation and individual risk-benefit evaluation. 
However, if an automated algorithm performs the screening it would be an easy task 
for a trained expert to review the approximately 6 alerts that would be generated per 
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day and subsequently recommend prescription changes in 1 to 2 patients per day. 
Although serious ADE following ME with BDZ are fortunately rare, our findings 
indicate that such a system may prevent approximately 10 severe ADE per year in a 
tertiary care hospital. This absolute number is clinically relevant and may stand in a 
favorable relation to the resources that are required for the maintenance of a semi-
automated proactive safety surveillance system. In addition, automated alerts for 
dose reduction of zolpidem in elderly patients and a generally more restrictive use of 
BZD may also prevent a considerable number of BDZ-related ADE and should be 
further investigated in future studies.  
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3.5. Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care 
Hospital: Administration of Contraindicated Comedication and QT-
Prolongation 
 
3.5.1. Authors 
David F. Niedrig, Sarah Mächler, Liesa Hoppe, Natascia Corti, Helen Kovari, Stefan 
Russmann 
 
3.5.2. Remarks 
Significance for thesis & notable features 
While basically similar to the previous two studies, this study considers potential ME 
related to drug-disease interactions and includes relative overdosing in patients with 
renal impairment. Using structured information about the patients’ current and past 
diagnoses, i.e. codes of the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10), it contributed to the identification of patients at 
risk of clinically relevant ME. However, using these codes needs careful 
consideration about their timing and overall quality since they are principally used as 
a administrative instrument for the hospital to request compensation from the 
insurance companies. Additionally this study focused on certain potential ME that are 
highly likely to be of clinical relevance due to very pronounced pharmacokinetic DDI. 
 
Contributions of the author of this thesis 
David Niedrig contributed to the study design, algorithm development and 
programming, manuscript writing, data compilation and interpretation, and wrote the 
first version of the manuscript. 
 
Publication 
This Study has been accepted for publication as original research in the European 
Journal of Clinical Pharmacology in March 2016.  
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3.5.3. Background 
Macrolide and quinolone antibiotics (MQAB) are among the most frequently 
prescribed drugs that are associated with life-threatening torsade de pointes (TdP) 
cardiac arrhythmia.124-128 Information on the assessment of their potential risk to 
cause TdP vs. therapeutic benefits are featured in their Summary of Product 
Characteristics (SPC) and other resources such as guidelines, websites and clinical 
decision support software.87,129 Patients’ resilience to drug-induced TdP is often 
described as ‘repolarization reserve’, referring to the ventricle’s capacity to 
compensate delayed repolarization.130 Prolongation of the QT-interval is an important 
predictor of TdP, and ECG monitoring is therefore indicated in patients exposed to 
QT-prolonging drugs with a high risk of TdP. The risk is partially dose-dependent and 
highest in patients with concomitant administration of several QT-prolonging drugs. 
Indeed, in clinical practice patients with drug-associated TdP had typically been 
exposed to several risk drugs. TdP is also associated with additional factors including 
high age, female sex, hypokalemia, heart diseases and renal impairment.131-133 If the 
QTc interval exceeds 500 ms or there is a drug-associated increase by more than 60 
ms, QT-prolonging drugs should usually be discontinued.134 However the risk of TdP 
may already be increased at QTc intervals above the upper limit of normal, which is 
commonly defined as 450 ms for men and 460 ms for women.135 Inpatients of a 
tertiary care hospital may frequently feature reduced repolarization reserves due to 
polypharmacy and other risk factors for TdP. Therefore, awareness of TdP-inducing 
drugs and careful ECG monitoring are important parts of proactive drug safety 
management in this population.136 
Furthermore, some MQAB are also well known for avoidable pharmacokinetic 
DDI.47,137 Clarithromycin, erythromycin and ciprofloxacin are strong inhibitors of 
cytochrome P450 isoenzymes (CYP). Their co-administration with certain substrates 
may outweigh any potential benefits, especially if ‘victim-drugs’ are prescribed in high 
doses and if therapeutic alternatives are available. The latency time of resulting 
adverse drug reactions (ADR) has a broad range. DDI with MQAB may lead to 
simvastatin-induced rhabdomyolysis only after several weeks of co-administration,138-
140 whereas ciprofloxacin may cause a 7- to 10-fold increase of tizanidine cmax and 
AUC within 24 hours and result in severe hypotension and reduced psychomotor 
functions.141 
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3.5.4. Objectives 
The present study aimed to quantify co-administration of MQAB with QT-prolonging 
and other potentially interacting drugs, relevant risk factors and the frequency of 
associated adverse events in the real-life setting of hospitalized patients. 
 
 
3.5.5. Methods 
Data Source 
The study was conducted using data from the calendar year 2012 of our previously 
described comprehensive pharmacoepidemiological hospital database.111 The 
database contains information on electronic drug prescriptions, demographics, 
laboratory results and diagnoses for hospitalized patients of a Swiss tertiary care 
hospital. For the assessment of ECG monitoring and outcome validation of potential 
DDI we reviewed original electronic medical records unless patients had refused 
consent to use their data for research upon admission. 
 
Study design 
Selection of the study population and overall study design are presented in Figure 
10. We conducted a retrospective observational study that analyzed usage patterns, 
ECG monitoring, potential DDI, laboratory data and relevant comorbidities in MQAB 
users of a tertiary care hospital. The cantonal ethics committee, the hospital’s 
medical director and the hospital’s center for clinical research had approved the data 
extraction, the setup and analysis of our anonymized pharmacoepidemiological 
database, and the access to original medical records for our research studies.  
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Figure 10: Study flowchart 
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Usage patterns of QT-prolonging MQAB, co-administration of potentially interacting 
drugs and risk-factors for TdP 
For the present study we developed, programmed and validated algorithms that 
searched our database for patients, patient-days and hospitalizations with exposure 
to MQAB and co-administered drugs of interest. Few hospitalizations with 
administration of two or more of the studied MQAB contributed to more than one 
exposure group and were accordingly counted more than once. We analyzed the 
following MQAB based on their established high potential to cause TdP according to 
information from their SPC and additional scientific resources:72,75,87,142,143 
ciprofloxacin, clarithromycin, erythromycin, azithromycin, levofloxacin and 
moxifloxacin. For all users of those MQAB we identified additional co-administered 
drugs that also have an established high risk for QT-prolongation and TdP. 
Furthermore we identified selected drugs with well-documented relevant CYP-
mediated pharmacokinetic interactions with the respective MQAB, i.e. concomitant 
administration of clarithromycin or erythromycin with simvastatin or high-dose 
atorvastatin (≥ 40 mg/d), and combined use of ciprofloxacin with tizanidine. 
Further algorithms identified additional risk factors for TdP. Current hypokalemia 
below 3.3 mmol/l or renal impairment with a decreased eGFR144 that requires dose-
reduction for clarithromycin, erythromycin, ciprofloxacin and levofloxacin. For patients 
with renal impairment we evaluated whether recommended dose-adjustments of the 
respective MQAB had actually been made.145 Furthermore, we identified relevant 
cardiac comorbidities that may increase the risk of TdP based on documented ICD-
10 codes of the following heart diseases: heart failure, cardiomyopathy, angina 
pectoris, myocardial infarction, heart murmurs, aortic stenosis, coronary artery 
stenosis, cardiac failure, QT prolongation, pacemaker implantation, ventricular 
septum defect, coronary interventions, palpitations, atrial fibrillation or flutter, 
supraventricular arrhythmia, tachycardia, and tachy-bradycardia.126 
 
ECG-monitoring and evaluation of adverse events associated with potential 
medication errors 
We assessed monitoring for QT-prolongation by reviewing all documented ECGs in 
patients’ original medical records performed up to one week before (baseline) or 
during the co-administration of potentially interacting drugs for each hospitalization. 
A corrected QT interval (QTc) of >450 ms in men and >460 ms in women is 
associated with increased cardiovascular mortality and defined as the upper limit of 
normal by the American Heart Association. Longer QTc-intervals were accordingly 
categorized as ‘abnormal QTc’ for the present study.135,146 A QTc-interval above 500 
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ms significantly increases the risk of TdP and sudden cardiac death, and was defined 
as ‘long QTc’.134 For patients with abnormal and long QTc-intervals we reviewed the 
original ECG and comprehensive medical records for other, not drug-related 
contributing QTc-prolonging factors such as pacemakers, left bundle branch blocks 
or presence of tachycardia (heart rate >100/min). Only if no such confounders were 
identified, we assessed the causal relationship with the respective QT-prolonging 
drugs according to standardized WHO/CIOMS causality assessment criteria.2 
For the studied pharmacokinetic DDI involving simvastatin and atorvastatin we 
identified symptoms, signs and diagnoses of myopathy in comprehensive medical 
records including laboratory results of creatine kinase (CK) measurements.145 For 
interactions involving tizanidine we evaluated any documentation of hypotension, 
drowsiness and reduced psychomotor functions.145 
 
Data analysis 
Data analysis was descriptive with presentation of results in tables as appropriate. 
Frequencies were calculated with regard to individual patients, hospitalizations and 
patient-days. Data management and analyses were performed with STATA Version 
13.1 (STATA Corporation, College Station, TX, USA). 
 
3.5.6. Results 
Characteristics of the study population 
Among 29969 patients from our database that had been hospitalized in 2012, 9777 
(32.6%) had received treatment with systemic antibiotics. Amoxicillin-clavulanic acid 
was by far the most frequently used antibiotic (n=4112, 42.1 %), and 29.1 % of 
patients with systemic antibiotic treatment had received MQAB associated with TdP. 
Characteristics of the studied MQAB users and frequency distribution of different 
MQAB are presented in Table 9. Ciprofloxacin was the second most frequently used 
antibiotic in the hospital (19.2% of all patients with systemic antibiotic treatment) and 
by far the most frequently used MQAB. Mean and median duration of hospitalization 
for MQAB users were 19.2 and 5 days.  
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Table 9: Characteristics of the study population 
 
 
Hospitalizations Patient-days 
 
n (%) n (%) 
All analyzed MQAB users 3240 100 20721 100 
     
Sex 
    
Male 1913 59.0 12296 59.3 
Female 1327 41.0 8425 40.7 
     
Age distribution 
    
<18 14 0.4 69 0.3 
18-44 694 21.4 4106 19.8 
45-64 1195 36.9 8537 41.2 
65-84 1205 37.2 7272 35.1 
≥85 132 4.1 737 3.6 
     
Use of studied antibiotics 
    
Macrolides 
    
Clarithromycin 476 14.7 4238 20.5 
Erythromycin 184 5.7 901 4.3 
Azithromycin 113 3.5 725 3.5 
Quinolones 
    
Ciprofloxacin 2247 69.4 12989 62.7 
Levofloxacin 321 9.9 2389 11.5 
Moxifloxacin 103 3.2 857 4.1 
     
Units with highest use of MQAB 
    
Urology 677 20.9 2366 11.4 
Viszeral- and transplantation surgery 386 11.9 1895 9.1 
Internal medicine 381 11.8 1601 7.7 
Pneumology 271 8.4 3671 17.7 
Haematology 170 5.2 1551 7.5 
     
Most frequent primary ICD-10 diagnoses 
    
Malignant neoplasms of lymphoid, hematopoietic and related tissue C81-C96 177 5.5 - - 
Complications of surgical and medical care, not elsewhere classified T80-T88 151 4.7 - - 
Other diseases of the urinary system N30-N39 142 4.4 - - 
Influenza and pneumonia J09-J18 139 4.3 - - 
Malignant neoplasms of digestive organs C15-C26 127 3.9 - - 
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Co-medication of MQAB with additional QT-prolonging drugs, other risk factors for 
TdP and dose-adjustment in renal impairment 
Co-medication of MQAB with other QT-prolonging drugs and prevalence of additional 
risk factors for TdP are presented in Table 10. Among 3444 courses of administered 
MQAB, additional drugs known to cause TdP were administered in 1332 (38.7 %). In 
14.2 % even two or more additional QT-prolonging drugs were administered. Some 
patients received up to 6 drugs known to cause TdP on the same day, frequently 
involving antiemetics, azole-antifungals and antidepressants. Patients using 
clarithromycin, azithromycin, levofloxacin or moxifloxacin were more frequently 
exposed to at least one additional drug known to cause TdP (between 51.5 and 60.4 
%) than patients receiving erythromycin (29.9 %) or ciprofloxacin (30.3 %). Current 
hypokalemia below 3.3 mmol/l, an important risk factor for TdP, was documented in 
15.9 %. For users of clarithromycin, erythromycin, ciprofloxacin and levofloxacin lack 
of recommended dose reduction of MQAB in the presence of impaired renal function 
was found in 122 (3.8 %) of administered courses. These occurred in 91 
hospitalizations with ciprofloxacin (daily doses of >500 mg while eGFR <30ml/min or 
>1000 mg while eGFR 30-60 ml/min), in 16 hospitalizations with clarithromycin (daily 
doses of >500 mg while eGFR <30 ml/min), and in 15 hospitalizations with 
levofloxacin (daily doses of >250 mg while eGFR <20 ml/min or >500 mg while eGFR 
20-50 ml/min). Approximately one in three patients exposed to the studied MQAB 
had a documented ICD-10 diagnosis of heart diseases associated with an increased 
risk for TdP. 
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Table 10: Prevalences of QT-prolonging comedication and other risk factors for TdP in MQBA users 
 
Clarithromycin  Erythromycin  Azithromycin  Ciprofloxacin  Levofloxacin  Moxifloxacin 
  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days 
  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%) 
Use of antibiotic 476 100 4238 100  184 100 901 100  113 100 725 100  2247 100 12989 100  321 100 2389 100  103 100 857 100 
  
   
   
   
   
   
   
   
   
   
   
   
  
Co-medication with at least 
one QT-prolonging drug 282 59.2 3163 74.6 
 
55 29.9 223 24.8 
 
67 59.3 561 77.4 
 
681 30.3 3923 30.2 
 
194 60.4 1165 48.8 
 
53 51.5 570 66.5 
Co-medication with two or 
more QT-prolonging drugs 166 34.9 2541 60.0 
 
27 14.7 72 8.0 
 
37 32.7 243 33.5 
 
174 7.7 1271 9.8 
 
58 18.1 198 8.3 
 
28 27.2 256 29.9 
  
   
   
   
   
   
   
   
   
   
   
   
  
Most frequently used QT-
prolonging co-medication 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
  Escitalopram 17 3.6 345 8.1  2 1.1 9 1.0  5 4.4 25 3.4  75 3.3 395 3.0  6 1.9 43 1.8  2 1.9 24 2.8 
  Fluconazole 17 3.6 30 0.7  10 5.4 23 2.6  0 0.0 0 0.0  72 3.2 311 2.4  33 10.3 93 3.9  6 5.8 14 1.6 
  Ondansetron 28 5.9 99 2.3  23 12.5 61 6.8  13 11.5 62 8.6  221 9.8 489 3.8  119 37.1 687 28.8  5 4.9 24 2.8 
  Domperidone 185 38.9 2446 57.7  22 12.0 87 9.7  56 49.6 495 68.3  269 12.0 2192 16.9  63 19.6 324 13.6  32 31.1 347 40.5 
  Clarithromycin - - - -  1 0.5 1 0.1  3 2.7 3 0.4  43 1.9 759 5.8  11 3.4 37 1.5  23 22.3 323 37.7 
  Azithromycin 3 0.6 3 0.1  1 0.5 1 0.1  - - - -  18 0.8 137 1.1  2 0.6 6 0.3  6 5.8 47 5.5 
  Itraconazole 131 27.5 2460 58.0  2 1.1 2 0.2  0 0.0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 
  Ciprofloxacin 43 9.0 759 17.9  14 7.6 45 5.0  18 15.9 137 18.9  - - - -  13 4.0 18 0.8  3 2.9 3 0.4 
  Erythromycin 1 0.2 1 < 0.1  - - - -  1 0.9 1 0.1  14 0.6 45 0.3  0 0 0 0  0 0 0 0 
  Mirtazapine 20 4.2 131 3.1  7 3.8 35 3.9  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 
  Levofloxacin 11 2.3 37 0.9  0 0 0 0  2 1.8 6 0.8  13 0.6 18 0.1  - - - -  0 0 0 0 
  Moxifloxacin 23 4.8 323 7.6  0 0 0 0  6 5.3 47 6.5  3 0.1 3 0  0 0 0 0  - - - - 
  
   
   
   
   
   
   
   
   
   
   
   
  
Hypokalemia (<3.3 mmol/l)1 110 23.1 474 11.2  16 8.7 65 7.2  18 15.9 40 5.5  321 14.3 1406 10.8  58 18.1 162 6.8  24 23.3 61 7.1 
  
   
   
   
   
   
   
   
   
   
   
   
  
Renal impairment with need 
for MQAB dose reduction2 87 18.3 724 17.1 
 
2 1.1 2 0.2 
 
- - - - 
 
660 29.4 3723 28.7 
 
67 20.9 347 14.5 
 
- - - - 
    without recommended  
        dose-reduction 16 3.4 29 0.7 
 
0 0 0 0 
 
- - - - 
 
91 4.0 236 1.8 
 
15 4.7 54 2.3 
 
- - - - 
  
   
   
   
   
   
   
   
   
   
   
   
  
ICD-10 diagnosis associated 
with elevated TdP risk 232 48.7 - - 
 
24 13.0 - - 
 
40 35.4 - - 
 
679 30.2 - - 
 
108 33.6 - - 
 
35 34.0 - - 
 
1 K+ < 3.3 mmol/l on day(s) of co-administration 
2 For clarithromycin if eGFR < 30 ml/min, for erythromycin if eGFR < 10 ml/min, for ciprofloxacin eGFR < 30 - 60 ml/min, for levofloxacin if eGFR < 20 - 50 ml/min  
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ECG-monitoring in patients at risk for TdP 
For 1332 administered MQAB courses with at least one additional QT-prolonging 
drug, medical records including performed ECGs could be further reviewed for 1236 
(92.8 %). Frequencies of ECG-monitoring and further risk factors for TdP in those 
patients are presented in Table 11. In 50.9 % adequate ECG monitoring was 
documented. Among patients with adequate ECG monitoring and abnormal QTc (n= 
55), patients with non-drug causes for ECG abnormalities (n= 28), or patients with an 
ECG performed before exposure to the DDI (n= 12) were excluded from the CIOMS 
causality assessment. Thereafter 15 individual patients with an abnormal / long QTc 
interval remained for formal causality assessment. For 7 patients with QTc between 
478 and 518 ms causality of the involved drugs known to prolong QT interval and 
cause TdP interval was classified as ‘possible’, and further details are presented in 
Table 12. We identified no episodes of TdP. 
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Table 11: ECG-monitoring in MQAB users at risk of TdP 
 
 
Macrolides  Quinolones 
 
Clarithromycin Erythromycin Azithromycin  Ciprofloxacin Levofloxacin Moxifloxacin 
 
Hospitalizations Hospitalizations Hospitalizations  Hospitalizations Hospitalizations Hospitalizations 
 
n (%) n (%) n (%)  n (%) n (%) n (%) 
       
 
      
Co-medication with at least one QT-prolonging drug1 259 100 48 100 65 100  632 100 180 100 52 100 
       
 
      
--> Thereof adequate QT monitoring: current / pretreatment ECG available2 128 49.4 27 56.3 21 32.3  334 52.8 92 51.1 27 51.9 
  --> Thereof administration during episode(s) of hypokalemia3 37 14.3 7 14.6 6 9.2  79 12.5 21 11.7 10 19.2 
  --> Thereof with ICD-10 codes predisposing for TdP 70 27.0 9 18.8 11 16.9  483 76.4 40 22.2 12 23.1 
  --> Thereof with renal insufficiency requiring dose adaptation 19 7.3 1 2.1 na na  123 19.5 14 7.8 na na 
     --> Thereof with supratherapeutic dosing 1 0.4 0 0 na na  7 1.1 3 1.7 na na 
  --> Thereof abnormal / long QT4 9 3.5 2 4.2 2 3.1  36 5.7 6 3.3 0 0 
  --> Thereof non-drug-related abnormal / long QT5 5 1.9 1 2.1 0 0  20 3.2 4 2.2 0 0 
  --> Thereof causality not assessable (no ECG while exposed to DDI) 0 0.0 1 2.1 0 0  10 1.6 1 0.6 0 0 
  --> Thereof suspected drug related abnormal QT 4 1.5 0 0 2 3.1  6 0.9 1 0.6 0 0 
     --> Thereof WHO / CIOMS causality 'possible' for DDI regarding TdP 3 1.2 0 0 0 0.0  3 0.5 1 0.6 0 0 
       
 
      
--> Thereof inadequate QT monitoring: no current / pretreatment ECG available2 131 50.6 21 43.8 44 67.7  298 47.2 88 48.9 25 48.1 
  --> Thereof with hypokalemia3 22 8.5 3 6.3 8 12.3  54 8.5 17 9.4 5 9.6 
  --> Thereof with ICD-10 codes predisposing for TdP 52 20.1 6 12.5 14 21.5  72 11.4 19 10.6 6 11.5 
  --> Thereof with renal insufficiency requiring dose adaptation 20 7.7 1 2.1 na na  73 11.6 14 7.8 na na 
     --> Thereof with supratherapeutic dosing 1 0.4 0 0 na na  5 0.8 2 1.1 na na 
 
1 After exclusion of patients without consent to access original medical records 
2 Current / pretreatment ECG available = ECG performed up to 7 days before co-administration of studied AB with drugs known to cause TdP 
3 K+ < 3.3 mmol/l on day(s) of co-administration 
4 Abnormal QTc = 450 ms for men / 460 ms for women; long QTc = > 500ms 
5 Presence of left bundle branch block / pacing pacemaker / use of amiodarone and (except AB) no other QT prolonging drugs 
na = not applicable 
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Table 12: Adverse events associated with potential medication errors in MQAB users 
 
Case code Sex Age Antibiotic(s) Dose Antibiotic 
Additional QT prolonging 
drug(s) 
Dose additional  drug(s) Route of admin. AB Route of admin. QT drug 
Lung 
transplant 
QTc K+ Mg2+ Heart rate CV diagnoses 
QT1 m 51 
Clarithromycin, 
Azithromycin, 
Ciprofloxacin 
250 mg/3x per week Domperidon, Ondansetron 30 mg/d, 4 mg/d p.o. p.o. yes 491 3.3 0.98 90 - 
QT2 f 67 Clarithromycin 500 mg/d Domperidone 30 mg/d p.o. p.o. yes 486 4 0.87 68 multiple heart diseases 
QT3 m 47 Clarithromycin 1000 mg/d Ondansetron 8-16 mg/d i.v. i.v., p.o. no 484 4.3 - 55 - 
QT4 m 42 Levofloxacin 500 mg/d Ondansetron 24 mg/d i.v. i.v. no 481 4.3 0.85 81 - 
QT5 f 80 Ciprofloxacin 500 mg/d Citalopram 40 mg/d p.o. p.o. no 513 3.3 0.66 90 - 
QT6 m 78 Ciprofloxacin 800 mg/d Dipiperon, Haloperidol (fix) 120 mg/d, 2 mg/d i.v. p.o. no 518 - 1 61 multiple heart diseases 
QT7 f 68 
Ciprofloxacin, 
Azithromycin 
250 mg/3x per week 
Ciprofloxacin, Domperidon, 
Citalopram 
500 mg/d, 30 mg/d, 10 mg/d p.o. p.o. yes 478 
  
78 cardiomypathy 
IA1 f 68 Ciprofloxacin 800 mg/d na 7 mg/d i.v. na no na na na na na 
IA2 f 59 Ciprofloxacin 500 mg /d na 4 mg/d p.o. na no na na na na na 
IA3 m 71 Ciprofloxacin 800 mg/d na 2 mg/d i.v. na no na na na na na 
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Pharmacokinetic interactions of MQAB with simvastatin, atorvastatin and tizanidine 
Among the 546 individual patients taking clarithromycin or erythromycin we detected 
9 patients with co-administration of simvastatin, 6 thereof taking 40 - 80 mg daily. An 
additional 22 patients were exposed to concomitant use of ≥40 mg atorvastatin daily. 
In none of these patients symptoms or signs of myopathy including elevated creatine 
kinase measurements indicated causally related adverse events. 
Among the 2247 administered courses of ciprofloxacin we detected 13 with 
concomitant exposure to tizanidine, 5 thereof with ≥6mg/d. Three patients 
experienced episodes of hypotension shortly after this combination was 
administered, and 2 patients were treated with cardiac stimulants (etilefrine and 
midodrin), but without cessation of tizanidine-ciprofloxacin co-administration (Table 
12). Causality for the decreases in blood pressure assessment in relation to the DDI 
was assessed as ‘possible’ in all three cases. 
 
3.5.7. Conclusion 
This study describes the use, co-medication and risk management of MQAB in the 
real-life setting of a tertiary care hospital with regard to TdP and to selected clinically 
relevant pharmacokinetic DDI. With the exception of ciprofloxacin, the studied 
potentially QT-prolonging MQAB were only used in a small proportion of patients. 
And ciprofloxacin is generally considered ‘less torsadogenic’ than other quinolones 
and was only recently added to the list of drugs with a known risk for TdP.125,147,148 At 
the same time, it is remarkable how many MQAB users had additional risk factors for 
TdP. Most notably, more than one third were exposed to additional QT-prolonging 
drugs, and about one in six MQAB users also had hypokalemia, a risk factor that is 
usually easy to correct in hospitalized patients.134,149 Indeed, the SPC of 
clarithromycin features hypokalemia as an explicit contraindication to its use,145,150 
yet we detected 361 patient-days in which clarithromycin was administered despite 
current serum potassium below 3.3 mmol/l, representing 8.5 % of all patient-days 
with exposure to clarithromycin. Renal impairment is another important risk factor for 
TdP, which may be explained by the reduced renal elimination of many drugs known 
to cause TdP and an increased risk for electrolyte disturbances.134 We identified lack 
of dose-adjustment for renally eliminated MQAB. Although this concerned only a little 
less than 5% of MQAB users it represents a risk that can be avoided if physicians are 
aware of it at the time of prescription. 
ECGs for the monitoring of abnormal or long QT intervals were available in about 
50% in MQAB users with additional QT-prolonging co-medication. The higher 
88 
proportion of patients with diagnosed heart diseases among the patients with 
adequate ECG monitoring may most likely be explained by confounding from the 
cardiac disease itself rather than a higher awareness for the drug-induced risk of 
TdP. A high proportion of patients without adequate ECG monitoring had at least one 
additional risk factors for TdP, and it is likely that additional cases of abnormal / long 
ECG remained undetected. On the other hand, medical records were searched for 
adverse events also in patients without ECG-monitoring, and overall only 7 cases of 
prolonged QTc between 478 and 518 ms were identified, and no case of TdP. The 
resources required for more intense and guideline-compliant ECG-monitoring must 
therefore be weighted against expected benefits. Some US tertiary care hospitals 
have successfully developed and introduced automated algorithms with subsequent 
alerts for ECG with QTc of >500 ms.151-154 However, in order for such a system to be 
effective, a current plus a recent pre-treatment ECG are needed, and also pre-
treatment ECGs must be justified.155,156 Our findings suggest that automated 
algorithms to improve the risk-assessment may include the following modifiable risk 
factors: hypokalemia, lack of dose adaptation to renal insufficiency, and ideally also 
suggestions for alternative co-medication. Nevertheless, the development of cost-
effective ECG-monitoring algorithms and their implementation remains challenging, 
for MQAB users as well as for other high risk groups such as users of psychiatric 
drugs.157 
In comparison to QT-prolonging combinations, management implications of our 
findings regarding selected contraindicated combinations of MQAB with known 
pharmacokinetic interactions are straightforward. A high proportion of patients with 
such combinations had associated adverse events, and review of individual 
situations in original medical record showed that these combinations could have 
been avoided, as there would have been alternative management options in all 
cases. Rather simple automated simple alert-algorithms would therefore be an 
efficient preventive measure with a favorable relation of costs vs. benefits.  
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In conclusion our study found a considerable number of MQAB users with additional 
QT-prolonging co-medication and other risk factors for TdP in hospitalized patients, 
and a high proportion of those had no ECG monitoring. However, adverse events 
were rarely found, and benefits of intense ECG monitoring as well as benefits of QT-
prolonging co-medication in MQAB users have to be weighted against costs. In 
contrast, correctable co-factors in MQAB users such as hypokalemia, lack of dose-
adjustment in renal impairment and selected contraindicated pharmacokinetic 
interactions are clear targets for implementation as preventive automated alerts in 
electronic prescribing systems.  
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3.6. Acetaminophen Overdosing in a Tertiary Care Hospital: Implementation 
and Outcome Analysis of an Automated Preventive Alert Program 
3.6.1. Authors 
David F. Niedrig, Guido Bucklar, Michael Fetzer, Sarah Mächler,  
Carmen Gött, Stefan Russmann 
 
3.6.2. Remarks 
Significance for thesis & notable feature 
This study represents another milestone for this thesis and proof of concept for the 
overall concept of Interventional Pharmacoepidemiology. The evidence from 
overdosing that occurred from  2011 to 2013 provided the rationale for the 
development of a pragmatic, yet highly efficient and effective alert algorithm. The IT 
department of the University Hospital Zurich provided a timely on-demand extraction 
of raw-data that was subsequently combined with an alert algorithm that identified 
patients at risk of clinically relevant overdosing. The challenge of efficiently 
distinguishing the frequent but purely formal overdosing from prescriptions that 
needed to be changed was overcome by determining a rational threshold for clinical 
relevance. 
 
Contributions of the author of this thesis 
David Niedrig contributed to the study design, algorithm development and 
programming, data compilation and interpretation, and wrote the first version of the 
manuscript. 
 
Publication 
This Study has been published as a conference abstract in: Pharmacoepidemiology 
and Drug Safety 2015; 24: 58-59 and has been submitted as original research for 
publication to Drug Safety and is currently in the review process.  
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3.6.3. Background 
Acetaminophen has analgesic and antipyretic properties and is one of the most 
frequently used drugs worldwide. If administered within labeled doses of no more 
than 4 g per day severe adverse effects are very rare, but if recommended doses are 
exceeded it is also an intrinsic hepatotoxin.158 Toxicity is enhanced in patients with 
cachexia or alcoholism and with repeated overdosing.87,159 Because of its over-the-
counter availability and frequent use intentional and unintentional acetaminophen 
overdosing frequently occurs in clinical practice, and acetaminophen-induced liver 
failure is indeed the leading cause of liver transplantations in the US.158,160 Zhou and 
colleagues recently investigated the frequency of unintentional acetaminophen 
overdosing in a tertiary care hospital and reported that 6.6% of acetaminophen users 
exceeded the recommended maximum dose of 4 g per day.161 Civan et al. performed 
a similar analysis and reported overdosing in 2.6%.162 
In hospitals that use clinical information systems (CIS) with computerized physician 
order entry (CPOE) all prescriptions are electronically documented, and integrated 
clinical decision support systems (CDSS) may in theory detect and prevent many 
medication errors including acetaminophen overdosing.24,163 However, in clinical 
practice automated alerts from CDSS are mostly oversensitive and clinically 
irrelevant.27,39 Such over-alerting without clinical implications may lead to alert fatigue 
and ultimately to indiscriminate alert overriding or deactivation of the CDSS.35 For an 
effective prevention of acetaminophen overdosing, alerts should therefore only be 
issued in clinically relevant situations, i.e. when they imply a high risk of adverse 
events and require the prescriber to take action.26 
 
3.6.4. Objectives 
Therefore the present study aimed to quantify clinically relevant acetaminophen 
overdosing and to develop, implement and evaluate the outcome of a highly specific 
preventive alert algorithm. 
 
3.6.5. Methods 
We analyzed acetaminophen overdosing occurring in a Swiss tertiary care hospital 
with about 1,000 beds and 40 clinical specialty divisions. For all retrospective 
analyses of acetaminophen overdosing we used our previously described 
pharmacoepidemiological database containing information on demographics, 
laboratory results and electronic drug prescriptions extracted on single patient-level 
from the hospital’s electronic clinical information system (CIS).111 Of note, the CIS 
92 
features not only prescriptions, but also a confirmation for each drug’s actual 
administration including its time. The cantonal ethics committee, the hospital’s 
medical director and the hospital’s center for clinical research had approved the 
extraction of anonymized patient data, setup of a pharmacoepidemiological database 
and analysis, and the access to patients’ original medical records for research 
purposes. We developed and validated an algorithm for the identification of patients 
with confirmed acetaminophen administrations of > 4 g per day and compared the 
time periods from 1 Jan 2011 until 31 Dec 2013 (before implementation of an alert 
system) vs. 1 Jan to 31 Dec 2014 (after implementation of an alert system). By 
reviewing comprehensive electronic medical records of patients with ≥ 2 subsequent 
days of overdosing the following additional information was compiled: number, dose, 
route of administration and Anatomical Therapeutic Chemical Classification System 
code (ATC-code) of prescribed and administered acetaminophen containing 
products, cachexia, alcoholism, laboratory results of alanine amino transaminase 
(ALT) before and after exposure to overdose and other signs and symptoms of 
acetaminophen-induced liver injury. 
For the effective prevention of acetaminophen overdosing we developed an 
algorithm within the hospitals CIS that identified patients at risk of repeated clinically 
relevant acetaminophen overdosing. The algorithm was implemented in 2014 and 
allowed local safety experts at the Department of Clinical Pharmacology an 
automated identification of patients with administrations of > 4 g acetaminophen per 
day. These patients were then validated through review of their electronic medical 
records. Based on the results from retrospective analyses and currently available 
literature we classified overdoses of ≥ 5 g per day for ≥ 3 subsequent days as a 
rational threshold for clinical relevance, i.e. clinicians should take action before 
patients are exposed to such an overdose. For patients suffering from cachexia or 
alcoholism a lower threshold was chosen, their prescribers were alerted immediately 
after any administration of ≥ 5 g / day. If our expert review confirmed clinical 
relevance we notified prescribing physicians through internal mail and if appropriate 
also through personal phone calls. Subsequent changes to acetaminophen 
prescriptions were also documented. 
 
3.6.6. Results 
Study design and principal results are presented in Figure 11. For the time period of 
2011 to 2013, i.e. before implementation of the preventive alert system we identified 
49,357 individual patients with at least one acetaminophen administration during 
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hospitalization. Among all acetaminophen users 2,965 patients (6.01 %) were 
exposed to at least one day with administration of > 4 g acetaminophen per day. 
Repeated overdosing with ≥ 5 g for ≥ 2 consecutive days occurred in 38 patients, 
and among these 4 suffered from cachexia and 2 had a documented current history 
of alcoholism. Clinically relevant overdosing with administrations of 5 to 8 g 
acetaminophen per day for up to 5 consecutive days had occurred in 11 patients. 
Alanine aminotransferase (ALT) values before and after exposure to clinically 
relevant overdosing were available for 9 of those patients. In one patient ALT after 
overdosing exceeded three times the upper limit of normal. In this case, clinicians 
suspected acetaminophen as a cause and stopped its administration after exposing 
this cachectic patient to 5 g acetaminophen for three consecutive days. 
In 2014 our proactive alert system was implemented and 19,589 individual patients 
received at least one acetaminophen administration during hospitalization. 914 
(4.67%) thereof were exposed to at least one day with administration of > 4 g per 
day. The automated screening algorithm of our alert system identified on average 
about 3 patients per day that were exposed to more than 4 g of acetaminophen per 
day. These were subject to timely expert review at the early morning of the following 
day. The assessment whether repeated relevant overdosing was likely took usually 
less than 5 minutes per patient. Alerts with recommendations to change current 
acetaminophen prescriptions were issued for 23 patients during one year. In 21 of 
these cases (91.3%) prescribing physicians were compliant with our 
recommendations and changed acetaminophen prescriptions accordingly on the 
same day as the alert was issued. An additional 8 alerts were issued for patients with 
presence of cachexia or alcoholism for which a maximum dose of 3 g per day was 
recommended. In 6 of those cases prescription were adapted accordingly. Following 
the implementation of proactive alerts clinically relevant acetaminophen overdosing 
of ≥ 5 g per day for more than two days did not occur anymore in 2014. 
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Figure 11: Acetaminophen overdosing in 2011 - 2013 vs. 2014 
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3.6.7. Conclusion 
Acetaminophen overdosing is a ubiquitous and frequent medication error. In fact the 
proportion of patients that were exposed to more than 4 g acetaminophen during 
their hospitalization was 6.0% in our setting and therefore almost identical to the 
number reported by Zhou et al. in a similar setting in the US.161 However, a single 
day with administration of only little more than 4 g acetaminophen, although a formal 
medication error, is usually clinically irrelevant. In order to avoid alert fatigue 
proactive preventive safety systems therefore have to find a rational alerting 
threshold for medication errors that are likely relevant and require prescription 
changes. Indeed, our further analyses confirmed that the vast majority of 
acetaminophen overdosing is not repeated and during three years we did not identify 
a single case of severe acetaminophen-induced liver injury. Typically, overdosing 
occurs only once per patient and is caused by early administration of a dose actually 
scheduled for the next day or overlapping administrations when the route of 
administration was changed from oral- to i.v. or vice versa. Another typical at risk 
scenario occurs when multiple acetaminophen-containing drugs are prescribed 
concomitantly, or when there are fixed-dose plus on-demand prescriptions of 
acetaminophen. On the other hand unintentional iatrogenic acetaminophen 
hepatotoxicity and even liver failure has been described and justifies preventive 
measures.158 Because of the extreme rarity of such tragic events preventive 
measures must be highly efficient and hence automated, but at the same time they 
must also be highly specific in order to assure physicians’ compliance with alerts. 
We therefore chose a pragmatic solution for our preventive system, i.e. automated 
highly sensitive screening was followed by highly specific expert evaluations. Our 
experience with this system shows that once installed the necessary resources for 
expert review of prescribed overdose are minimal and that there was a complete 
absence of clinically relevant acetaminophen overdosing after implementation of our 
safety system in 2014. 
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Although we cannot formally prove that our program was the exclusive cause for this 
absence, it is striking that in the three years before we identified 11 patients with ≥5g 
acetaminophen per day for ≥3 consecutive days. Furthermore, such a program may 
have a lighthouse effect regarding a proactive open drug safety culture in a hospital 
and can serve as a proof-of-concept not only against acetaminophen overdosing but 
also for the prevention of other suitable relevant medication errors. Such locally 
customized semi-automated safety programs can be implemented in clinical routine 
of any hospital with a CIS and dedicated IT specialists and clinical safety experts.  
97 
3.7. Development, Implementation and Outcome Analysis of Semi-
Automated Alerts for Metformin Dose-Adjustment in Hospitalized 
Patients with Renal Impairment 
3.7.1. Authors 
David F. Niedrig, Regina Krattinger, Annika Jödicke, Carmen Gött, Guido Bucklar, 
Stefan Russmann 
  
3.7.2. Remarks 
Significance for thesis & notable features  
This study was already initiated in 2012 (i.e. even before the development of alerts 
against overdosing described above) by Stefan Russmann and supported by Regina 
Krattinger and the IT department of the University Hospital of Zurich. As of February 
2013 David Niedrig managed the alerts in clinical practice. It provided the first local 
proof of concept that combining a highly sensitive screening for potential ME 
combined with a highly specific assessment by dedicated drug safety specialists can 
successfully prevent clinically relevant ME without causing alert fatigue. 
 
Contributions of the author of this thesis 
David Niedrig contributed to programming the analyses of data from 2011 and 2012 
and contributed to data collection, analysis and interpretation of the data from 2013 
to 2015, and wrote the first version of the manuscript. 
 
Publication 
This Study was presented as oral presentation and abstract in 2015 at the 
International Conference of Pharmacoepidemiology (ICPE) in Boston, MA, USA. It 
was also presented as a poster and abstract at the Congress of the Swiss 
Association of Public Health Administration and Hospital Pharmacists (GSASA) 2015 
in Zurich. 
It is published as a congress abstract in: Pharmacoepidemiology and Drug Safety 
2015; 24: 230 and has been submitted as original research to 
Pharmacoepidemiology and Drug Safety and is currently in the review process under 
consideration for publication in.  
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3.7.3. Background 
Metformin is primarily used as first line treatment for type 2 diabetes and the most 
frequently prescribed oral antidiabetic drug worldwide. Its efficacy and tolerability are 
well established.164 Because metformin is not metabolized but eliminated unchanged 
via the kidneys, it can accumulate in impaired renal function. These patients may 
develop metformin associated lactic acidosis (MALA), a severe adverse drug event 
with reported fatality rates of 25 - 50 %.165 Quantification of this risk is challenging 
and its relevance in clinical practice is subject of ongoing debates.166 The SPC of 
metformin states contraindications regarding its use in patients at an increased risk 
for lactic acidosis, e.g. alcoholics, severe infections, patients suffering from 
decompensated heart failure or severe impaired renal function with a glomerular 
filtration rate (GFR) below 30 ml/min. Since 2015, regulatory authorities in 
Switzerland and the EU allow the use of metformin in patients with mild to 
moderately impaired renal function if its dose is adapted accordingly and the GFR is 
regularly monitored, which is in line with many expert recommendations and common 
clinical practice.87,167 
Patients in a tertiary care hospital have a high prevalence and incidence of impaired 
renal function as well as further risk factors for MALA including comorbidities and 
administration of intravenous contrast agents. Failure to adapt metformin dosing in 
response to impaired renal function is a preventable medication error. If hospitals use 
electronic clinical information systems (CIS) data on patients’ metformin prescriptions 
and renal function are documented in a structured electronic format. This information 
can be linked and used for the automated systematic prevention of MALA. A 
proactive safety system must be efficient, effective and avoid overalerting. 
Recommendations to prescribers must therefore not only be highly sensitive, but also 
highly specific because clinically irrelevant alerts will not be accepted and may lead 
to alert fatigue and indiscriminate alert overriding.26 
 
3.7.4. Objectives 
Therefore the present study’s aim was the development, implementation and 
outcome analysis of a highly sensitive and specific automated alert for the prevention 
of metformin overdosing in hospitalized patients with impaired renal function. 
 
3.7.5. Methods 
This proactive medication safety project was performed in a tertiary care hospital that 
provides medical care to a population of about 1.5 million people and has 
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approximately 1000 beds and 40 clinical specialty divisions. It features a clinical 
information system (CIS) by Cistec AG with integrated laboratory data, computerized 
physician order entry (CPOE) and comprehensive electronic medical records.168  
We designed and implemented a sensitive automated algorithm that detected any 
metformin prescription entered through the hospital’s computerized physician order 
entry (CPOE), and for all metformin users the latest available estimated glomerular 
filtration rate according to the CKD-EPI formula (eGFR) was checked daily. If the 
eGFR in current metformin users was below 60 ml/min, an automated alert was 
immediately sent via the CIS’s internal email-system to clinical safety experts (SR, a 
clinical pharmacologist; DN and RK, clinical pharmacists). In a second step these 
highly sensitive alerts were then subject to a highly specific expert evaluation 
regarding their clinical relevance. For that purpose patients’ original medical records 
were reviewed not only for the latest prescribed daily metformin dose, but also for 
unstructured information including causes and circumstances of decreased eGFR, 
medical diagnoses and further risk factors for MALA. If the current metformin dose 
exceeded expert consensus, i.e. in-house recommendations supported by published 
guidelines,167 a personal alert with metformin dosing recommendations was issued to 
the prescribers via internal email and if deemed necessary also via telephone. The 
overall project design is presented as a closed-loop quality control system in Figure 
12. The project was first initiated in 2011 and is fully operational in its current form 
since 2012. For the years 2012 to 2014 we also retrospectively analyzed patients for 
whom an alert had been forwarded to the prescribers in order to evaluate the 
system’s acceptance by the prescribing physicians. The cantonal ethics committee, 
the hospital’s medical director and the hospital’s center for clinical research had 
approved the data extraction, the setup and analysis of the database and the access 
to original medical records for research purposes. 
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Figure 12: Study flowchart of semi-automated alerts 
 
101 
3.7.6. Results 
During three years since its implementation, the initial highly sensitive screening 
algorithm generated 2145 automated alerts to the local safety experts, i.e. 
approximately 2 per day. The subsequent daily evaluation of the alerts including 
review of the respective patients’ electronic medical records required approximately 2 
to 10 minutes per patient. Following this highly specific expert evaluation that 
included also non-structured medical information changes of metformin therapy were 
recommended for 381 cases (17.8 %), i.e. approximately 2 to 3 per week (Table 13). 
In order to evaluate the outcome of the system we also analyzed follow-up data, 
which was available for 240 patients. Among those, metformin dose had been 
reduced or stopped in 191 patients, corresponding to a compliance of 79 % with our 
recommendations. In case of non-compliance we found that there were typically only 
mild discrepancies between recommended and administered doses, e.g. 1700 
instead of 1500 mg metformin per day. 
In addition we were also able to search our local clinical records and databases for 
cases of MALA. From 2011 to 2014 we identified 8 cases of MALA in patients with 
renal impairment. They had all occurred in circumstances where no timely 
recommendation could have been generated, such as metformin overdosing before 
hospital admission. In all MALA cases we identified also other contributory and 
triggering causes and risk factors for lactic acidosis. While the overall number of 
alerts issued to the prescribers remained constant during three years, the number of 
any metformin prescription in patients with an eGFR < 45 ml/min and the number of 
patients with pronounced metformin overdosing declined from 2012 to 2014 (Table 
13). 
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Table 13: Metformin prescriptions in patients with eGFR < 60 ml/min and subsequently issued alerts  
 
 
Year 
Automated 
alerts to safety 
experts 
Expert alerts 
to prescribers 
Patients with 
available follow-up 
Sex 
m / f 
Mean age 
eGFR 31 - 44 ml/min 
at time of alert 
eGFR < 30 ml/min 
at time of alert 
Overdose ≥ 1000 mg 
compared to recommended 
dose at time of alert 
Compliance 
n           % 
2012 643 135 90 57 / 33 73 41 16 52 81 90.0 
2013 693 123 88 51 / 37 72 30 13 36 67 76.1 
2014 809 123 62 40 / 22 74 19 7 24 43 69.4 
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3.7.7. Conclusion 
There is an ongoing debate regarding the causal role of metformin in cases of lactic 
acidosis, and we realize that metformin overdosing is rather a contributory cause in 
patients with other acute conditions associated with hypoxia, than a single sufficient 
cause. However, regardless of the interaction of several contributing causes, there is 
no doubt that metformin aggravates any lactic acidosis, that its dose must be at least 
reduced in moderate to severe renal impairment, and that particularly in patients with 
several risk factors for lactic acidosis metformin must be stopped. The observed 
cases of MALA, some with metformin doses clearly exceeding current 
recommendations, underline that the issued alerts address a clinically relevant 
adverse drug event. 
The presented proactive drug safety project against metformin overdosing in 
impaired renal function applied an innovative 2-step approach, hence called “semi-
automated”. First, a highly sensitive fully automated screening algorithm identified 
any current metformin users with an eGFR below 60 ml/min. It is important to note 
that this ongoing daily screening algorithm also detects patients with a normal eGFR 
at the time of the first in-hospital metformin prescription when the eGFR later 
decreases below this threshold during hospitalization. In a second step local clinical 
safety experts performed a highly specific expert review that is difficult to automate 
because also unstructured medical information and the latest specific situation of 
individual patients have to be considered. However, the initial screening was a 
necessary prerequisite in order to increase the system’s efficiency. Even with limited 
resources, i.e. approximately 5 minutes per patient, it was then possible to evaluate 
on average two patients per day that the screening algorithm had detected. The 
compliance of 79% indicates that such a combined system can provide a solution for 
a major challenge that current clinical decision support systems face. For most 
potential medication errors only the additional consideration of unstructured medical 
information and clinical expertise can increase the specificity of an alert to a level that 
does not cause alert fatigue and non-compliance of prescribing physicians. Therefore 
the current project is also an important proof-of-concept for an approach that can 
reach high efficiency and efficacy in clinical practice and is yet easy to implement 
with limited resources. Furthermore, the decrease regarding metformin overdosing in 
the most vulnerable patients with an eGFR < 45 ml/min suggests that such a system 
may also have an educative effect and thereby contribute to an increased awareness 
of local prescribing physician  
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4. Conclusions and Outlook 
 
4.1. Preventing Medication Errors in the Past 
Before the advent of CPOE and CDSS, the identification of ME relied on manual 
chart review and individual assessment of a patient’s prescriptions. Systematic 
analyses of medical records revealed that many ME were related to transcription 
errors or incomplete or misleading prescriptions. Additionally, knowledge about 
potentially critical ME such as pharmacokinetic DDI or dose adaptations in patients 
with renal impairment was not readily available upon prescription or administration of 
drugs. In clinical practice, local specialists, e.g. clinical pharmacologists or 
pharmacists, aimed to prevent ME by contacting the prescribers after detecting a 
potentially problematic medication during ward rounds or upon dispensing of the 
drugs. While the introduction of CPOE clearly improved drug safety in hospital 
clinical practice by reducing certain ME, CDSS did not fulfill the initially high 
expectation regarding improvements to pharmacotherapy. These systems typically 
focused on DDI and produced too many highly sensitive but non-specific alerts that 
were deemed mostly irrelevant for the management of individual patients. Lately, 
drug safety and the prevention of avoidable ADE in hospitals became increasingly 
important topics and incentives were announced in order to promote the 
implementation of CPOE and CDSS. 
 
4.2. Preventing Medication Errors Today 
Currently approximately 50 % of the Swiss hospitals use CPOE with various degrees 
of CDSS implementation. The lack of standardization regarding CDSS and their 
knowledge databases as well as the wide variety of CIS and CPOE are considerable 
challenges for the development, implementation and validation of efficient and 
effective alerts. Despite considerable efforts to improve CDSS, they are only rarely 
fully integrated in hospital clinical routine. However, targeted individual evaluations 
and mass-analyses of hospital drug prescription- and administration data can be 
performed efficiently if the required data is available in a suitable format and quality. 
By subsequently validating potential ME in patients’ medial records, their frequency 
and clinical relevance can be systematically assessed. Subsequently, individually 
developed highly specific alert algorithms can be implemented in hospital clinical 
routine. Some preventive alerts use timely patient-related data and have been shown 
to successfully prevent clinically relevant ME. Changes to patients’ pharmacotherapy 
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upon admission and discharge have been identified as a major source of ME. A 
national eHealth system for an automated and secure transfer of patient data 
between healthcare providers would be necessary to systematically prevent these 
and certain other ME, but is not yet available. 
 
4.1. Preventing Medication Errors in the (not too Distant) Future 
If computers are to discriminate between potential ME and clinically relevant ME 
reliably and fully automated, they will often need to assess a multitude of complex, 
dynamic and occasionally non-structured data. Making computers understand free 
text or images, such as an ECG readout or a nurses note on a suspected drug-
related ADE, is highly challenging. This is however necessary because CDSS need 
to consider certain risk factors for ME, e.g. crucial differential diagnoses, suspected 
alcoholism or already manifest signs and symptoms of an ADE. But even reliable 
structured basic information, e.g. the dose of prescribed or administered drugs, will 
not be available in many hospitals in the next few years. Considering the moderate 
progress of the implementation of CPOE / CDSS in Swiss hospitals and the national 
eHealth infrastructure, more pragmatic and system-independent solutions for the 
prevention of ME in hospitals are needed - especially for those ME with potentially 
severe ADE. Increasing healthcare costs and the limited availability of clinical 
pharmacists and pharmacologists will not allow an intensified manual monitoring for 
ME and ADE in hospitals. Although their advice is usually well accepted by clinicians 
and has been shown to significantly improve patient outcomes, it is not possible to 
comprehensively and constantly monitor all hospitalized patients with their prescribed 
and administered drugs, lab parameters and current diagnoses.  
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A more promising strategy might be to pragmatically combine the best of these two 
worlds: The data formats and infrastructure of CIS and CPOE in hospitals will likely 
continue to vary considerable. It is therefore unlikely that a standardized interface for 
CDSS will be established anytime soon. However, this thesis demonstrated that it is 
possible to build a local pharmacoepidemiological database if an interface with a 
commercially available CIS is used. Using similar methods as applied in this thesis, 
the data can then be used by local drug safety specialists for an ongoing analysis 
and prevention of ME. Identifying the clinical relevance of ME would be performed by 
using a CDSS software application specifically designed for the semi-automated 
detection of ME running on data in the most simple conceivable format. 
Clinical pharmacists or pharmacologists could use such a CDSS to efficiently assess 
which patients are at risk of potential ME and which thereof are of clinical relevance. 
Such local drug safety specialists could act as gatekeeper for alerts to the 
prescribers. The CDSS would support this process by facilitating benefit risk 
assessments, providing default management recommendations and document 
issued (and withheld) alerts. Thereby prescribers would only be alerted if a local drug 
safety specialist deemed a ME as clinically relevant and would be contacted by a 
known hospital staff member that has already reviews the patient in the CIS.  
 
 
 
 
Figure 13: Concept for Drug Safety Management in Hospitals by Local Experts Through Semi-
automated Alert Algorithms, concept adapted from: Drug Safety Manager - Development of an 
Integrated Concept and Application for Drug Safety Analyses, Interventions and Outcomes Research in 
Hospitals presented by Stefan Russmann and David Niedrig at the International Congress of 
Pharmacoepidemiology 2015 in Boston, MA, USA and at the Swiss ISoP Chapter Meeting in Zurich 
2014. 
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Pooling and comparing different local hospital pharmacoepidemiological databases 
and their daily routine of assessing and preventing potential ME would also support 
benchmarking of hospitals’ drug safety. The knowledge database of the CDSS could 
be constantly improved by crowed-sourced feedback and best practice sharing. 
Finally, combining such datasets would also allow a highly efficient signal detection 
of other potential safety issues for automated pharmacovigilance signal generation. 
 
Combining the high sensitivity of computers and their ability to handle an almost 
unlimited amount of structured data with the human ability to understand the specific 
clinical context of a potential ME is likely the key to a paradigm shift in hospital drug 
safety that has the potential to significantly improve patients’ pharmacotherapy in 
clinical practice.  
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While this study is not directly related to the prevention of ME in hospitalized patients 
it nevertheless contributes to raise awareness of potential risks associated with a 
commonly used new drug. It is a good example for the fast analysis of several very 
large international pharmacovigilance databases in response to a new safety signal. 
Later, signs and symptoms of ADE, i.e. increased liver parameters and jaundice 
could be used to trigger semi-automated alerts that notify local drug-safety experts to 
a potentially drug-related adverse event. Algorithms for such alerts could specifically 
include drugs that currently require careful monitoring of exposed patients in order to 
issue timely recommendations. 
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300.  
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8.1.3. Background 
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide 
since 2008 for the primary and secondary prevention and treatment of 
thromboembolic disorders.169,170 Although liver injury was observed in premarketing 
trials of rivaroxaban171, postmarketing cases of liver injury associated with 
rivaroxaban have not been published so far. Safety issues of newly marketed drugs 
including drug-induced liver injury (DILI) are typically identified during the first five 
years after marketing, and spontaneous reporting systems play an important role as 
a sensitive source of information for the detection of new postmarketing safety 
signals. 
 
8.1.4. Objectives 
We therefore evaluated postmarketing cases of liver injury associated with 
rivaroxaban reported to our regional pharmacovigilance center and performed search 
queries in three large international pharmacovigilance databases for comparable 
cases. 
 
8.1.5. Methods 
Report of 14 cases of liver injury associated with rivaroxaban, including two with liver 
biopsy, and search queries in three large international pharmacovigilance databases 
for comparable cases. 
 
8.1.6. Results 
Case #1 
A 78-year-old male patient had total knee replacement for which he received 
thromboprophylaxis with dalteparin for 10 days and thereafter rivaroxaban (Xarelto®, 
Bayer HealthCare) 10 mg/d. Approximately 14 days after start of rivaroxaban the 
patient developed painless jaundice, pruritus, fatigue, nausea and unintentional 
weight loss of 5 kg. Rivaroxaban was stopped 19 days after start, but it was not until 
another 10 days later that the patient was rehospitalized with determination of 
laboratory values. Upon admission alanine aminotransferase (ALT), alkaline 
phosphatase (AP) and total bilirubin (TB) were increased 2.5, 2.9 and 15.5 times the 
upper limit of normal (ULN), respectively. Viral serology and autoantibodies were 
negative. Abdominal ultrasound and computer tomography (CT) showed 
cholecystolithiasis but no signs of biliary obstruction. A liver biopsy was performed 20 
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days after discontinuation of rivaroxaban. Histology showed cholestasis and portal 
inflammation with eosinophilic infiltrates, compatible with drug-induced liver injury 
(Figure 14). Other recently administered drugs were a single i.v. dose of 2g cefazolin 
before knee replacement and postoperative analgesic treatment with acetaminophen 
and metamizole (=dipyrone) up to 4 g/day each for 10 days. During the further 
course the patient eventually developed a paralytic ileus and died 6 weeks after 
rehospitalization. The findings are also summarized in Table 14. 
According to standardized RUCAM criteria for the assessment of drug-induced liver 
injuries 172-174 we assigned a causality of “highly probable” (total score: 9) to 
rivaroxaban. Key criteria for this assessment were a close and plausible temporal 
relationship, a known and labeled adverse drug reaction, compatible histological 
findings, and negative differential diagnosis for alternative causes. Specifically, 
temporal relationship, only mild ALT increase and histology were not compatible with 
acetaminophen hepatotoxicity; dalteparin and metamizole had been stopped 
approximately 14 days, and cefazolin single dose was given 24 days before onset of 
symptoms. Other drugs were therefore classified as unlikely alternative causes.  
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Figure 14: Liver histology in cases #1 and #2 
Histology in the two patients where needle liver biopsies were performed revealed 
almost identical morphological findings with more pronounced changes in case #2. 
Liver parenchyma shows a centrilobular accentuated cholestasis (A, arrow) with 
prominent Kupffer cells and focal ballooning of periportal hepatocytes (B). There is a 
mainly portal inflammation of mixed cellularity, focal with many eosinophilic 
granulocytes and some periductal reinforcement (C, B). Interlobular bile ducts show 
an alteration of the epithelium with intraepithelial lymphocytes (D and inset, arrow) 
and some ductular reaction (D, inset, arrowhead). No ductopenia or fibrosis is 
present. (H&E; inset panel D: cytokeratin 7 immunohistochemistry stain of bile 
ducts). 
 
Liver histology, case #1 
 
 
 
 
 
 
 
Liver histology, case #2 
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Table 1: Case presentations, continued on next 2 pages 
 
Case 
# 
Age Sex RVXB 
indication 
RVXB 
dose/day 
(mg) 
RVXB 
treatment 
duration 
(days) 
Latency 
time1 
(days) 
Symptoms ALT 
(xULN)2 
initial           
max 
AP 
(xULN)3 
initial       
max 
R4 TB 
(xULN)5 
initial          
max 
Outcome Differential diagnosis RUCAM6 
causality 
score 
RUCAM6 
causality 
class 
Comments 
1 78 m Knee 
replacement 
20 19 14 Painless 
jaundice, 
nausea 
2.5 
(day30) 
2.9  
(day 30) 
0.8 15.5  
(day 30)   
21.6  
(day 42) 
Death 
(paralytic 
ileus) 
Vira serology for HBV, HCV, 
CMV, EBV negative; 
autoantibodies and imaging 
negative. No other suspicious 
drugs or events causing liver 
injury identified. 
9 Highly 
probable 
Liver biopsy 
performed (see 
Figure) 
2 83 f Knee 
replacement 
10 21  16  Painless 
jaundice, 
nausea 
7.8 
(day20) 
6.8 
(day20) 
7.1 
(day 29) 
1.2 13.9  
(day 20)  
17.1  
(day 27) 
Recovery Viral serology for HAV, HBV, 
HCV, CMV, EBV negative; 
autoantibodies and imaging 
negative. Diclofenac alternative 
possible cause. 
5 Possible Liver biopsy 
performed (see 
Figure) 
3 74 m Atrial 
fibrillation 
20 51  <50  Painless 
jaundice 
4  
(day 51)       
5.1  
(day 55) 
<1  
(day 51) 
5.1 3.1 
(day 51)     
3.7  
(day 52) 
Recovery Viral serology for HBV negative; 
IgG and imaging negative. No 
other suspicious drugs or events 
causing liver injury identified. 
7 Probable Meets biochemical 
criteria for Hy's 
case7. 
4 63 m Atrial 
fibrillation 
20 6  5  Nausea and 
vomiting 
7.8 
(day 7) 
<1  
(day 6) 
7.8 <1  
(day 6) 
Recovery Amiodarone 600 mg/d may be 
alternative or contributory cause. 
No other events that suggest 
alternative cause.  
3 Possible Nausea improved 
immediately after 
stop of RVXB while 
high dose 
amiodarone was 
continued (no follow-
up of ALT available). 
5 91 f Atrial 
fibrillation 
15 34  14  Painless 
jaundice, 
nausea 
2.5  
(day 34) 
7.8  
(day 37) 
0.3 8.4  
(day 34) 
Recovery Viral serology for HAV, HBV, 
HCV, HDV, HEV negative; ANA, 
ANCA, Anti-MPO, Anti-PR3 
negative; imaging negative. No 
other suspicious drugs or events 
causing liver injury identified. 
9 Highly 
probable 
  
6 64 f Atrial 
fibrillation 
20 40  <40  No 
symptoms 
6.3  
(day 40) 
1.5  
(day 40) 
4.1 n.a. Recovery No other suspicious drugs or 
events causing liver injury 
identified. 
7 Probable   
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Case 
# 
Age Sex RVXB 
indication 
RVXB 
dose/day 
(mg) 
RVXB 
treatment 
duration 
(days) 
Latency 
time1 
(days) 
Symptoms ALT 
(xULN)2 
initial           
max 
AP 
(xULN)3 
initial       
max 
R4 TB 
(xULN)5 
initial          
max 
Outcome Differential diagnosis RUCAM6 
causality 
score 
RUCAM6 
causality 
class 
Comments 
7 75 m Knee 
replacement 
20 15  15  Painless 
jaundice 
10.6 
(day 18)  
11.3 
(day 22) 
3.2  
(day 18)   
6.2  
(day 33) 
3.4 4.5  
(day 18)     
9.0  
(day 22) 
Recovery Imaging negative; HBV, HCV, 
EBV, CMV, ANA, Anti-dsDNA 
and IgG negative. No other 
suspicious drugs or events 
causing liver injury identified. 
9 Highly 
probable 
  
8 69 f Knee 
arthroscopy 
10 10  13  Fatigue, loss 
of appetite 
2.7  
(day 12) 
<1  
(day 26) 
2.7 n.a. Recovery No differential diagnostic 
investigations performed, 
because presentation and history 
did not suggest alternative 
causes. No other suspicious 
drugs or events causing liver 
injury identified. 
9 Highly 
probable 
"Positive 
rechallenge": 
Reexposure to 
RVXB after knee 
replacement 6 
months later with 
subsequent increase 
of AP (2.8 xULN) 11  
after surgery and 
restart of RVXB; 
again recovery after 
stop. 
9 61 f Knee 
surgery 
(cruciate 
ligament 
plasty) 
10 24  20  Jaundice, 
nausea, 
pruritus 
13.6 
(day 24) 
1.5  
(day 24) 
9.3 3.7 
(day 24) 
Recovery HBV vaccinated. Acetaminophen 
possibly contributory but unlikely 
primary cause (only 3g/day, 
jaundice and long latency time 
not typical for intrinsic 
acetaminophen hepatotoxicity). 
6 Probable Meets biochemical 
criteria for Hy's 
case7. 
Acetaminophen may 
have contributed to 
ALT increase. 
10 60 f Knee 
replacement 
10 17  14  Jaundice, 
fatigue, 
vomiting,  
18.6 
(day 17) 
19.9 
(day 20) 
n.a. n.a. 4.2  
(day 17)     
8.4  
(day 13) 
Recovery Imaging negative; HAV, HBV, 
HCV, ANA, Anti-
SLA/SM/mitochondria negative. 
No other suspicious drugs or 
events causing liver injury 
identified. 
6 Probable Meets biochemical 
criteria for Hy's 
case7. 
Acetaminophen may 
have contributed to 
ALT increase. 
11 41 f Leg surgery 
after 
trimalleolar 
Fx 
10 27  20  Jaundice, 
nausea and 
vomiting, 
pruritus 
 53.7 
(day 27) 
3.4  
(day 27) 
15.6 4.8  
(day 30)      
Recovery HAV, HBV, HCV, HEV, CMV, 
EBV, ANA and Anti-sm negative, 
IgG normal. Imaging negative. No 
other suspicious drugs or events 
causing liver injury identified. 
7 Probable Meets biochemical 
criteria for Hy's 
case7. 
Acetaminophen may 
have contributed to 
ALT increase. 
12 78 f Knee 
replacement 
10 62  62  Jaundice, 
nausea, 
diarrhea 
14  
(day 62) 
2.1  
(day 62) 
6.5 n.a. Recovery Acetaminophen postoperatively 
not documented but possible. No 
suggestion for alternative causes 
but no formal exclusion. 
5 Possible   
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Case 
# 
Age Sex RVXB 
indication 
RVXB 
dose/day 
(mg) 
RVXB 
treatment 
duration 
(days) 
Latency 
time1 
(days) 
Symptoms ALT 
(xULN)2 
initial           
max 
AP 
(xULN)3 
initial       
max 
R4 TB 
(xULN)5 
initial          
max 
Outcome Differential diagnosis RUCAM6 
causality 
score 
RUCAM6 
causality 
class 
Comments 
13 73 m Knee 
replacement 
10 3  3  Jaundice, 
nausea, mild 
pain 
6.1  
(day 5) 
2.5  
(day 5) 
2.5 n.a. Recovery Imaging negative. No other 
suspicious drugs or events 
causing liver injury identified. 
6 Probable Unusually short 
latency time. 
Cefazolin 
preoperative single 
i.v. application, but 
cefazolin previously 
well tolerated. 
14 42 f Leg surgery 
after 
Maisonneuv
e-Fx 
10 31  29  Jaundice, 
nausea 
23.5 
(day 30) 
3.2  
(day 30) 
7.3 2.8  
(day 30)     
3.0  
(day 54) 
Recovery Viral serology and autoantibodies 
negative. No other suspicious 
drugs or events causing liver 
injury identified. 
8 Probable   
                 
Legend Table 1               
1 Time from start of RVXB to first symptoms or signs of liver injury.        
2 Alanine aminotransferase, expressed as multiples of upper limit of normal. Time in relation to start of RVXB.     
3 Alkaline phosphatase, expressed as multiples of upper limit of normal. Time in relation to start of RVXB. 
     4 Laboratory classification of drug-induced liver injury (see also reference 2), where R = ratio ALT/AP, where both are expressed as multiples of upper limit of normal 
  5 Total bilirubin, expressed as multiples of upper limit of normal. Time in relation to start of RVXB. 
     6 Roussel Uclaf Causality Assessment Method, endorsed by the Council of International Organizations of Medical Sciences (see also references 1 and 2). 
   7 Hy's case criteria: ALT >3x ULN and TB >2x ULN without initial AP increase / cholestatic enzyme pattern (see also reference 6). 
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Case #2 
An 83-year-old female patient had total knee replacement for which she received 
thromboprophylaxis with dalteparin for 9 days and thereafter rivaroxaban 10 mg/d. 
Approximately 13 days after start of rivaroxaban the patient developed painless 
jaundice, pruritus, fatigue, nausea and unintentional weight loss of 5 kg. Twenty days 
after start of rivaroxaban the patient was rehospitalized, and another day later 
rivaroxaban was replaced by dalteparin. Upon admission ALT, AP and TB were 
increased 7.8, 6.8 and 13.9 times the ULN, respectively (Table 14). Viral serology 
and autoantibodies were negative. Abdominal ultrasound and CT showed 
cholecystolithiasis but no signs of biliary obstruction. A liver biopsy was performed 5 
days after stop of rivaroxaban and was compatible with drug-induced liver injury 
showing a similar histology (Figure) as in case #1. Other recently administered drugs 
were a single i.v. dose of 2g cefazolin before knee replacement and analgesic 
treatment with acetaminophen 4 g/day and diclofenac 150 mg/d for 9 days 
postoperatively (followed by an on-demand prescription for another 20 days, but 
unknown actual use), and metamizole 1000 mg and 500 mg on postoperative days 1 
and 3, respectively. The patient was treated with cholestyramine and subsequently 
recovered over the following weeks. 
Formal RUCAM assessment classified rivaroxaban‘s causality as “possible” (total 
score: 5), based on the key criteria of a close and plausible temporal relationship, a 
known and labeled adverse drug reaction, compatible histological findings and 
negative differential diagnosis for alternative causes except for diclofenac use. 
Nevertheless, in contrast to rivaroxaban, fixed-dose diclofenac was stopped 16 days 
before onset of symptoms, and rivaroxaban therefore remains the most likely cause 
of liver injury. 
 
Cases #3-14 
Over the past 4 years and in our function as a regional pharmacovigilance center we 
received another 12 reports of liver injury associated with rivaroxaban and an at least 
possible causal relationship based on RUCAM criteria. In addition to our primary 
documentation we now performed an extensive reevaluation including formal 
causality assessment. For that purpose we contacted primary reporters and other 
treating physicians and hospitals and obtained all available relevant follow-up 
information. These cases are summarized in Table 14, and their detailed RUCAM 
classifications are presented in Table 15. 
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Table 15: Detailed RUCAM causality assessment and scores for all 14 cases 
 
Case # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
               
RUCAM criteria 
 
hepatocell or chol/mix  chol chol hepatocell hepatocell chol mix mix ? hepatocell ? hepatocell hepatocell mix hepatocell 
1 (temporal relationship) 2 2 2 2 2 2 2 1 2 2 2 2 1 2 
2 (course after drug cessation) 2 0 2 0 2 2 1 2 3 2 3 2 2 2 
3.1 (risk factors, alcohol) 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
3.2 (risk factors, age) 1 1 1 1 1 1 1 1 1 1 0 1 1 0 
4 (concomitant drugs) 0 -2 0 -2 0 0 0 -2 -2 -2 -2 -2 0 0 
5 (exclusion of non-drug 
causes) 
2 2 0 0 2 0 2 2 0 1 2 0 0 2 
6 (labeling / previous 
information on hepatotoxicity) 
2 2 2 2 2 2 2 2 2 2 2 2 2 2 
7 (rechallenge) 0 0 0 0 0 0 0 3 0 0 0 0 0 0 
TOTAL SCORE 9 5 7 3 9 7 9 9 6 6 7 5 6 8 
               
Score interpretation 
highly 
prob. 
possible probable possible 
highly 
prob. 
probable 
highly 
prob. 
highly 
prob. 
probable probable probable possible probable probable 
               
For detailed description of RUCAM criteria see also references 167 (Aithal et al. 2011) and 168 (Danan and Benichou 1993) 
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Reports in International Pharmacovigilance Databases 
Cases of liver injury associated with rivaroxaban should be reported to 
pharmacovigilance systems worldwide, and we therefore also performed searches in 
databases of international postmarketing spontaneous reporting systems. The 
database of the World Health Organization (WHO UMC VigiBase, access date 2013-
11-28) contains, including our own cases, reports of 179 cases that are compatible 
with DILI (classified under 19 selected hepatobiliary WHO-ART reaction terms) 
where rivaroxaban was reported as a suspected cause; the database of the 
European Medicines Agency (EMA EudraVigilance, access date 2013-11-03, data 
censored 30 September 2013) contains 375 events classified under 21 selected 
hepatobiliary MedDRA reaction terms where rivaroxaban was a suspected cause; 
and the database of the US Food and Drug Administration (FDA FAERS, data 
censored 31 December 2012, extracted in November 2013 by the FDA in response 
to our request under the Freedom of Information Act) contains 87 cases classified 
under the 21 selected MedDRA terms. For details on searched terms and reported 
hepatic events see supplementary material (S.1). 
These reports have limitations and must therefore be interpreted with caution: in the 
absence of detailed information the causal role of rivaroxaban regarding the reported 
hepatic outcomes remains uncertain; due to unknown reporting rates and population 
exposure spontaneous reporting systems cannot provide reliable quantitative risk 
estimates; pharmacovigilance systems may contain duplicate reports, and in our 
EudraVigilance search several adverse events may refer to only one individual case. 
Nevertheless, these reports can be interpreted as a signal in support of the 
hypothesis that our cases may represent just the “tip of the iceberg” of a considerably 
larger number of serious liver injuries worldwide caused by rivaroxaban. 
 
8.1.7. Conclusion 
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide 
since 2008 for the primary and secondary prevention and treatment of 
thromboembolic disorders. Five years after market launch we are not aware of any 
published detailed postmarketing case reports of liver injury associated with 
rivaroxaban. However, liver injury is known under rivaroxaban, labeled adverse 
reactions include icterus and increased transaminases, alkaline phosphatase, and 
total and conjugated bilirubin.87 Of note, the direct thrombin inhibitor ximelagatran 
was associated with hepatotoxicity during clinical development, which contributed to 
non-approval by the US FDA, and in other countries marketing was discontinued 
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after serious cases of liver injury associated with ximelagatran appeared in the 
postmarketing phase.175 Looking at premarketing data of rivaroxaban, a published 
evaluation of rivaroxaban’s hepatic events in clinical trials was based on its phase III 
RECORD studies and included 6131 patients exposed to rivaroxaban. The featured 
analysis used state of the art eDISH plots171 and identified ALT increases ≥3x ULN in 
2.3% of patients including 9 apparent “Hy’s cases” with a simultaneous ≥2x increase 
in total bilirubin. Further validations concluded that there was only one “true” Hy’s 
case either caused by rivaroxaban or possibly by other incompletely excluded 
alternate etiologies.171 A recent systematic review and meta-analysis of premarketing 
data on liver injury associated with new oral anticoagulants reported ambiguous 
results. There were a large number of cases with ALT elevations >3x ULN including 
many with concomitant total bilirubin >2x ULN subsequent to the use of those drugs. 
At the same time there were no evident risk differences between the individual 
studied new oral anticoagulants, and a lower risk of such events when compared to 
low molecular weight heparins.176 However, safety analyses of clinical trials’ data 
have intrinsic limitations. According to the “Rule of 3” 177,178 the 6131 exposed 
patients in the RECORD studies are insufficient to reliably detect risks of less than 
approximately 1:2000, which is typical for idiosyncratic drug-induced liver disease 
(DILI) but can still be relevant for a drug’s overall risk-benefit evaluation.179 Another 
limitation is that the duration of treatment in these trials was only 35±2 or 12±2 days, 
respectively.171 This is shorter than the currently labeled treatment time for some 
indications, and 12±2 days are also less than the median latency time of 15.5 days in 
our case series. Risk factors are another issue of particular interest, as they are often 
underrepresented in clinical trial populations. Rivaroxaban is often started after 
orthopedic surgery and many patients concomitantly receive potentially hepatotoxic 
analgesic drugs. Our series included three patients meeting biochemical criteria of 
Hy’s cases but concomitant use of acetaminophen in therapeutic doses. Dose, long 
latency time and histology were not compatible with acetaminophen-induced 
hepatotoxicity in these cases. However, according to current mechanistic concepts 
acetaminophen in doses below the hepatotoxic threshold may attenuate hepatotoxic 
“downstream” pathways via glutathione depletion and cytokine-mediated signal 
transduction. Acetaminophen could therefore have acted as a risk factor for 
rivaroxaban-induced liver injury.180,181 Some patients also received metamizole, but 
hepatotoxicity is not amongst its labeled adverse reactions. Indeed, we found only 
one case of metamizole-associated liver injury in the literature,182 but it presented 
with an allergic skin reaction after short latency, which is different from the pattern 
observed in our cases. In order to further clarify the causality in our case series, we 
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planned the conduct of lymphocyte transformation tests (LTT) with in-vitro exposure 
of lymphocytes from our patients to rivaroxaban. This method has been successfully 
used for the evaluation of DILI in the past.183 These planned studies have been 
delayed because we were unable to obtain rivaroxaban pure substance from the 
manufacturer of Xarelto®, but we now aim to perform these tests with commercially 
available rivaroxaban. 
 
Possible mechanisms of rivaroxaban-induced hepatotoxicity are unknown and 
probably involve complex interactions of several rare factors, possibly also immune-
mediated reactions. Of further note, previous studies indicated that rivaroxaban is a 
shared substrate of the drug transport proteins MDR1 and BCRP, whereas 
anticoagulant vitamin K antagonists are no strong substrates of MDR1.184-186 MDR1 
inhibitors and loss-of-function BCRP polymorphisms may therefore alter rivaroxaban 
pharmacokinetics, and further studies may explore the potential role of these factors 
for rivaroxaban-induced DILI.  
 
The diagnosis of drug-induced liver injury mainly depends on temporal relationship 
and the exclusion of other causes, which can never be done with absolute certainty. 
Furthermore, even the widely accepted RUCAM causality scale for DILI has 
limitations, and discrepancies between expert evaluations vs. standardized scales 
have been widely discussed and studied.174,187,188 At least all cases reported to our 
center were evaluated using senior expertise and the most recognized standardized 
DILI-specific criteria. In contrast, the routine evaluation of cases that are reported to 
large pharmacovigilance databases usually lacks detailed case information and 
sufficient resources for standardized DILI-specific causality assessments. In order to 
avoid over-interpretation it is therefore reasonable that publicly available search 
results from those databases only contain the information whether a specific drug is 
considered as an at least possible cause. Furthermore, we also recognize that some 
individual cases may have been reported to more than one of the searched 
databases. Spontaneous reports are neither meant to provide definite proof for the 
causative role of rivaroxaban in the presented cases, nor can they be used for 
reliable calculations of quantitative risk estimates. However, we applied the best 
possible combination of standardized causality assessment plus expert evaluation, 
and in our long-term experience as a pharmacovigilance center the presented case 
series of liver injury in association with a newly marketed drug is unusual and reason 
to raise concern. Premarketing experience and information from international 
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pharmacovigilance databases are also compatible with the possibility that 
rivaroxaban continues to cause a considerable absolute number of liver injuries 
worldwide. In conclusion, we therefore interpret the presented case series as a 
potentially serious signal that requires follow-up by pharmacoepidemiological cohort 
studies in suitable databases in order to estimate the absolute and relative risks of 
serious liver injury associated with rivaroxaban versus alternative anticoagulants.179 
Meanwhile, the apparently rare but potentially serious risk of rivaroxaban-induced 
liver injury should be considered in the risk-benefit evaluation versus alternative 
antithrombotic drugs with established safety profiles. In patients treated with 
rivaroxaban incident symptoms and signs of liver disease should be considered as a 
potential adverse drug reaction, and if no other likely cause can be identified 
rivaroxaban should be stopped as soon as possible.  
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with herbal drugs that are commonly perceived as “safe” and it analyzes reports from 
the world’s largest international pharmacovigilance database. Risks of allergic 
reactions towards herbal remedies have to be considered in light of the sometimes 
very limited evidence for their benefits, especially if used in hospitalized patients with 
an already high drug and disease burden. This study uses the term adverse drug 
reaction (ADR) in its pharmacovigilance context as defined by the WHO in 1972. 
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8.2.3. Background 
There is an increased prevalence in use of herbal medicines among the adult 
population in many western countries.189-191 The most recent 2012 US National 
Health Interview Survey showed that 18% of adults used natural products including 
herbal medicine during the past 12 months.191 The public often considers herbal 
products as safe since they are natural and is unaware that Complementary and 
Alternative Medicines (CAM) are not tested by regulatory agencies for their safety 
and efficacy.192 In most countries, herbal medicines are defined as dietary 
supplements and as such do not have to meet pre- and post-marketing drug policy 
regulations.193 However, use of herbal medicines can be associated with 
development of severe adverse reactions as a result of complex chemistry of herbals 
as well as their inappropriate use and a lack of quality control.194,195 In addition, 
patients may not disclose self-medication with herbal medicines to their health care 
professionals, and even if they do there may be limited knowledge of their potential 
adverse reactions and interactions with concomitantly used prescription drugs.196,197 
In the absence of comprehensive systematic safety evaluations of herbal medicines, 
spontaneous reporting systems of adverse drug reactions (ADR) play a major role for 
their worldwide safety surveillance and signal detection.198 Although there are many 
case reports of ADR associated with herbals in the literature, the majority of reports 
are documented in large pharmacovigilance databases, and those valuable 
resources should be systematically analyzed for ADR associated with 
herbals.195,199,200  ADR to herbals cover a wide range of manifestations that are 
mostly mild and followed by full recovery. However, immediate-type allergic reactions 
are also a typical, potentially life threatening and therefore clinically most relevant 
adverse reaction to herbal products.  
 
8.2.4. Objectives 
Therefore, we conducted a study that aimed to investigate the reporting patterns and 
characteristics of immediate allergic adverse reactions associated with herbal 
medicines in international pharmacovigilance. 
 
8.2.5. Methods 
Study settings 
VigiBase®, the largest international pharmacovigilance database of spontaneous 
ADR reports was the source of our reports. VigiBase® is maintained by the Uppsala 
Monitoring Centre (UMC) in association with the World Health Organization’s (WHO) 
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international pharmacovigilance program. The UMC is an independent foundation 
and a center for international service and scientific research. It collaborates with 118 
member countries around the world that collect and evaluate spontaneous ADR 
reports.201 These centers forward anonymized ADR reports received from various 
primary reporting sources to the UMC in a standardized format, containing structured 
information on adverse events, involved patients and drugs including standardized 
semi-quantitative causality assessments.2  
The database of the UMC, Vigibase currently contains over 9 million case reports. 
The WHO Adverse Drug Reaction Terminology (WHOART) and WHO Drug 
Dictionary/WHO Herbal Dictionary are used for coding of clinical information in 
relation to drug therapy and reported drugs on the reports.201 MedDRA terminology 
has been made the standard in VigiBase for several years, and there are automated 
algorithms that convert codes form those two dictionaries in both directions. Herbal 
medicine refers to herbs, herbal materials, herbal preparations and finished herbal 
products. Herbal products are assigned herbal anatomical-therapeutic-chemical 
(HATC) codes specifying their therapeutic use according to the Guidelines for Herbal 
ATC classification.202 HATC classification aggregates herbal remedies according to 
their medical uses that have been found in the literature and does not indicate that 
the remedy has been proven as effective or safe. Herbal pharmacovigilance 
terminology is used in accordance with WHO guidelines.203 
 
Study design and selection of cases 
A flowchart of the study design and case selection process is presented in Figure 
15. The aim of our study was to focus on immediate-type allergic ADR associated 
with herbals, because those are potentially life threatening and therefore clinically 
highly relevant. The level of documentation within VigiBase® is heterogeneous, and it 
may be difficult to make an exact medical diagnosis based on the available 
information. With this limitation in mind we defined case selection criteria that are 
likely indicators of immediate-type allergic reactions (see Table 2 for a listing of 
included WHOART terms). Because VigiBase® does not allow for a validation of type 
1 immediate hypersensitivity reactions according to comprehensive clinical 
diagnostic criteria we carefully refer to included cases as “allergy-like immediate 
reactions” in our study. For inclusion in the study population we used the following 
inclusion criteria: exposure to manually validated herbal products, which must be 
classified by the primary reporter as “suspect” with regard to the reported ADR; 
documented causality assessment between herbal product and ADR classified as 
“possible”, “probable” or “certain”; documented latency time from herbal exposure to 
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ADR onset of no more than one day; manual selection of WHO-ART preferred terms 
indicating an ADR that is a likely symptom of an immediate-type hypersensitivity 
reaction. In contrast, reaction terms that are compatible with but have a low 
specificity for immediate type allergic reactions such as cough, dyspnea, larynx pain, 
gastrointestinal symptoms or pruritus were on their own not considered sufficient for 
inclusion. Furthermore, we excluded ADR associated with the HATC term “herbal 
pollen not otherwise specified” from the main analysis because these are likely to 
refer to desensitization vaccines for the treatment of pollen allergies (ADR that may 
have a distinct special relationship to the indication for the suspected herbal 
products). ADR were also stratified over asthma-like reactions (defined by WHO-ART 
preferred terms “asthma”, “stridor” or “bronchospasm”) vs. all other ADR terms with 
high specificity for immediate-type allergic reactions.  
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Figure 15: Flowchart of study design and case selection process  
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Statistical analysis 
Descriptive statistics was used to analyze case report characteristics. The 
unexpected ADR to herbals was quantitatively analysed using the Bayesian 
Confidence Propagation Neural Network methodology (BCPNN), a data-mining 
technique used for the detection of new signals in spontaneous reporting of ADR.204 
The measure of disproportionality expressed as the Information Component (IC) is 
used to indicate the frequency of specific drug-ADR combination that occurs more 
frequently in the database than expected in relation to the number of all reports with 
the particular drug and ADR and the total number of reports in the database. The IC 
is a logarithmic measure of association and is calculated as IC = log2 p(x,y) / ( p(x) * 
p(y) ), where: p(x) = probability of a specific drug x is listed on a case report; p(y) = 
probability of a specific drug-ADR combination x and y is listed on a case report; 
p(x,y) = probability of a specific drug x is listed on a case report.  
An IC of 0 results from drug-ADR combinations for which the number of observed 
cases is the same as that which might be expected from the overall reporting in the 
data set. Accordingly, an IC above 0 indicates that a specific drug-ADR combination 
occurs more frequently in the dataset than expected from the background of the 
database. For the IC analysis we used the dataset of all reports that met our 
inclusion criteria and calculated the IC for all specific combinations that occurred with 
a frequency of 10 or more. Data management and analyses were performed using 
STATA Version 13.1 (StataCorp LP, College Station, TX, USA). 
 
8.2.6. Results 
The initial dataset extracted from VigiBase® comprised 26,909 unique ADR reports 
with documented exposure to herbal products. These reports were received between 
1969 and August 2014. After application of exclusion criteria 757 unique reports 
remained with 1,039 ADR (more than one reaction term can be reported per case) 
related to herbal products for the analyses (Figure 15). The chronology for receipt of 
those reports is presented in Figure 16, showing a pronounced increase of the 
reporting frequency in recent years. More than 50% of all included reports came from 
only three countries, i.e. Germany (22.3%), Australia (14.9%) and Thailand (11.2%). 
The most frequent primary reporters were physicians (32.1%), followed by hospitals 
(24.7%) and pharmacists (14.1%) 
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Figure 16: Number of reports of immediate allergy-like adverse reactions after 
the use of herbals per year (N=757) 
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Patients’ characteristics 
Patient demographics and reporting information of the 757 included reports are 
presented in Table 16. Women were overrepresented among included cases 
(68.6%), and more than one third of cases fell into the age category from 18 to 44 
years. 
 
 
Table 16:  Case report characteristics (N=757) 
 n % 
   
Gender   
   Female 519 68.6 
   Male 225 29.7 
   Not specified 13 1.7 
   
Age group (years)   
   <18 109 14.4 
   18 - 44 278 36.7 
   45 - 64 199 26.3 
   ≥ 65 117 15.5 
   Not specified 54 7.1 
   
Reporting country   
   Germany 169 22.3 
   Australia 113 14.9 
   Thailand 100 13.2 
   South Korea 49 6.5 
   Spain 43 5.7 
   Sweden 39 5.2 
   Switzerland 37 4.9 
   Cuba 29 3.8 
   United Kingdom 17 2.3 
   Malaysia 16 2.1 
   New Zealand 15 2.0 
   Norway 11 1.5 
   Other (<10 reports per country) 119 15.7 
   
Reporting source   
   Physician 243 32.1 
   Hospital 187 24.7 
   Pharmacist 107 14.1 
   Manufacturer 38 5.0 
   Consumer / non health professional 14 1.9 
   Other / not specified 168 22.2 
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Allergy-like immediate reactions 
Characteristics of allergy-like immediate reactions under herbal remedies are 
presented in Table 17 along with stratifications over the three given causality 
categories. The likelihood of a causal connection in the 1,039 reported ADR had 
been assessed as “possible”, “probable” and “certain” in 59.2%, 32.2% and 8.6%, 
respectively. Outcome was favorable with recovery in 77.7% of all ADR, and there 
were no lethal cases. One should note however that there was no information 
available on the outcome for 9.2%. Asthma-like reactions accounted for only 4.8% of 
all ADR. The most commonly reported allergy-like immediate adverse reactions 
associated with herbals were “rash” (16.2%), “urticaria” (15.3%) and “rash 
erythematous” (13.4%). Anaphylactic and anaphylactoid reactions accounted 
altogether for 9.5% of reported ADR (anaphylactic reaction 4.5%, anaphylactic shock 
2.8%, anaphylactoid reaction 2.2%), and Table 16 shows other serious ADR such as 
bronchospasm or larynx oedema.  
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Table 17: Characteristics of immediate allergy-like reactions after the use of 
herbal remedies (N=757) 
 
 Causality Overall 
 Possible Probable Certain   
 n % n % n % n % 
         
Total number of reported ADRs a 
 
615 59.2 335 32.2 89 8.6 1039 100 
Type of ADRs a          
   Allergic 584 95.0 319 95.2 86 96.6 989 95.2 
   Asthma-like b 31 5.0 16 4.8 3 3.4 50 4.8 
         
Specification of reported ADRs a 
(WHOART c preferred term) 
 
        
   Rash 108 17.6 53 15.8 7 7.9 168 16.2 
   Urticaria 86 14.0 57 17.0 16 18.0 159 15.3 
   Rash erythematous 91 14.8 37 11.0 11 12.4 139 13.4 
   Allergic reaction 42 6.8 13 3.9 3 3.4 58 5.6 
   Angioedema 27 4.4 21 6.3 5 5.6 53 5.1 
   Flushing 29 4.7 15 4.5 4 4.5 48 4.6 
   Anaphylactic reaction 28 4.6 10 3.0 9 10.1 47 4.5 
   Face oedema 34 5.5 10 3.0 2 2.3 46 4.4 
   Rash maculo-papular 23 3.7 21 6.3 - - 44 4.2 
   Oedema mouth 14 2.3 14 4.2 10 11.2 38 3.7 
   Oedema periorbital 24 3.9 9 2.7 3 3.4 36 3.5 
   Anaphylactic shock 11 1.8 15 4.5 3 3.4 29 2.8 
   Bronchospasm 14 2.3 11 3.3 1 1.1 26 2.5 
   Anaphylactoid reaction 11 1.8 8 2.4 4 4.5 23 2.2 
   Tongue oedema 12 2.0 6 1.8 3 3.4 21 2.0 
   Asthma 11 1.8 5 1.5 2 2.3 18 1.7 
   Dermatitis contact 5 0.8 8 2.4 3 3.4 16 1.5 
   Dermatitis 6 1.0 7 2.1 1 1.1 14 1.4 
   Oedema pharynx 4 0.7 6 1.8 1 1.1 11 1.1 
   Oedema generalized 5 0.8 4 1.2 - - 9 0.9 
   Eosinophilia 8 1.3 - - - - 8 0.8 
   Allergy 6 1.0 - - 1 1.1 7 0.7 
   Larynx oedema 4 0.7 3 0.9 - - 7 0.7 
   Stridor 5 0.8 - - - - 5 0.5 
   Erythema multiforme 3 0.5 - - - - 3 0.3 
   Skin reaction localized 2 0.3 - - - - 2 0.2 
   Bronchospasm aggravated 1 0.2 - - - - 1 0.1 
   Drug hypersensitivity syndrome - - 1 0.3 - - 1 0.1 
   Purpura allergic - - 1 0.3 - - 1 0.1 
   Urticaria acute 1 0.2 - - - - 1 0.1 
         
Outcome          
   Recovered 431 70.1 296 88.4 80 89.9 807 77.7 
   Not recovered (yet) 97 15.8 18 5.4 4 4.5 119 11.5 
   Recovered with sequelae 10 1.6 7 2.1 - - 17 1.6 
   Died - - - - - - - - 
   Unknown / Not specified 77 12.5 14 4.2 5 5.6 96 9.2 
         
a ADRs, adverse drug reactions; b asthma-like ADRs included WHO-ART preferred terms “asthma,” “stridor” and “bronchospasm,” c 
WHOART, The WHO Adverse Reactions Terminology 
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Suspect Herbals  
Descriptions of specific herbals associated with reported ADR and their route of 
administration are presented in Table 18. Preparations that contained a mixture of 
several herbals were the suspected cause in 36% of all ADR and therefore by far the 
most frequently reported herbal products in association with ADR, followed by 
Phleum pratense (common name: Timothy grass, 6.5%), Andrographis paniculata 
(several common names including kalmegh, 5.0%), Echinacea purpurea (3.8%) and 
Ginkgo biloba (3.6%). Oral administrations accounted for almost two thirds of ADR, 
followed by topical / cutaneous and sublingual administrations in 9.0% and 6.4%, 
respectively.  
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Table 18: Characteristics of suspect herbals associated with immediate 
allergy-like reactions (N=757) 
 Causality Overall 
 Possible Probable Certain   
 n % n % n % n % 
         
Total number of reported ADRs a 
 
615 59.2 335 32.2 89 8.6 1039 100 
         
Herbs reported in association with ADRs a 
 
        
   Mixed herbals 220 35.8 126 37.6 28 31.5 374 36.0 
   Phleum pratense 16 2.6 25 7.5 27 30.3 68 6.5 
   Andrographis paniculata 27 4.4 25 7.5 - - 52 5.0 
   Echinacea purpurea 30 4.9 6 1.8 3 3.4 39 3.8 
   Ginkgo biloba 29 4.7 6 1.8 2 2.3 37 3.6 
   Hedera helix 25 4.1 4 1.2 1 1.1 30 2.9 
   Plantago ovata 6 1.0 9 2.7 4 4.5 19 1.8 
   Hypericum perforatum 13 2.1 4 1.2 1 1.1 18 1.7 
   Viscum album 13 2.1 4 1.2 1 1.1 18 1.7 
   Valeriana officinalis 10 1.6 6 1.8 1 1.1 17 1.6 
   Cimicifuga racemosa 11 1.8 5 1.5 - - 16 1.5 
   Mentha x piperita 6 1.0 9 2.7 1 1.1 16 1.5 
   Other (<15 ADRs per herbal) 209 34.0 106 34.0 20 22.5 335 32.2 
         
Administration route of reported herbal 
   
      
   Oral 394 64.1 234 69.9 29 32.6 657 63.2 
   Topical / cutaneous 57 9.3 26 7.8 10 11.2 93 9.0 
   Sublingual 18 2.9 21 6.3 27 30.3 66 6.4 
   Intravenous 29 4.7 6 1.8 4 4.5 39 3.8 
   Subcutaneous 11 1.8 12 3.6 6 6.7 29 2.8 
   Other (≤10 ADRs per route) 38 6.2 14 4.2 6 6.7 58 5.6 
   Not specified 68 11.1 22 6.6 7 7.9 97 9.3 
         
a ADRs, adverse drug reactions         
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Disproportionality analysis 
Calculations of IC values for all 16 specific herbal / allergy-like reaction combinations 
that had been reported at least 10 times are presented in Table 19. Accordingly, 
significantly higher frequencies than expected by chance were found for Phleum 
pratense (Timothy grass) linked to oedema of the mouth (IC= 1.81, 95%CI 0.67-2.86) 
and to anaphylactic reactions (IC= 1.23, 95%CI 0.03-2.33). 
 
Table 19: Most frequently reported (N≥10) specific combinations of herbal 
remedies and allergic reactions with their IC values 
 
Herbal remedy WHOART b preferred term N 
reports 
% IC a (95% CI) 
      
Mixed herbals Rash 75 (7.2) -0.15 (-0.60 - 0.30) 
Mixed herbals Urticaria 58 (5.6) -0.44 (-0.93 - 0.04) 
Mixed herbals Rash erythematous 36 (3.5) -0.93 (-1.53 - -0.36) 
Mixed herbals Face oedema 21 (2.0) -0.11 (-0.95 - 0.68) 
Mixed herbals Allergic reaction 20 (1.9) -0.52 (-1.35 - 0.26) 
Mixed herbals Rash maculo-papular 20 (1.9) -0.12 (-0.98 - 0.70) 
Mixed herbals Oedema mouth 19 (1.8) 0.02 (-0.88 - 0.87) 
Mixed herbals Anaphylactic reaction 15 (1.4) -0.63 (-1.59 - 0.26) 
Mixed herbals Angioedema 15 (1.4) -0.80 (-1.76 - 0.07) 
Mixed herbals Flushing 15 (1.4) -0.66 (-1.62 - 0.22) 
Mixed herbals Anaphylactoid reaction 12 (1.2) 0.08 (-1.08 - 1.16) 
Phleum pratense Oedema mouth 12 (1.2) 1.81 (0.67 - 2.86) 
Andrographis 
paniculata Urticaria 11 (1.1) 0.01 (-1.11 - 1.01) 
Mixed herbals Oedema periorbital 11 (1.0) -0.69 (-1.83 - 0.33) 
Mixed herbals Anaphylactic shock 10 (1.0) -0.52 (-1.74 - 0.58) 
Phleum pratense Anaphylactic reaction 10 (1.0) 1.24 (0.03 - 2.33) 
      
a IC, information component; b WHOART, The WHO Adverse Reactions Terminology 
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8.2.7. Conclusion 
We report on a series of 757 case-reports indicative of allergy-like adverse reactions 
during the use of herbal remedies from the Vigibase of spontaneous ADR reports 
coming from 42 countries since 1969. Our study documents that a large number of 
different herbal remedies cause immediate allergy-like reactions in the population. 
Among all reports, mixed herbals, Phleum pratense and Andrographis paniculata 
were most frequently reported in association with ADR. Andrographis paniculata is 
well known in Ayurveda medicine and typically used for the treatment of common 
cold. Previously reported findings from Thailand investigating the safety of 
Andrographis paniculata showed a similar range of hypersensitivity reactions ranging 
from skin reactions to anaphylaxis.205 Case-reports indicative of hypersensitivity to 
other most frequently reported herbals in our study have been published 
previously.206-211 
High proportion of reports concerned women between the age of 18 and 44. The 
most frequently reported manifestations of allergy-like immediate reactions were skin 
reactions, and also anaphylactic / anaphylactoid reactions most frequently observed 
after oral administration. Such severe ADR are rarely seen after oral use of herbals. 
The occurrence of allergic reactions is rather more likely to be expected after 
cutaneous and mucosal exposure, a known risk factor for sensitization to allergens. It 
is reasonable to assume that rather easy to diagnose reactions with a short time to 
onset and skin manifestations as well as serious reactions are more frequently 
reported compared to other reactions. Oral administration of herbals in females may 
be most common in the population. Such observation is often made in CAM/herbal 
use prevalence studies.189-191 It is therefore expected that this population is also 
overrepresented in all included reports. A higher reporting rate of ADR by females 
could be another factor contributing to such pattern.212 On the other hand, a higher 
proportion of females experiencing an adverse reaction in our study may confirm 
results of other studies where a higher incidence of hypersensitivity reaction in 
females compared to males was found.213,214 Nevertheless, this finding does not 
allow conclusions regarding the role of those characteristics as risk factors although 
they are further discussed in the literature.  
Asthma-like reactions were found in 4.8% of reports. Some commonly used herbals 
display a wide spectrum of cross-reactivity to other common inhalation or food 
allergens. Therefore a preexisting diagnosis of asthma and other atopic diseases 
may be a risk factor for the development of allergic reactions to herbals.  There is a 
relevant incidence of herbal use among patients with known allergies.215 For 
example, herbal medicine was shown to be the third popular choice among patients 
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suffering from asthma with a prevalence of 60-70% in patients with a history of 
moderate or severe asthma in the United Kingdom.216 These findings imply that in 
the presence of known atopic diseases health professionals and patients should only 
use herbals with great care in order to prevent severe allergic reactions to herbals in 
this special population. Other relevant factors that were not recorded and could have 
contributed to the development of allergy-like reactions could have been user's 
genetics, nutrition status, concurrent medication, disease states (e.g.: food allergies) 
and exercise induced anaphylaxis. Also, unrecognized herbal-drug interactions could 
result in a lack of allergy control and manifestation of allergy symptoms. 
Strengths of our study include the international collection of reports from 42 countries 
over more than four decades and the use of standardized HATC drug classification, 
WHOART nomenclature and formal causality assessment for adverse reactions. At 
the same time it is important to recognize special characteristics and inherent 
limitations of this data source for the study design and interpretation of findings. Most 
important, spontaneous reporting data do not provide information on the actual 
exposure to herbals in a population or on the incidence of related ADR. Therefore, 
qualitative descriptive analyses and signal detection for previously unknown drug 
safety issues are the primary strength of spontaneous reporting systems rather than 
quantitative analyses. Furthermore, the level of documentation in VigiBase® is 
heterogeneous, the extracted reports do not contain original detailed free-text 
descriptions by the primary reporters, and particularly for early reports formal 
causality assessment may not be available requiring exclusion from our study 
population. One must also realize that a standardized reaction term has many 
advantages, but it is not the same as a clinical diagnosis based on established 
clinical diagnostic criteria.217 In light of those limitations we used a restrictive study 
design emphasizing high specificity with regard to the likely diagnosis of immediate-
type allergic reactions and consequently excluded the majority of reports from the 
extracted original raw dataset. Such a conservative approach implies reduced 
sensitivity for signal detection, but we believe that overall it improves the 
interpretability of our findings. There are several other challenges that 
pharmacovigilance studies investigating risks associated with herbal remedies face 
in general. As a result of insufficient herbal product regulations, some ADR may be 
attributable to a lack of standardization, contamination, adulteration, plant 
misidentification/substitution, improper use of herbal medicines including their 
inappropriate labeling rather than pharmacological/toxicology effects of herbals.193-
195,218 Also, implementation of innovative preparation methods of traditionally used 
herbal remedies may alter pharmacological/toxicological properties of herbs and lead 
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to their toxicity rather than therapeutic use. In the era of market globalization, the 
knowledge of traditional preparation and use of herbals is therefore necessary given 
the increase in use of traditional herbal remedies outside of their culture of origin.   
An estimate of the frequency of ADR to herbals is not possible based on analyses of 
spontaneous reporting data, but we must assume that our findings represent only the 
“tip of the iceberg” regarding safety issues with herbal remedies.198 Moreover, 
underreporting of adverse events particularly herbals by patients as well as health 
care professionals is high and health care professionals are not always aware of 
potential safety issues associated with herbal use.196-198,219,220  
In summary, any pharmacologically active product including herbal has the potential 
to cause harm. We found that herbal medicines for oral use carry a risk for allergy-
like immediate ADR and that studies using the WHO-UMC pharmacovigilance 
database can identify specific associations between particular herbals and adverse 
reactions. As the prevalence of herbal use is increasing, health care professionals as 
well as patients need to become better informed about the possible risks associated 
with herbal medicines. When health care professionals take drug histories they 
should actively ask their patients also about all self-administered herbal remedies 
and dietary supplements. Further studies are needed to establish associations and 
risk factors that are related to herbal use and allergic reactions.  
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